Approved, 18 January 2017Janssen Research & Development *
Clinical Protocol
A Multicenter, Randomized, Double -blind, Placebo -controlled, Proof -of-Concept Study of 
Ustekinumab in Subjects W ith Acti ve Systemic Lupus Erythematosus
CNTO1275SL E2001; Phase 2a 
AMENDMENT 3
STELARA®(ustekinumab)
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the Sponsor for Janssen Research & Development 
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen 
Biologics, BV; Janssen- Cilag International NV; Janssen, Inc; Janssen Infectious Diseases BVBA; Janss en 
R&D Ireland; or Janssen Research & Development, LLC. The term “Sponsor” is used throughout the 
protocol to represent these various legal entities; the Sponsor is identified on the Contact [CONTACT_23756]. 
This study  will be conducted under US Food & Drug Administration I ND regulations 
(21 CFR Part 312).
EudraCT NUMBER: 2014 -005000 -19
Status: Approved
Date: 18 January 2017
Prepared by: [CONTACT_12945] & Development, LLC  
EDMS number : EDMS- ERI-89608352, 10.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements . 
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and may 
not be disclosed unless such disclosure is required by [CONTACT_784]. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by 
[CONTACT_476]. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as priv ileged or 
confidential.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327483] OF IN -TEXT T ABLES A ND FIGU RES ................................................................................................ 6
PROTOCOL A MENDMENTS ....................................................................................................................... 7
SYNOPSIS .................................................................................................................................................. 28
TIME AND EVENTS SCHE DULE .............................................................................................................. 35
ABBREVIA TIONS ...................................................................................................................................... 42
1. INTRODUCTION ................................................................................................................................ 44
1.1. Background .................................................................................................................................... 45
1.2. Overall Rationale for the Study ...................................................................................................... 45
1.2.1. Scientific Rationale for Use of Anti -IL-12/23p40 Therapy in Systemic Lupus 
Erythematosus ............................................................................................................................ 45
[IP_ADDRESS]. Subgroup of Subjects with Active Cutaneous Manifestations of Systemic Lupus 
Erythematosus ......................................................................................................................... [ADDRESS_327484] POPUL ATION.................................................................................................................. 54
4.1. Inclusion Criteria ............................................................................................................................ 55
4.1.1. Inclusion Criteria Applicable to All Subjects ............................................................................... 55
4.1.2. Additional Inclusion Criteria for the Cutaneous Lupus Substudy ............................................... 61
4.1.3. Inclusion Criteria Applicable to All Subjects Entering into the Study Extension (W eek 48 
or Week 56 visits) ....................................................................................................................... 61
4.2. Exclusion Criteria ........................................................................................................................... 62
4.3. Prohibitions and Restrictions ......................................................................................................... 66
5. TREA TMENT A LLOCA TION AND BLINDING ................................................................................. 67
5.1. Procedures for Rando mization ...................................................................................................... 67
5.2. Blinding .......................................................................................................................................... 68
6. DOSA GE A ND A DMINISTR ATION.................................................................................................. 69
6.1. IV administration ............................................................................................................................ 69
6.2. SC administration ........................................................................................................................... 69
7. TREA TMENT COMPLIA NCE ............................................................................................................ 70
8. CONCOMIT ANT THERA PY.............................................................................................................. 71
8.1. Immunomodulators ........................................................................................................................ 72
8.2. Antimalarial Medications ................................................................................................................ 72
8.3. Corticosteroid Therapy ................................................................................................................... 72
8.4. Nonsteroidal Anti -inflammatory Drugs ........................................................................................... 74
8.5. Anti-hypertensive Medications ....................................................................................................... 74
8.6. Topi[INVESTIGATOR_267245] ....................................................................................................................... 74
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
3
Approved, 18 January [ZIP_CODE]. STUDY EVA LUATIONS .................................................................................................................... 75
9.1. Study Procedures ........................................................................................................................... 75
9.1.1. Overview ..................................................................................................................................... 75
9.1.2. Screening Phase ........................................................................................................................ 75
[IP_ADDRESS]. Screening Procedures ............................................................................................................. 75
[IP_ADDRESS]. Retesting .................................................................................................................................. 76
[IP_ADDRESS]. Rescreening ............................................................................................................................. 77
9.1.3. Double -Blind Treatment Phase .................................................................................................. 77
[IP_ADDRESS]. Week 0/Day of Randomization ................................................................................................ 77
[IP_ADDRESS]. Placebo -controlled Treatment Period (Through Week 24)...................................................... 77
9.1.4. Cross -over Treatment (Through Week 40)................................................................................. 77
9.1.5. Study Extension (W eek 48/W eek 56 through W eek 104) .......................................................... [ADDRESS_327485]- treatment Safety Follow -up................................................................................................ 78
9.2. Efficacy ........................................................................................................................................... 78
9.2.1. Evaluations ................................................................................................................................ .78
[IP_ADDRESS]. SLEDAI- 2K and S2K RI -50...................................................................................................... 78
[IP_ADDRESS]. BILAG ...................................................................................................................................... 79
[IP_ADDRESS]. CLASI ...................................................................................................................................... 79
[IP_ADDRESS]. Physician Global Assessment of Disease Activity ................................................................... 80
[IP_ADDRESS]. Patient Global Assessments .................................................................................................... 80
[IP_ADDRESS].1. Patient Global Assessment of Disease Activity ................................................................... 80
[IP_ADDRESS].2. Patient Assessment of Pain ................................................................................................ .80
[IP_ADDRESS]. Short- Form -36......................................................................................................................... 80
[IP_ADDRESS]. Fatigue Severity Scale ............................................................................................................. 81
9.2.2. Definitions ................................................................................................................................... 81
[IP_ADDRESS]. SRI-4........................................................................................................................................ 81
[IP_ADDRESS]. BILAG -based Combined Lupus Assessment .......................................................................... 81
[IP_ADDRESS]. Flares ....................................................................................................................................... 82
[IP_ADDRESS]. S2K RI -50 Response ............................................................................................................... 82
[IP_ADDRESS]. No Worsening in PGA ............................................................................................................. [ADDRESS_327486] COMPLETION/W ITHDRA WAL....................................................................................... [ADDRESS_327487] Information ........................................................................................................................ 91
11.2. Sample Size Determination ........................................................................................................... 91
11.3. Efficacy  Analyses ........................................................................................................................... 92
11.3.1. Primary Endpoint Analysis .......................................................................................................... 92
11.3.2. Major Secondary Analy ses......................................................................................................... 93
11.3.3. Other Planned Efficacy Analy ses............................................................................................... 94
11.3.4. Efficacy  Analyses in the Study Extension ................................................................................... 94
11.4. Interim Analyses ............................................................................................................................. 94
11.5. Pharmacokinetic Analy ses............................................................................................................. 94
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327488] ................................................. 105
16.2.3. Informed Consent ..................................................................................................................... 107
16.2.4. Privacy of Personal Data .......................................................................................................... 108
16.2.5. Long- Term Retention of Samples for Additional Future Research .......................................... 108
16.2.6. Countr y Selection ..................................................................................................................... 109
17. ADM INISTRA TIVE REQUI REM ENTS ............................................................................................ 109
17.1. Protocol Amendments .................................................................................................................. 109
17.2. Regulatory Documentation .......................................................................................................... 109
17.2.1. Regulatory Approval/Notification .............................................................................................. [ADDRESS_327489] Identif ication, Enrollment, and Screening Logs .............................................................. 110
17.4. Source Documentation ................................................................................................................. 111
17.5. Case Report Form Completion .................................................................................................... 111
17.6. Data Quality Assurance/Quality Control ...................................................................................... [ADDRESS_327490] Retention ......................................................................................................................... 112
17.8. Monitoring .................................................................................................................................... 113
17.9. Study Com pletion/Termination ..................................................................................................... 114
17.9.1. Study Com pletion ..................................................................................................................... 114
17.9.2. Study Termination ..................................................................................................................... 114
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
5
Approved, 18 January 201717.10. On-Site Audits .............................................................................................................................. 114
17.11. Use of Information and Publication .............................................................................................. 115
REFERENCES .......................................................................................................................................... 117
ATTACHMENT 1: EFFICA CY EVA LUATIONS A ND ENDPOINTS ........................................................ 120
ATTACHMENT 2:  QUA NTIFERON-TB GOLD TESTING .................................................................... 122
ATTACHMENT 3:  TUBER CULIN SKIN TESTING ................................................................................. 124
ATTACHMENT 4:  HBV S CREENING A ND MONITOR ING................................................................... 125
ATTACHMENT 5: SLEDA I-2K/S2K RI- 50 A T SCREENING VISI T......................................................... 126
ATTACHMENT 6: SLEDA I-2K / S2K RI -50 (BA SELINE) ....................................................................... 129
ATTACHMENT 7: S2K RI -50 (FOLLOW -UP).......................................................................................... 133
ATTACHMENT 8: BILA G 2004 ................................................................................................................ 137
ATTACHMENT 9: CLA SI......................................................................................................................... 138
ATTACHMENT 10: PHYSI CIAN GLOBA L ASSESSME NT OF DISEA SE A CTIVI TY............................ 139
ATTACHMENT 11: PA TIENTS GLOBA L ASSESSMEN TS OF DISEA SE A ND PA IN ACTIVITY ........ 140
ATTACHMENT 12: SF -36........................................................................................................................ 141
ATTACHMENT 13: FA TIGUE SEVERITY SCA LE.................................................................................. 147
INVESTIGA TOR A GREEMEN T............................................................................................................... 148
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327491] OF IN -TEXT TA BLES A ND FIGU RES
TABLES
Table 1: Time and Events Schedule for the Main Study Design (Screening through 8 -Week/16-
Week Safety Follow -up)............................................................................................................ 35
Table 2: Time and Events Schedule in the CNTO1275SLE2001 Study Extension (W eek 48/56 
through Extension Safety Follow -up)........................................................................................ 39
Table 3: Clinical and Immunological Criteria Used in the SLICC Classification Criteria*25.................... 55
Table 4: Power to Detect a Significant Treatment Difference in the Proportion of Subjects with 
SRI-4 Response at W eek 24.................................................................................................... 92
Figures
Figure 1: Schematic Overview of the Main Study (Screening through 16 -Week Safety  Follow -
Up)............................................................................................................................................ 52
Figure 2: Schematic Overview Including the Study Extension ................................................................ 53
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327492] recent amendment.
Amendment INT -3(18January 2017)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.
The overall reason for the amendment: The overall reason for the amendment is to further evaluate the safety and 
efficacy of long-term ustekinumab administration in subjects with Systemic Lupus Erythem atosus (SLE) who are 
participating in the CNTO1275SLE2001 study extension .
Applicable Section(s) Description of Change(s)
Rationale: The primary purpose of the amendment is to allow further evaluation of the safety and efficacy of long -
term ustekinumab administration in subjects with Systemic Lupus Erythematosus (SLE) who are participating in the 
CNTO1275SLE2001 study extension.
Synopsis
Exploratory 
Objectives Safety and efficacy during long -term  administration of ustekinum ab.
 Reduction in corticosteroid dosing during long-term administration of 
ustekinumab.
Synopsis
Overvie w of Study 
DesignDatabase locks (DBLs) will occur at Weeks [ADDRESS_327493]’s Week 
[ADDRESS_327494]’s Week 16 safety follow -up visit from  the main study .
Synopsis
Overvie w of Study 
DesignThe amended study design will continue to provide open- label ustekinumab 90 mg 
q8w SC administration through Week 104. Subjects will be eligible to continue study 
treatm ent through Week 104 if they meet the study inclusion criteria (Section 4.1.3) 
including:
 must not have permanently discontinued study treatment on or before their 
Week 40 visit , and
 are able to continue q8 week study treatm ent at approximately 8 weeks (±2
week s) after their Week 40 visit
or
 are able to resume study treatm ent with no more than 16 weeks ( ±2 weeks ) since 
their Week [ADDRESS_327495]’s Week [ADDRESS_327496]’s Week 16 safety follow -up visit from  the main study, there will be an 
additional DBL at the end of the study extension (following Study Extension 16-week 
safet y follow -up visit) .
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
8
Approved, 18 January 2017Applicable Section(s) Description of Change(s)
Synopsis
Dosage and 
AdministrationEvery reasonable effort should be made to keep concomitant medications stable at least 
through Week 28, with some adjustments allowed beyond Week 28 through Week 48 the 
8-Week Safety Follow -Upor study extension as defined in the protocol.
Subjects who are enrolled in the study extension will continue to receive ustekinumab 
90 m g SC administration every 8 weeks through Week 104. With the exception of 
corticosteroids, concom itant m edications sho uld be maintained at stable doses 
through the study extension.
After Week 40 to 16-Week Safety Follow -Up(Safety Follow -up Phase)
Groups 1 and 2: Subjects will who do not participate in the study extension are 
expected toreturn for safety follow -up visits at Week s44,48, and 56and for 8-and 16-
weeks safety follow up .
Study Extension (Week 48 /Week 56 through Week 120)
Subjects who meet the study extension inclusion criteria (Section 4.1.3) will receive 
an additional [ADDRESS_327497] diary cards will be used to capture medication changes that occur in b etween study 
visits during the main portion of this study .
Time and Events 
ScheduleTable 1: Time and Events Schedule for the Main Study Design (Screening through 8 -
Week/1 6-Week Safety F ollow -up)
Time and Events 
ScheduleMain Study Safety Follow -up Phase
8-Week Safety Follow -up48b
16-Week Safety Follow -up/Final Visitb
Time and Events 
Scheduleb. Subjects, who discontinue study agent administrations on or before the Week [ADDRESS_327498] study agent administration for 
safety follow -up visits (analogous to assessments done at Week 48 and Week 56, 
respecti vely) . The 8 -week and/or 16 -week safety follow -up visits are not required for 
subjects who continue treatment in the study extension within 8 (±2 weeks) or 16 (±2 
weeks) weeks, respectively, of their Week 40 visit (refer to Table 2 ).
Time and Events 
Schedulec. All assessments (except for injection -site evaluation) are to be completed prior 
to study agent administration, unless otherwise specified.
Time and Events 
ScheduleTable 2: Time and Events Schedule in the CNTO1275SLE2001 Study Extension
(Week 48/56 through Extension Safety Follow -up) added .
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
9
Approved, 18 January 2017Applicable Section(s) Description of Change(s)
Section 1.3.
Justification for 
Dosing RegimenAlthough the dosing rationale has not changed, some additional safety and efficacy 
inform ation has become available from the ustekinumab Phase 3 CD(UNITI) studies 
which supports the treatment extension planned for this study. These results from the 
UNITI CDstudies are summarized later in this section (Section 1.3) .
In addition, there were also [ADDRESS_327499] recently provided additional safety and efficacy data; UNITI -1, UNITI 2, 
and IM-UNITI. UNITI -[ADDRESS_327500] but who had failed conventional 
immunom odulator or steroid therapi[INVESTIGATOR_014]. The IM-UNITI study evaluated maintenance 
treatm ent for patients enrolled from both UNITI -1 and UNITI -2 studies. The UNITI 
studies rando mized 1,367 subjects to either placebo, 130 mg IV or approximately 6 
mg/kg IV. After Week [ADDRESS_327501] been published,7and the results supported the approval of 
ustekinumab in patients with active moderate to severe CD. The approved dose in 
induction is a single IV weight-based dose approxim ating 6 mg/kg and the approved 
maintenance dose is 90 mg either every 8 or 12 weeks depending on the approval 
region. The results of these studies are particularly relevant to the 
CNTO1275SLE2001 SLE study in that a similar dose is being evaluated. In addition, 
similar to the SLE population, about 1/3 of the CD patients enrolled into the UNITI 
studies were using conco mitant immunom odulators (e.g MTX, AZA, 6-MP) and 
approximately 46% were on concom itant glucocorticoids. The results of these studies 
are reviewed in detail in the prim ary publication7and the highlights are presented 
below:
 In the 2 UNITI induc tion studies, the primary endpoint and all m ajor secondary 
endpoints were met for both doses studied including the 6 m g/kg dose.
 In the IM-UNITI maintenance study, both the 90 mg every 8 or every 12 week  
regim ens were superior to placebo in maintaining response or achieving 
remission compared to placebo at Week 44.
 Importantly, the safety profile of both maintenance doses were comparable to 
placebo over 44 weeks and no new safety signals were identified .The safety 
profile was sim ilar to that seen in the psoriatic indications.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
10
Approved, 18 January 2017Applicable Section(s) Description of Change(s)
In summary, these CD studies support the dosing regimen planned for this proof -of 
concept SLE study including body weight-range based IV loading dose approximating 
6mg/kg follow ed by 90 mg SC q8w will be employ edto ensure a high level of systemic 
exposure of ustekinumab to inhibit the actions ofIL-12/23 in this proof -of-concept study 
in subjects w ith active SLE .
Open label 90 m g SC q8w ustekinumab dosing will be pro vided to subjects starting at 
Week 24 though Week 40. Per the amended study design, subjects who are able to 
continue q8w study treatm ent at approximately 8 weeks (±2 weeks) after their Week 
40 visit, or are able to resume study treatm ent with no more than 16 weeks (±2 
weeks) since their Week 40 visit will be eligible for continued 90 mg SC q8w 
ustekinumab treatment through Week 104, followed by [CONTACT_33018] 16-week safety 
follow -up period.
2.1.Objectives
Exploratory 
Objectives Safety and efficacy during long-term  administration of ustekinum ab.
 Reduction in corticosteroid dosing during long-term administration of 
ustekinumab.
3.Study Design and 
RationaleA complete list describing all efficacy evaluations and endpoints, and which evaluations 
are included in the composite endpoints is provided in Attachment 1. The main study is 
defined from the original protocol as screening through the Main Study 8-week and 
16-week safety follow -up visits. Note that the Main Study 8-week and 16-week safety 
follow -up visits were previously described in the original protocol as the Week 48 and 
Week 56 visits. However ,with this amendment, the Week 48 and Week 56 visits will 
only be used to describe treatm ent visits for those subjects who are participating in 
the study extension. The study extension (applicable to subjects meeting the inclusion 
criteria) is defined as the Week 48 or Week 56 visits through the Study Extension 16-
week safety follow -up visit.
3.1. Overview of 
Study DesignDatabase locks (DBLs) will occur at Weeks [ADDRESS_327502]’s Week [ADDRESS_327503]’s 16-week safety follow -up visit from  the main 
study.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
11
Approved, 18 January 2017Applicable Section(s) Description of Change(s)
3.1. Overview of 
Study DesignThe amended study design will continue to provide open- label ustekinumab 90 mg 
q8w SC administration through Week 104(study extension) . Subjects will be eligible
to continue study treatm ent through Week 104 if they meet the study inclusion 
criteria (Section 4.1.3 ):
 must not have permanently discontinued study treatment on or before their 
Week 40 visit , and
 are able to continue q8 week study treatm ent at approximately 8 weeks 
(±2weeks ) after their Week 40 visit
or
 are able to resume study treatm ent with no more than 16 weeks ( ±2 week s) since 
their Week [ADDRESS_327504]’s Week 56 visit or the final 
16-week safety follow -up visit from  the main study, there will be an additional DBL 
following the Extension 16 -Week Safety Follow -up period.
A diagram of the mainstudy design is provided below in Figure 1, and a diagram of the 
extended study is provided in Figure 2 .
3.1. Overview of 
Study DesignFigure 1: Schematic Overview of the Main Study (Screening through 16-Week 
Safety Follow -Up)
3.1. Overview of 
Study DesignFigure 1 updated
3.1. Overview of 
Study DesignFigure 2: Schematic Overview Including the Study Extension added.
4.Subject 
PopulationThe study extension population will be comprised of those subjects who have not 
perm anently discontinued study treatm ent before or atthe Week 40 dose and for 
whom  the investigators judge that there is a potential benefit that outweighs the
potential risks to continued ustekinumab treatment.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
12
Approved, 18 January 2017Applicable Section(s) Description of Change(s)
4.1. Inclusion 
Criteria4.1.3. Inclusion Criteria Applicable to All Subjects Entering into the Study
Extension (Week 48 or Week 56 visits)
Any subjects who do not meet the inclusion criteria for the study extension must 
follow the Time and Events schedule for the main study design (Table 1), and have 
safety follow -up visits conducted at [ADDRESS_327505] permanently discontinued stud y treatm ent on or before 
their W eek 40 visit and are able to either continue q 8w SC dosing at 
approximately 8 weeks (±2 weeks ) after their Week 40 visit, or are able to resume 
dosing at Week 56 with no more than 16 weeks (±2 weeks) since their Week [ADDRESS_327506] be willing and able to adhere to the following prohibitions and 
restrictions during the course of the study (including the study extension) to be eligible 
for continued dosing in the study:
6.2.
Subcutaneous 
administrationAfter Week 40 to 16-week Safety F ollow up (Safety Follow -up Phase)
Groups 1 and 2:Subjects will who do not participate in the study extension are 
expected to return for safety follow -up visits at Weeks 44,48, and 56and for 8-and 16-
weeks safety follow up .
Study Extension (Week 48 /Week 56 through Week 120)
Subjects who meet the study extension inclusion criteria will receive open -label 
ustekinumab adm inistration for the purpose of expanding the safety experience and 
maintenance of efficacy in lupus patients continuously exposed to ustekinumab 90 mg 
q8w. Subjects who continue dosing in the extended study starting at Week 48 or at 
Week 56 will receive open -label ustekinumab SC dosing through Week 104. If the 
development of ustekinumab in SLE is terminated, then the study extension will also 
be discontinued.
7. Treatm ent 
Compliance.Through the Week 32visit, the visit and study agent administration should occur within 
± 7 day s of the scheduled visit day (relative to Week 0). Following the Week 32visit, the 
study agent administrations are allowed to occur within ±2 weeks of the scheduled 
visit day (rel ative to Week 0).
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
13
Approved, 18 January 2017Applicable Section(s) Description of Change(s)
8. Concom itant 
TherapyEvery reasonable effort should be made to keep concomitant medications stable at least 
through Week 28, and if possible also through Week 48the main study 8-week safety 
follow -up orthrough the study extension (ifapplicable) . With the exception of 
corticosteroids (see Section 8.3 regarding corticosteroid tapering), all other 
concom itant medications should be maintained at stable doses throughout the study.
8. Concom itant 
TherapySubject diary cards will be used to capture changes in subject -administered medications 
that occur in between study visits during the main portion of this study , and these 
changes must also be recorded in the concomitant therapy section of the eCRF.
8.1.
ImmunomodulatorsBeyond Week 28, immunomodulators should remain as stable as possible through Week 
48the 8-week safety follow -upor through the study extension (if applicable) , 
however, dose adjustment is allow ed for unacceptable side effects.
8.2 Antimalarial 
MedicationsStable treatment with hydroxychloroquine, chloroquine, or quinacrine is permitted through 
Week 48 the 8-week safety follow -up.
8.3.
Corticosteroid 
TherapyUnnecessary dose changes are discouraged, and any dose adjustments should be made in 
increments. Changes in corticosteroids through Week 48the 8-week safety follow -upor 
through the study extension (if applicable) are allow ed for medical necessity, but the 
degree and timing of the adjustment should be carefully considered as this may have an 
impact on the study results, especially during the period between [ADDRESS_327507] on the study.
8.3.
Corticosteroid 
TherapyGradual tapering of oral corticosteroid dosing in the study extension (recommended 
reductions of no more than 10 to 20% of the original dose per week) is encouraged 
starting after the Week [ADDRESS_327508] possible maintenance dose of corticosteroids is recommended, including 
complete weaning off of corticosteroids if possible. It is recommended that subjects 
should be educated and monitored by [CONTACT_269265] 
(eg, Addisonian symptoms) during periods of steroid tapering, as appropriate.
If subjects experience a worsening in their disease activity while tapering 
corticosteroids, further dose decreases may be suspended, and/or their oral 
cortic osteroid dose may be temporarily increased if deem ed necessary by [CONTACT_1275]. For subjects whose corticosteroid taper is interrupted, investigators are 
encouraged to resum e tapering within [ADDRESS_327509] to be 
considered a treatm ent or steroid tapering failure. Susta ined oral corticosteroid doses 
of 40 m g/day or higher m ay result in discontinuation of study agent.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
14
Approved, 18 January 2017Applicable Section(s) Description of Change(s)
8.3.
Corticosteroid 
TherapyFor subjects in the cutaneous lupus substudy, the initiation of, or an increase from baseline 
in, the use of potent topi[INVESTIGATOR_269230], or intra -lesional corticosteroid injections, is not 
recommended allowed and should be avoided through Week [ADDRESS_327510] being classified at a treatment failure . Subjects should not 
initiate any new ARB or ACE inhibitor therapy between randomization and Week 
28.
8.6. Topi[INVESTIGATOR_269231]; however, topi[INVESTIGATOR_269232] a 
prohibited medication. Topi[INVESTIGATOR_269233] A are prohibited 
through Week 28 ; however ophthalmic use is permitted. Low potency topi[INVESTIGATOR_269234]. Medium to high potency topi[INVESTIGATOR_269235] 48the 8-week safety follow -up, and high 
potency topi[INVESTIGATOR_269236] n. For subjects in the cutaneous lupus substudy, topi[INVESTIGATOR_269237]. For [ADDRESS_327511] over the course of the main 
portion of thestudy will be approximately 640 mL. The total blood volume to be 
collected in the study extension between Weeks 48 and 120 will be approxim ately 
250mL.
9.1. Study 
Procedures
[IP_ADDRESS]. Week 0/Day 
of Random izationSubject’s diary card which was distributed during screening will be review ed at Week 0, 
and a new card will be provided at each study visit to record medication changes during 
the subsequent [ADDRESS_327512]-
treat ment Phase 
(Follow -Up)9.1.[ADDRESS_327513] -treatm ent Phase (Follow- Up)
Post-treatment follow up visits will occur at [ADDRESS_327514] dose 
received at Week 40 (ie, through Week 56). Assessments will be performed as indicated in 
the Time and Events Schedule (Table 1). The final efficacy and safety assessments will be 
performed at Week 56.
9.1.5. Study Extension (Week 48 /Week 56 through Week 104)
Subjects who qualify for participation in the study extension through Week 104 will 
continue ustekinumab 90 mg q8w SC dosing at approxim ately 8 weeks (±2 weeks) 
after their Week 40 visit, or resume ustekinum ab dosing at Week 56 with no more 
than 16 weeks ( ±2 weeks) since their Week 40 visit.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
15
Approved, 18 January 2017Applicable Section(s) Description of Change(s)
[IP_ADDRESS] Subjects 
Who Perm anently 
Discontinue Study 
Agent before Week 
[IP_ADDRESS] Subjects Who Permanently Discontinue Study Agent before Week 40
9.1.7 Safety Follow -up for S ubjects Who Permanently Discontinue Study Agent at 
or before Week 104
Subjects who permanently discontinue study agent at or before Week 40 , or perm anently 
discontinue at or before Week 104 if they are participating in the study extension , but 
do not withdraw from study participation, should be followed for approximately 16 weeks 
(5 half-lives) after the last study agent administration according to the visit schedule and 
assessments indicated in the appropriate Time and Events Schedule s(Table 1 and Table 
2). Follow -up visits should occur approximately [ADDRESS_327515] has died, the date and cause of death will be 
collected and documented on the CRF .
9.2.3. Endpoints 4.  
 
 
5.  
 
16. The proportion of subjects with meaningful changes in selected SLE medications 
from Week 12 through Week 48Main Study 8-week Safety Follow -up Visit /Week 
48.
17. Change in corticosteroid dose from  Week 48through Week [ADDRESS_327516] diary cards will be used to 
capture medication changes that occur in between study visits through the main portion 
of this study .
9.8. Safety 
EvaluationsThe study will include the follow ing evaluations of safety and tolerability according to the 
time points provided in Table 1 and Table 2 for the extended study .
9.8. Safety 
EvaluationsClinical Laboratory Tests
Blood samples for serum chem istry and hematology will be collected according to the 
Time and Events Schedule (Table 1 and Table 2 for the extended study ).
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
16
Approved, 18 January 2017Applicable Section(s) Description of Change(s)
9.8. Safety 
EvaluationsPhysical Exa mination
A full body  physical examination will be performed pre-treatm ent and during the study as 
shown in Table 1 and Table 2 for the extended study .
9.9. Sample 
Collection and 
HandlingRefer to the Time and Events Schedule (Table 1 and Table 2 for the extended study )for 
the timing and frequency of all sample collections.
10.1. Completion A subject who does not enter into the study extension will be considered to have 
completed the main study if he or she has completed assessments through Week 5616-
week safety follow -upof the main study. A subject who has enrolled into the study 
extension will be considered to have completed the main portion of this study if he or 
she has completed assessments through either the 8-week safety follow -up visit of the 
main study. Subjects who prem aturely discontinue study treatm ent for any reason before 
Week 56 the Week 8 or Week 16 safety follow -up visits (from  the main study) ,will not 
be considered to have completed the main portion of thestudy. A subject who has 
enrolled into the study extension will be c onsidered to have completed the study 
extension if he or she has completed assessments through Week [ADDRESS_327517]'s study treatment must be discontinued before or atWeek 40 (for subjects 
who do not participate in the study extension) or before Week 104 (for subjects who 
do participate in the study extension), this will not result in autom atic withdrawal of the 
subject from the study and follow -up assessments should be obtained approxim ately [ADDRESS_327518] dose of study agent.
11.3.1. Prim ary 
Endpoint Analyses Initiation of new ARB or ACE inhibitor therapy after first dose of study agent and 
before Week 24. Subjects who were not receiving ARB or ACE inhibitor therapy 
who then initiated a new ARB or ACE inhibitor therapy between Week 12 and 
Week 24. Subjects who substitute an ARB or ACE inhibitor for a comparable 
medication would not be considered treatment failures.
11.3.4. Efficacy 
Analyses in the 
Long- Term 
ExtensionLong- term evaluations of efficacy including SRI-4, SLEDAI -2K, PGA, reduction in 
corticosteroid dosing, and evaluations of flare over time will also be perform ed for 
those subjects who participate in the study extension.
11.11. Data 
Monitoring 
CommitteeThe DMC will no longer be active after the assessment of the prim ary endpoint in 
this study.
REFERENCES 7. Feagan, BG, Sandborn WJ, Gasink C, et al. Ustekinum ab as Induction and 
Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016;375(20):1946 -
1960.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
17
Approved, 18 January 2017Amendment INT -2(24 November 2015 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union. 
The overall reason for the amendment: The overall reason s for the amendm ent areto provide clarification and 
additional detail regarding 1) subject eligibility and enrollment, 2) use of restricted and prohibited concomitant 
medications, 3) refine the definition of the prim ary endpoi nt, 4) specify conditions under which subjects may 
undergo retesting at screening, 5) elaborate on the statistical procedures to be used to conduct the interim and 
planned data analyses, and 6) provide additional information regarding the collection of sam ples during the Time 
and Events Schedule.
Applicable Section(s) Description of Change(s)
Rationale: Clarification s in several sections in the Synopsis regarding :how the SLEDAI -2K scoring , and the 
BILAG A and BILAG B domain scores will be used to assess subject eligibility for randomization; increased 
medication use after randomization may result in assessment of the subject as a treatment failure; and evaluation of
photographs and /orbiopsy samples in subjects who consent to participate in the cutaneous lupus substudy .
Synopsis
Overvie w of Study 
DesignSubjects must also demonstrate at least 1 British Isles Lupus Assessment Group 
(BILAG) A and/or 2 BILAG B dom ain scores observed during screening .. and/or 
Week [ADDRESS_327519] a 
clinical SLEDAI -2K score ≥4 (excluding laboratory results ) at week 0, prior to 
randomization .
Synopsis
Subject PopulationScreening for eligible subjects must be performed no more than 6 weeks prior to the 
randomization visit (Week 0).
Subjects must also have at least 1BILAG A and/or [ADDRESS_327520] a clinic al 
SLEDAI -2Kscore 4 (excluding laboratory results) for clinical features at Week 0
(prior to randomization ),and have received approval for study randomization 
following review and adjudication of screening lupus assessments by [CONTACT_63307]/or Sponsor -selected independent reviewer(s).
SLE subjects enrolling into the main study with active cutaneous lupus (including subjects 
with discoid lupus erythematosus, subacute cutaneous lupus erythematosus, alopecia or 
SLE malar rash or other SLE skin lesions characterized by [CONTACT_269266]) will be 
evaluated using CLASI scoring.
Synopsis
Dosage and 
AdministrationIf concomitant medications have been adjusted after randomization as allowed per 
protocol, every effort should be made to return subject back to the baseline (Week 0) dose 
level by [CONTACT_56421] 12 visit; or increased medication use may render a subject to be 
considered a treatm ent failure.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
18
Approved, 18 January 2017Applicable Section(s) Description of Change(s)
Synopsis
Cutaneous Lupus 
SubstudySubjects who provide consent will be enrolled in the cutaneous lupus substu dy evaluating 
the histology of cutaneous biopsies and/or skin photographs. Biopsy samples (2 samples, 4 
mm size) from consenting subjects will be collected prior to dosing at Week 0 and at 
Week 24 from a single lesion or area of active cutaneous disease. Photographs and skin 
biopsies can target a different area of active disease , but the follow- up photographs 
or biopsies should re -evaluate the same area of active disease as originally assessed at 
week 0.
Subjects with cutaneous lupus deemed unsuitable for biopsy (eg, malar rash or alopecia) 
can also be enrolled in the substudy, and may be evaluated by [CONTACT_249985].
Rationale: Clarification and addition of explanatory footnotes for key data collection time points specified in the 
Time and Events Schedule .
TIME AND 
EVENTS 
SCHEDULE
Footnote a.a.Screening visit must be performed no more than 6 weeks prior to the 
randomization visit (Week 0). To be eligible for study participation, subjects must 
have SLEDAI score ≥4 (excluding laboratory results) for clinical features at Week 
[ADDRESS_327521] received approval for study randomization following review and 
adjudication of screening lupus assessments by [CONTACT_1052]/or Sponsor -
selected independent reviewer(s).
Footnote j. j. Subjects should be monitored for the occurrence of infusion or injection -site 
reactions for 30 m inutes after administration of the infusion (IV administration) or 
injection.
Footnote q. q. These tests will be performed on -site or at local lab(s ).
Footnote w . w.Biopsies are allowed to occur on the day of random ization or m ay occur 1 -2 days  
prior to random ization and at the Week 24 visit .
Footnote x . x.Photographs do not need to be taken at the same area of active disease as the 
biopsy; however, follow -up pho tographs or biopsies should re-evaluate the same 
area of active disease as originally assessed at week 0.
Rationale: Clarification of the Study Design with regard to use of the BILAG A and BILAG B domain scores at 
screening; conduct of [ADDRESS_327522] (ANA, anti-dsDNA 
antibodies, and/or anti-Smith antibodies) observed during screening, as well as a well-
documented positive autoantibody test in their medical history. Subjects must also 
demonstrate at least 1 BILAG A and/or 2 BILAG B dom ain scores observed during 
screening. and/or Week [ADDRESS_327523] a clinical SLEDAI -2K score ≥ 4 (excluding laboratory results) at 
week 0, prior to randomization.
Interim analyses (IA) will be conducted when approximately 1/3 and 2/[ADDRESS_327524] across regions will be 
incorporated into the interim analys es.
Rationale: Clarification regarding how  the SLEDAI -2K score ,and theBILAG A and BILAG B domain scores are
used to screen the Subject Population prior to randomization .
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
19
Approved, 18 January 2017Applicable Section(s) Description of Change(s)
4. Subject Population Subjects must have at least 1 BILAG A and/or [ADDRESS_327525] 
(ANA, anti dsDNA antibodies, and/or anti-Smith antibodies) observed during screening, 
as well as a well -documented positive autoantibody test in their medical history, and they 
must also have a clinical SLEDAI -2K score ≥4 (excluding laboratory results ) prior to 
randomization at week 0. Subjects must be scored as having at least 1 BILAG A and/or 2 
BILAG B domain scores observed during screening.
Subjects with cutaneous lupus deemed unsuitable for biopsy (eg, malar rash or alopecia) 
can also be enrolled in the substudy, and may be evaluated by [CONTACT_249985].
Rationale: Clarification of Inclusion Criteria and how the SLEDAI -2K scoring, and the BILAG A and BILAG B 
domain scores will be used to assess subject eligibility for randomization ; clarifications regarding antimalarial
medication sand immunodulatory drugs ,and table formatting in the SLICC C lassification criteria (leukopenia and 
lymphopenia).
4.1.1. Inclusion 
Criteria Applicable 
to All Subjects
Table 2, 10a, 10b
Criterion 3; bullet 3.
Criterion 4.
Criterion 7.
Criterion 8.Table 2: Clinical and Immunological Criteria Used in the SLICC Classification 
Criteria*23
10a. Leukopenia (<4000/mm3at 
least once), or
10b. Lymphopenia (<1000/mm3 at 
least once)In the absence of other known causes such as 
Felty’s ,drugs ,and portal hypertension
In the absence of other known causes such as 
corticosteroids, drugs ,and infection
3. Bullet 3—At least 1 BILAG A and/or [ADDRESS_327526] administration of study agent.
4. Dem onstrate active disease based on SLEDAI -2K score ≥[ADDRESS_327527] 
SLEDAI -2K ≥4 for clinical features (ie, SLEDAI excluding laboratory results ) at Week 
[ADDRESS_327528] administration of study agent.
7.  If using antimalarials (eg, chloroquine, hydroxychloroquine, orquinacrine), subjects 
must have used the medication for ≥[ADDRESS_327529] administration of study agent.
8. If using immunosuppressiveimmunomodulatory drugs (mycophenolate mofetil 
[MMF]/mycophenolic acid [MPA] ≤2g/day, azathioprine/6 mercaptopurine (AZA /6 
MP) ≤2 mg/kg/day and/or MTX ≤25 mg/wk with concomitant folic acid [recommend 
≥5 mg/wk]), subjects must be receiving a stable dose for at least [ADDRESS_327530] administration of study agent.
Rationale: Clarification of Additional Inclusion Criteria forsubjects who may not be appropriate for biopsy 
sample collection in the cutaneous lupus substudy.
4.1.2. Additional 
Inclusion Criteria for 
the Cutaneous Lupus 
Substudy
Criterion 4.4. Subjects with cutaneous lupus deemed unsuitabl e for biopsy (eg, malar rash or
alopecia) can also be enrolled in the substudy, and may be evaluated by [CONTACT_249985].
Rationale: Clarification of Exclusion Criteria for subjects w ho have active Lyme disease; treatment with B cell
depletion therapy; status as an em ployee of the investigator; cross -reference to restriction on vaccination with BCG; 
have used or are using certain immunomodulatory therapi[INVESTIGATOR_269238] ; investigational drug or vaccine treatment; 
lives in an institution on court or authority order .
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
20
Approved, 18 January 2017Applicable Section(s) Description of Change(s)
4.2. Exclusion 
Criteria
Criterion 1.1. Have other inflammatory diseases that might confound the evaluations of efficacy, 
including but not limited to rheumatoid arthritis (RA), psoriatic arthritis (PsA), 
RA/lupus overlap, psoriasis or active Lyme disease.
Criterion 3. 3.Have received system ic or topi[INVESTIGATOR_68549] /ointment preparations of cyclosporine A 
or other systemic immunosuppressive immuno modulatory agents other than those 
described in the inclusion criteria within the past 3months prior to first adm inistration 
of study agent (Sectio n 4.1). Corticosteroids are not included in this criterion; see 
Sections 4.[ADDRESS_327531] study 
agent administration ;or received more than [ADDRESS_327532] administration of 
the study agent ;or received B celldepleting therapy (eg, rituximab) within [ADDRESS_327533] received prior immunosuppressiveimmunomodulatory biologic ther apy for lupus 
not described in Exclusion Criterion #[ADDRESS_327534] administration of study agent. For BCG vaccination criterion, 
see Exclusion Criterion 10 and Prohibition/Restriction Criterion 8.
Criterion 30. 30. Has received an investigational drug that is not previously defined in other 
exclusion criteria (including investigational vaccines orother m edications specified 
in section 4.3, prohibition/restricti on number 3) within 5 half-lives or 3 months, 
whichever is longer (eg, thalidomide and lenalidomide ), or used an invasive 
investigational medical device within [ADDRESS_327535] is an employ ee of the investigator or study site (i.e. personnel to whom the 
investigator has delegated a role or responsibility for conducting the study) , with 
direct involvement in the proposed study or other studies under the direction of that 
investigator or study site, as well as family members of the employees or the 
investigator.
Criterion 37. 37. Lives in an institution on court or authority order, unless permitted by [CONTACT_13125].
Rationale: Additions to the list of Prohibit ions and Restrictions (medications )that must not be used by [CONTACT_269267].
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
21
Approved, 18 January 2017Applicable Section(s) Description of Change(s)
4.3. Prohibitions and 
Restrictions
Prohibition and 
Restriction 3.
Bullet 11
Bullet 12
Bullet 14
Bullet 15
Bullet 163.  Use of additional immunosuppressants or immunom odulators, other than those 
explicitly allowed in the inclusion/exclusion criteria, are prohibited including but not 
limited to the following:
•Cyclosporine A (oral or topi[INVESTIGATOR_269239]/cream preparations)
•Tacrolimus or pi[INVESTIGATOR_180781], oral or topi[INVESTIGATOR_12469]
•Thalidomide or lenalidomide
•Dapsone
•Adrenocorticotropic horm one (ACTH) by [CONTACT_269268] 4.4.  Use of cytotoxic drugs is prohibited including ,but not limited to ,cyclophosphamide, 
chlorambucil, nitrogen mustard, or other alkylating agents.
Prohibition and 
Restriction 5.5. Multiple administrations of high doses of corticosteroids , and initiation of medium 
or high potency topi[INVESTIGATOR_11930], are prohibited during the study as defined 
in Section 8.3 .
Prohibition and 
Restriction 6 .6.   The initiation of a new permitted immunosuppressive immuno modulatory agent 
(MTX, azathioprine, 6-mercaptopurine, mycophenolate mofetil/mycophenolic 
acid) in addition to an ongoing immunosuppressive immuno modulatory therapy 
is prohibited.
Rationale: Clarification of Concom itant Therapy restrictions for subjects who may be receiving treatment with 
immunomodulators, antimalarials, or corticosteroids (topi[INVESTIGATOR_269240]) during screening through specified study 
time points.
8. Concom itant 
TherapyIf concomitant medications have been adjusted after randomization as allowed per 
protocol, every effort should be made to return subject back to the baseline (Week 0) dose 
level by [CONTACT_56421] 12 visit; or increased medication use(relative to baseline) may 
rend er a subject to be considered a treatm ent failure.
8.1. 
ImmunomodulatorsHow ever, immunomodulator dose increases will generally not lead to the discontinuation 
of study agent administration or termination of study participation. Perm anent 
discontinuation of the study treatm ent must be considered for subjects receiving an 
increase (relative to baseline) in their immunom odulator dose.
8.2. Antim alarial 
MedicationsStable treatment with hydroxychloroquine ,chloroquine , or quinacrine is permitted 
through Week 48. Beyond Week 28, it is permitted to introduce or adjust dosing of 
antimalarials. Antim alarials produced by a licensed compounding pharm acy (eg, 
quinacrine) in the country of adm inistration and using pharm acaceutical grade 
components are allowed.
8.3. Corticosteroid 
Therapy
Oral Corticosteriods* *Rectal administration of corticosteroids, if necessary, should be short -term and 
using topi[INVESTIGATOR_12469].
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
22
Approved, 18 January 2017Applicable Section(s) Description of Change(s)
Epi[INVESTIGATOR_13873], Intravenous, 
Intramuscular, Intra -
articular, and Intra -
lesional 
CorticosteroidsEpi[INVESTIGATOR_13873], IV, IM, IA, or intra-lesional administration of corticosteroids is strongly 
discouraged within [ADDRESS_327536] administration of study agent and throughout the study.
Corticosteroid Use in 
Cutaneous Lupus 
SubstudyFor subjects in the cutaneous lupus substudy, initiation of medium to high potency 
topi[INVESTIGATOR_11930], or an increase from  baseline in the use of medium to high 
potency topi[INVESTIGATOR_11930] , or intra-lesional corticosteroid injections should be 
avoided through Week 48.
8.6 Topi[INVESTIGATOR_269231]; however, topi[INVESTIGATOR_269232] a 
prohibited medication. Topi[INVESTIGATOR_269241] A are prohibited ;
however ,ophthalmic use is permitted .
Rationale: Clarification of conditions under which Retesting of subjects for screening laboratory test(s) will 
bepermitted, and further definition of the SLEDAI -2K score as a composite endpoint and the SRI -4 response 
endpoint based on various efficacy meas ures.
[IP_ADDRESS]. Retesting If a subject has signed the ICF and failed to meet at least [ADDRESS_327537](s) analyzed by [CONTACT_269269], or a study entry 
procedure may be repeated once during the screening period if needed. A request to use a 
local test to replace acentral lab test should be discussed with the medical monitor 
prior to retesting.
Exce ptions to this are positive QuantiFERON® -TB Gold , hepatitis C or B, or HIV tests; 
unless there is a suspected error in sample collection or analysis perform ance, these 
tests m ay not be repeated to meet eligibility criteria.
Rationale: To incorporate the updated versions of the Attachments illustrating the SLEDAI -2Kand S2K RI-50
scoring assessments ; define values to be used in the assessment of the composite endpoint, SRI-4.
[IP_ADDRESS]. SLEDAI -2K 
and S2K RI -50At screening (Attachment 5), features are scored by [CONTACT_269270] 30 days with more severe features having higher scores, and then simply 
added to determ ine the total SLEDAI -2K score, which ranges from 0 to 105.31At baseline 
(Attachm ent 6), the features assessed in the SLEDAI -2K are used for comparison to the 
S2K RI -50 index described below .
The SLEDAI -2K has been adapted and developed into the SLEDAI -2K Responder Index 
(S2K RI-50 [Follow -up], Attachm ent 7)33, a measure that can document partial 
improvement in the 24 disease features betw een SLEDAI -2K assessments.32
[IP_ADDRESS]. SRI-[ADDRESS_327538] a 4 point reduction in SLEDAI 2Kscore 
(Section [IP_ADDRESS]) , no worsening (˂10 mm increase) from baseline in the Physician’s 
Global Assessment of Disease Activity score (PGA) (Section [IP_ADDRESS]), and no new 
BILAG Domain A and no morethan 1 new BILAG Dom ain B scores (Section 
[IP_ADDRESS]) .9SRI-5 and SRI-6 are similarly defined with response requiring a ≥5 point 
reduction or ≥6 point reduction in SLEDAI 2K, respectively.
Rationale: Clarification of how and when photographs and biopsy samples should be collected for exploratory 
assessments and maintenance of subject confidentiality.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
23
Approved, 18 January 2017Applicable Section(s) Description of Change(s)
9.7 Cutaneous Lupus 
SubstudyIndependent of cutaneous biopsy collection, subjects who participate in the cutaneous 
lupus substudy will be requested to provide consent for photographs to be collected from 
an identified cutaneous lesion or an area of active disease. Consenting subjects with 
cutaneous lupus unsuitable for biopsy (eg, malar rash or alopecia) may be evaluated by 
[CONTACT_249985]. The photographs are for exploratory purposes only. The photographs will be 
used to assist in a qualitative evaluation of clinical response. The photographs and skin 
biopsies can target a different area of active disease , but the follow- up photographs 
or biopsies should re-evaluate the same area of active disease as originally assessed at 
week 0.Confidentiality of the subjects involved in this study will be maintained; 
specifically photographs of subjects in this study will not be published or otherwise made 
public witho ut blocking adequate portions of the subject’s face or body so that the 
individual cannot be identified.
Rationale: Clarification on when study treatment should be withheld or perm anently discontinued depending on 
the type of infection a subject has developed and whether it resolves or not ; clarification on urinalysis for laboratory 
tests.  Urine a nalyses will be required for all subjects, not only subjects w ith a history of nephritis or if the primary
investigator suspects nephritis may be present.
9.[ADDRESS_327539] with a clinically important, active 
infection. Treatment with study agent should be withheld until serious and/or severe
infections are completely resolved. If a subject develops a serious or severe infection, 
including but not limited to sepsis or pneumonia, discontinuation of study treatment must 
be considered. Treatm ent must be permanently discontinued for subjects who d evelop 
an opportunistic infection. For active varicella -zoster infection or a significant exposure 
to varicella zoster infection in a subject without history of chickenpox, the subject should 
be evaluated for symptoms of infection and if the subject has received appropriate 
treatment and/or recovered or no symptoms of infection, may continue study 
administration after discussion w ith the study Sponsor.
Clinical Laboratory 
TestsThe investigator must review the laboratory report immediately upon availabilit y, 
document this review, and record any clinically relevant changes occurring during the 
study in the AE section of the eCRF. Coom b’s direct test, urine dipstick, urine sediment 
microscopy and urine pregnancy test will be performed by [CONTACT_269271].
Urine Analyses –Fresh spot urine
Urinalysis using urine dipstick. Urine sample will be further analyzed at   
Central laboratory.
Rationale: Clarification of specific criteria requiring permanent discontinuation of study treatment, as well as 
criteria whereby [CONTACT_269272] .  
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
24
Approved, 18 January 2017Applicable Section(s) Description of Change(s)
10.2. Discontinuation 
of Study Treatm ent
Criterion 3.
Criterion 4.
Criterion 9.
Concluding paragraph.A subject's study treatment must be permanently discontinued if any of the following 
occur:
3.Pregnancy or planning to becom e pregnant within the study period or within [ADDRESS_327540] study agent injection.
4. The initiation of prohibited medications or treatm ents (as per Sections 4.3).
9.Significant worsening of SLE disease activity from  baseline or having high disease 
activity for 2 or more consecutive visits starting at Week 16 based on overall 
clinical assessments; or if a subject requires the addition of a new 
immunom odulator to the ex isting treatm ent regimen after Week 16.
In addition, permanent discontinuation of study agent treatm entmust be considered
for subjects who: 
•  Receive an increase (relative to baseline) in their immunom odulator dose.
•Develop any of the following adverse events that arereported as serious or 
severe: study agent infusion reaction, injection -site reaction, or infection.
Rationale: Clarification of the statistical procedures to be used for sample size determination, interim and planned 
data analyses of the prim ary and m ajor secondary endpoints, and other efficacy analyses during the study.
11.2.Sample Size 
Determ inationThe sample size calculation is based upon the primary endpoint, proportion of SRI-4 
responders at Week 24. Approximately 60 subjects treated with ustekinumab and 
approximately 40 subjects with placebo is projected to give approximately 80% power to 
detect a significant difference in response rate compared with placebo (assume 35% and 
60% response rates in placebo and ustekinuma b respectively, which translates to 25% 
absolute increase over placebo or an odds ratio of 2.79) with an alpha level of 0.1. The 
assumption of a 35% responder rate for placebo is based upon a previous study  in which a 
similar SLE population was treated.34Recent studies have shown very high placebo 
rates in certain regions, thus it is possible that the power for the study could be 
reduced depending on enrollm ent and patient assessments conducted in specific 
regions .[ADDRESS_327541] ics will be presented. Details will be outlined in the SAP.
11.3.2. Major 
Secondary Analyses• The proportion of subjects with BICLA response at Week 24.
The BICLA response will be analyzed as defined in the SAP.
Continuous responses will be analyzed using an analysis of covariance model with 
treatment group as a fixed factor and baseline stratifications (eg, regions) as a covariate.
11.3.3. Other 
Planned Efficacy 
AnalysesContinuous responses will be analyzed using an analysis of covariance model with 
treatment group as a fixed factor and baseline stratifications ( eg, regions ) as a covariate.
11.4. Interim  
AnalysesInterim analyses (IA) will be conducted when approximately 1/3 and 2/[ADDRESS_327542] across regions will be incorporated into the interim 
analyses .Details concerning the IAs are described in the IA Statistical Analysis Plan.
Rationale: Clarification and inclusion of the revised definition of the SRI -4as a com posite endpoint based on 
other key efficacy measures.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
25
Approved, 18 January 2017Applicable Section(s) Description of Change(s)
ATTACHMENT 1 : 
EFFICACY 
EVALUATIONS
AND ENDPOINTS
SRI-4Com posite endpoint requiring at least a 4 point reduction in SLEDAI 2K, no worsening 
(˂10 mm increase) from baseline in PGA and no new BILAG Domain A or B scores.
Composite endpoint requiring at least a 4 point reduction in SLEDAI 2K, no 
worsening (˂10 mm increase) from  baseline in PGA and no new BILAG Domain A 
and no m ore than 1 new BILAG Domain B scores (see Section [IP_ADDRESS].).
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
26
Approved, 18 January 2017Amendment INT -1(19May 2015 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union
The overall reason for the amendment: The overall reason for the amendment is to clarify the use of highly 
effective methods of contraception for subject inclusio n and continuation in the study, and correct ion of minor 
errors and omissions.
Applicable Section(s) Description of Change(s)
Rationale: Clarification of highly effective method of contraception
4.1.1. Inclusion 
Criterion #10 .Of childbearing potential and practicing a highly effective method of birth control 
consistent with local regulations regarding the use of birth control methods for subjects 
participating in clinical studies: eg, established use of oral, injected or implanted hormonal 
methods of contraception associated with inhibition of ovulation ; placement of an 
intrauterine device  or intrauterine system; barrier methods: condom with spermicidal 
foam/gel/film/crea m/suppository or occlusive cap (diaphragm or cervical/vault caps) with 
spermicidal foam/gel/film/cream/suppository; male partner sterilization (the vasectomized 
partner should be the sole partner for that subject); true abstinence (when this is in line 
with the preferred and usual lifestyle of the subject).  
Rationale: Clarification of highly effective method of contraception .Two methods of pregnancy prevention arenot 
required for w omen using hormonal methods of birth control.
4.3.Prohibitions and 
Restrictions , #1.If a w oman is capable of pregnancy, she must remain on a highly effective method of birth 
control during the study and for [ADDRESS_327543] or her male partner is sterilized; 
this situation does not require birth control. A woman must not donate eggs (ova, oocytes) 
for the purposes of assisted reproduction during the study and for [ADDRESS_327544] dose of study agent.
Rationale: An additional exclusion criterion was added
4.2. Exclusion 
Criterion ,#27.Subject has a history of m alignancy within 5 years before screening (exceptions are 
squamous and basal cell carcinom as of the skin that has been treated with no 
evidence of recurrence for at least [ADDRESS_327545] study agent 
administration and carcinoma in situ of the cervix that has been surgically cured).
Rationale: An additional exclusion cri terion was added .
4.2. Exclusion 
Criterion, #[ADDRESS_327546] or authority order .
Rationale: Changed number of categories for region to ‘approximately 4’ .
5.1. Procedures for 
Randomization .Dynamic central randomization targets to balance the distribution of subjects to achieve 
the randomization ratio (3:2) at the study level and w ithin the levels of each individual 
stratification factor: skin biopsy (y/n, when n<16 for y), presence of lupus nephritis (y/n), 
baseline SLE medications and SLEDAI -2K score (combined factor)*, site, region 
(approximately 34categories), and race (3 categories).
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
27
Approved, 18 January 2017Applicable Section(s) Description of Change(s)
Rationale: Changed ‘should’ to ‘must’ .
10.2. Discontinuation 
of Study Treatment .A subject's study treatment should must be perm anently discontinued if any of the 
following occur:
Rationale: Minor errors w ere noted
Throughout the 
protocolMinor grammatical, formatting, or spelling corrections were made.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
28
Approved, 18 January 2017SYNOPSIS
A Multicenter, Randomized, Double -blind, Placebo -controlled, Proof -of-Concept Study of 
Ustekinumab in Subjects with Active Systemic Lupus Erythematosus
STELARA®(ustekinumab) is a fully human G1 kappa monoclonal antibody thatbinds with high affinity  
and specificity to the shared p40 subunit of human interleukin (IL)-12 and IL-23 cytokines. The binding 
of ustekinumab t o the I L-12/23p40 subunit blocks the binding of IL -12 or I L-23 to the I L-12R 1 receptor 
on the surface of natural killer and CD4+T cells, inhibiting IL-12- and IL-23-specific intracellular 
signaling and subsequent activation and cytokine production. Abnormal regulation of IL -12 and IL -23 has 
been associated with multiple immune -mediated diseases including Systemic Lupus Erythematosus 
(SLE) . Therefore, inhibition of IL -12 and IL -23 has the potential to be effective in the treatment of SLE.
OBJECTIVE AND HYPOTHESIS
Primary Objective
The primary objective is to evaluate the efficacy of ustekinumab as measured by a reduction in disease 
activity for subjects with activ e SLE.
Secondary Objectives
The secondary objectives are to evaluate:
 The safety and toler ability of ustekinumab in subjects with SLE.
 The effect of ustekinumab administration on health -related quality of life in subjects with SLE.
 The effects of ustekinumab on cutaneous manifestations of SLE.
 Pharmacokinetics and immunogenicity of ustekinumab in subjects with SLE.
Exploratory Objective
The exploratory objectives are to evaluate:
 Safety and efficacy during long -term administration of ustekinumab.
 Reduction in corticosteroid dosing during long -term administration of ustekinumab.
 Additional composite clinical endpoints or methods of calculation of clinical response with potential 
for greater sensitivity to improvement and/or worsening of SLE.
 Biomarkers related to lupus disease (genetic, systemic, and skin -related).
Hypothesis
The hypothesis is that dosing with ustekinumab is significantly superior to placebo as measured by [CONTACT_269273] 2000 (SLEDAI -2K) Responder Index (SRI -4) 
composite measure at Week 24.
OVERVIEW OF STUDY DESIGN
CNTO1275SLE2001 is aPhase 2a, proof -of-concept, multicenter, randomized, double -blind, placebo -
controlled study of the efficacy and safety of ustekinumab added to standard of care background in 
subjects with active SLE. Subjects to be enrolled must have SLE according to Systemic Lupus 
International Collaborating Clinics ( SLICC )criteria and Systemic Lupus Erythematosus Disease Activity 
Index 2000 ( SLEDAI -2K) score ≥6, despi[INVESTIGATOR_88913] (eg, immunomodulators, antimalarial 
drugs, corticosteroids, nonsteroidal anti-inflammatory drugs , anti-hypertensive drugs , and/or topi[INVESTIGATOR_269242]0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
28
Approved, 18 January 2017medications). In addition, subjects must have at least [ADDRESS_327547] (antinuclear antibodies 
[ANA], anti-double stranded deoxyribonucleic acid (anti-dsDNA )antibodies, and/or anti-Smith 
antibodies) observed during screening, as well as a well- documented positive autoantibody test in medical 
history . Subjects must also demonstrate at least 1British Isles Lupus Assessment Group (BILAG )A 
and/or [ADDRESS_327548] a clinical 
SLEDAI -2K score ≥4 (excluding laboratory results ) at week 0 , prior to randomization .
Approximately 100 subjects will be randomly assigned in a 3:2ratio to receive either ustekinumab or 
placebo through Week 24. Following randomization at Week 0, subjects will receive an initial body 
weight -range based IV dose approximating 6 mg/kg of ustekinumab (ustekinumab 260 mg [weight 
≥35kg to ≤55 kg]; ustekinumab 390 mg [weight >55 kg and ≤85 kg]; ustekinumab 520 mg [weight 
>85kg]) followed by 90mgSC administered every 8 weeks ( q8w).
At Week 24, subjects receiving placebo will cross -over and all subjects will receive ustekinumab 90 mg 
SC at Weeks 24, 32, and 40 followed by [CONTACT_211697] -up through Week 56 in a blinded fashion for 
16weeks (ie, approximately 5 half -lives) after last study agent SC administration. 
A placebo comparator (added to standard of care background therapy) will be used through Week [ADDRESS_327549] be recorded through out the study. 
All subjects with cutaneous disease will beevaluated using Cutaneous Lupus Erythematosus Disease 
Areaand Severity Index (CLASI )scoring. Additionally ,subjects with cutaneous disease who consent to 
participate in the cutaneous lupus substudy will have other assessments including collection of skin 
biopsies (optional consent) and/or photographs of a cutaneous lesion or area of active disease (optional 
consent). There will not be any restrictions on the number of subjects with cutaneous disease who can 
enroll into either the main study or the cuta neous lupus substudy. 
Interim analyses (IA) will be conducted when approximately 1/3 and 2/[ADDRESS_327550] IA, only an assessment of notable efficacy will be performed . In the second IA, evidence for 
notable efficacy as well as treatment futility will be analyzed. Database locks (DBLs) will occur at Weeks 
[ADDRESS_327551]’s Week [ADDRESS_327552]’s Week 16 safety follow -up visit 
from the main study . In addition, an independent data monitoring committee (DMC) will review interim 
safety data periodically including a formal review when approximately 1/3 and 2/3 of subjects reach 
Week 24, as well as at the Week 24 D BL. The DMC will make a recommendation to the Sponsor 
committee whether the study should be stopped for futility or for safety concerns or if data meet 
prespecified criteria demonstrating notable efficacy. The content of the summaries, the DMC role and 
responsibilities, and the general procedures (including communications) will be defined in the DMC 
charter.
The amended study design will continue to provide open -label ustekinumab 90 mg q8w SC 
administration through Week 104. Subjects will be eligible to continue study treatment through Week 104 
if they meet the study inclusion criteria (Section 4.1.3 ) including:
 must not have permanently discontinued stud y treatment on or before their W eek 40 vis it,and
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
28
Approved, 18 January 2017 are able to continue q8 week study treatment at approximately 8 weeks (±2 weeks ) after their 
Week 40 visit
or
 are able to resume study treatment with no more than 16 weeks (±2 weeks ) since their Week [ADDRESS_327553]’s Week [ADDRESS_327554]’s W eek 16 
safety follow -up visit from the main study, there will be an additional DBL at the end of the study 
extension (following Study Extension 16- week safety follow -up visit) .
SUBJECT POPULAT ION
Screening for eligible subjects must be performed no more than 6 weeks prior to the randomization visit 
(Week 0). The target study population is subjects with SLE according to SLICC criteria and SLEDAI -2K
score ≥6, despi[INVESTIGATOR_88913] (eg, immunomodulators, antimalarial drugs, corticosteroids,
nonsteroidal anti-inflammatory drugs , anti-hypertensive drugs, and/or topi[INVESTIGATOR_5910]). In addition, 
subjects must have at least [ADDRESS_327555] (ANA, anti-dsDNA antibodies, and/or anti-Smith 
antibodies) observed during screening, as well as a well- documented positive autoantibody test in medical 
history . Subjects must also have at least 1BILAG A and/or [ADDRESS_327556] a clinical SLEDAI -2K score 4 
(exclud ing laboratory results) for clinical features at Week 0(prior to randomization) and have received 
approval for study randomization following review and adjudication of screening lupus assessments by 
[CONTACT_1052]/or Sponsor -selected independent reviewer(s).
SLE subjects enrolling into the main study with active cutaneous lupus (including subjects with discoid 
lupus erythematosus , subacut e cutaneous lupus erythematosus , alopecia or SLE malar rash or other SLE 
skin lesions characterized by [CONTACT_269266]) will be evaluated using CLASI scoring. In addition, 
subjects who provide consent will be enrolled in the cutaneous lupus substudy evaluating the histology of 
cutaneous biopsies and/or skin photographs .Subjects participating in the cutaneous lupus substudy are 
not required to undergo biopsies, and may allow only photographs to document changes in an identified 
lesion or area of active disease.
DOSAGE AND ADMINISTRATION
All subjects will receive a body weight range -based IV administration of study agent (placebo or 
ustekinumab) at Week 0and then SC administration of placebo or ustekinumab at Weeks 8and 16, 
followed by [CONTACT_269274] 24, 32, and 40.Every reasonable effort 
should be m ade to keep concomitant medications stable at least through Week 28, with some adjustments 
allowe d beyond Week [ADDRESS_327557]’s 
medical record. If concomitant medications have been adjusted after randomization as allowed per 
protocol, every effor t should be made to return subject back to the baseline (Week 0) dose level by [CONTACT_269275] 12 visit ; or increased medication use may render a subject to be considered a treatment failure.
Subjects who are enrolled in the study extension will continue to recei ve ustekinumab 90 mg SC 
administration every 8 weeks through Week 104. With the exception of corticosteroids, concomitant 
medications should be maintained at stable doses through the study extension.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
28
Approved, 18 January 2017Week 0 up to Week 24 (Blinded Study Agent Administration Phase)
Group 1: Subjects will receive weight -range based IV dosing of approximately 6 mg/kg of ustekinumab at 
Week 0 followed by [CONTACT_269276] 90 mg SC administrations at Weeks 8 and 16. 
Group 2: Subjects will receive weight-range based IV dosing of placebo at Week 0 followed by [CONTACT_269277] 8 and 16.
Week 24 to Week 40 (Cross -over Administration Phase)
Group 1: Subjects will receive anustekinumab 90 mg SC administration at Week 24 followed by q8w 
administrations through Week 40. 
Group 2: Subjects in the placebo dosing group will cross -over to ustekinumab 90 mg SC administrations 
at Week 24 followed by q8w administrations through Week 40.
After Week 40 to 16- Week Safety Follow -Up (Safety Follow -up Phase)
Groups 1 and 2: Subjects who do not participate in the study extension are expected to return for safety 
follow-up visits at Week 44 and for 8- and 16- weeks safety follow up.
Study Extension (Week 48 /Week 56 through Week 120)
Subjects who meet the study extension inclusion criteria (Section 4.1.3) will receive an 
additional 1 year of open label ustekinumab administration for the purpose of expanding the 
safet y experience and maintenance of efficacy  in lupus patients exposed to ustekinumab 90 mg 
q8w. Subjects who continue dosing in the extended study starting at Week 48 or at Week 56 will 
receive open -label ustekinumab SC dosing through Week 104. If the development of 
ustekinumab in SL E is terminated, then the study  extension will also be discontinued.
EFFICAC Y EVALUATIONS
The primary efficacy endpoint of this study is to compare the proportion of subjects with a composite 
SRI-4 response at Week 24 for subjects receiving ustekinumab as compared to placebo treatment.
Efficacy evaluations and patient reported quality of life measures include:
 SLEDAI -2K
 S2K RI-50
 BILAG
 CLASI
 Physician’s Global Assessment of Disease Activity
 Patient’s Global Assessment of Disease Activity
 Short -form 36 questionnaire
 Fatigue Severity Scale
 Patient’s Assessment of Pain
PHARMACOKINETIC AND IMMUNOGENICITY EVALUATIONS
Serum samples will be used to evaluate the pharmacokinetics of ustekinumab, as well as the 
immunogenicity of ustekinum ab (antibodies to ustekinumab).
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
28
Approved, 18 January 2017 EVALUATIONS AND SEROLOGIC MARKERS
The collection, preparation, storage and shipment of skin biopsies, blood, serum and urine are detailed in 
the Laboratory Manual. Biomarkers may include, but are not limited to, inflammatory markers, 
ribonucleic acid (RNA), cell surface markers, autoantibo dies, T cell and B cellrepertoire, target specific 
markers, and other categories of biomarkers potentially involved in the development and the progression 
of lupus.
Serum Analyses
Serum will be analyzed for levels of specific proteins  
 
 
Skin Biopsy Analys es
Skin biopsies will be utilized for cellular, molecular, and gene expression analyses.
Whole Blood Gene Expression Analyses
Whole blood will be collected from all subjects for RNA, flow cytometry, T cell and B cell repertoire and 
epi[INVESTIGATOR_269243] (eg , deoxyribonucleic acid [ DNA] methylation).
Serologic Markers
Autoantibodies ( eg, ANA, anti -dsDNA , etc.), complement C3 and C4 will be collected as described in the 
Table of Events ( Table 1).
PHARMACOGENOMIC (DNA) EVALUATIONS
DNA samples will be used for research related to this study (CNTO1275SLE2001). Specific genomic 
testing will be undertaken for consenting subjects (subjects participating in this portion of the study must 
sign a separate informed consent form . The procedure will involve taking a blood sample that may be 
analyzed for specific target genes that may play a role in lupus. Any genomic assessments will be 
performed in strict adherence to current subject confidentiality standards for genetic testing. Refusal to 
participate in genomics testing will not result in ineligibility for participation in the rest of the clinical 
study.
CUTANEOUS L UPUS SUBSTUDY
All subjects with cutaneous disease will be evaluated using CLASI scoring. Additionally subjects with 
cutaneous disease who consent to participate in the cutaneous lupus substudy will have other assessments 
including collection of skin biopsi es (optional consent) and/or photographs of an identified cutaneous 
lesion or area of active disease (optional consent). There will not be any restrictions on the number of 
subjects with cutaneous disease who can enroll into either the main study or the cutaneous lupus 
substudy. 
Subjects who provide consent will be enrolled in the cutaneous lupus substudy evaluating the histology of 
cutaneous biopsies and/or skin photographs. Biopsy samples (2samples, 4 mm size) from consenting 
subjects will be collected prior to dosing at Week 0 and at Week 24 from a single lesion or area of activ e 
cutaneous disease. Photographs and skin biopsies can target a different area of active disease , but the 
follow -up photographs or biopsies should re-evaluate the same area of active disease as originally 
assessed at week 0. Subjects participating in the cutaneous lupus substudy are not required to undergo 
biopsies, and may allow only photographs to document changes in an identified lesion or area of active 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
28
Approved, 18 January 2017disease. Subjects with cutaneous lupus deemed unsuitable for biopsy (eg, malar rash or alopecia) can also 
be enrolled in the substudy, and may be evaluated by [CONTACT_249985].
Independent of cutaneous biopsy collection, subjects who participate in the cutaneous lupus substudy will 
be requested to provide consent for photographs to be collected from an identified lesion or area of active 
disease . The photographs are for exploratory purposes only. The photographs will be used to assist in a 
qualitative evaluation of clinical response. Confidentiality of the subjects involved in this study will be 
maintained; specifically photographs of subjects inthis study will not be published or otherwise made 
public without blocking adequate portions of the subject’s face or body so that the individual cannot be 
identified. 
SAFETY EVALUATIONS
Safety assessments include vital signs, general physical exam and skin evaluations, adverse events (AE) , 
serious AEs, concomitant medication review, pregnancy testing, infusion reactions, chemistry and 
hematology laboratory tests, and antibodies to ustekinumab . Chest x-ray and tuberculosis , human 
immunodeficiency virus , hepatitis B, and hepatitis C testing will be required at time of screening. Any 
clinically significant abnormalities persisting at the end of the study will be followed by [CONTACT_269278] a clinically stable endpoint is reached. Subject diary cards will be used to capture 
medication changes that occur in between study visits during the main portion of this study . Safety data 
collected up to 16 weeks after the final administration of study agent will be evaluated.
STATISTICAL METHO DS
Sample Size Determination
Approximately 100 subjects will be randomly assigned in a 3:2 ratio to receive either ustekinumab or 
placebo through Week 24.Approximately sixty subjects treated with ustekinumab and approximately 
40subjects with placebo is projected to give approximately 80% power to detect a significant difference 
in response rate compared with placebo (assume 35% and 60% response rates in placebo and 
ustekinumab respectively, which translates to 25% absolute increase over placebo or an odds ratio of 
2.79) with an alpha level of 0.1.
Efficacy Analyses
The primary endpoint of this study is the proportion of subjects with a composite measure of SLE disease 
activity (SLE Responder Index [SRI] -4 response) at Week 24. The primary analysis will be based upon 
the primary endpoint and will be conducted on the modified intent -to-treat (mITT) population, which 
includes all randomized subjects who receive at least 1dose of study agent, have at least [ADDRESS_327558] (LOCF) procedure will be used to im pute the missing SRI-[ADDRESS_327559] achieved the SRI -4 response .
In addition, subjects who meet any of a variety of treatment failure criteria, such as receiving a dose of 
immunomodulator that is higher at Week 24 than at baseline, or initiated prohibited treatment (dose or
timing) with corticosteroids, or discontinue d study agent due to a lack of efficacy will be considered to 
have not achieved the primary endpoint, SRI -4 response at Week 24.
Logistic regression, adjusting for baseline stratifications and baseline SLEDAI, will be used to analyze 
the primary endpoint. The baseline SLEDAI value is defined as the closes tnon-missing measurement 
taken prior to the Week 0 infusion. If significant non-norm ality is observed, appropriate nonparametric
tests will be used to evaluate the differences between treatments.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
28
Approved, 18 January 2017The study will be considered positive if the primary analysis achieves statistical significance at a 
significance level of 0.1 (2-sided) and ustekinumab shows a positive treatment effect relative to placebo 
treatment.
Safety Analyses
Safety will be assessed by [CONTACT_269279], SAEs, reasonably related AEs, 
infections, and infusion reactions.  Safety assessments will also include analyses of laboratory parameters 
and change from baseline in laboratory parameters (hematology and chemistry) and incidence of 
abnormal laboratory parameters (hematology and chemistry).
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
35
Approved, 18 January 2017TIME A ND EVENTS SCHE DULE
Table 1: Time and Events Schedule for the Main Study Design (Screening through 8-Week/16 -Week Safety Follow -up)
Blinded Study Agent Administration PhaseCross -over Administration 
PhaseSafety Follow -up
Week Screen inga0 4 8 12 16 20 24 28 32 36 40 448-Week 
Safety 
Follow -
upb16-
Week 
Safety 
Follow
-up/
Final 
visitb
Study Proceduresc
Screening/Administrative
Informed consent X
Inclusion/exclusion criteria X Xa
Medical history and demographics X
SLE classification by [CONTACT_269280] X
Study Dr ug Administration
Randomi zation X
Study agent administration XdX X X X X
Diary card
Train on diary card and distribute X
Collect , review and distribute diary cards X X X X X X X X X X X X X X
Safety Assessments
Physical examination X X X X
HIV, HBV, and HCV X
QuantiFERON®-TB Gold test X
Tuberculin skin testeX
TB evaluationfX X X X X X X X X
Serum pregnancy testgX
Urine pregnancy testhX X X X X X X X
Vital signs X X X X X X X X X X X X X X X
Height X
Weight X X X
Chest x -rayiX
Concomitant therapy X X X X X X X X X X X X X X X
Adverse Events X X X X X X X X X X X X X X X
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
36
Approved, 18 January 2017Table 1: Time and Events Schedule for the Main Study Design (Screening through 8-Week/16 -Week Safety Follow -up)
Blinded Study Agent Administration PhaseCross -over Administration 
PhaseSafety Follow -up
Week Screen inga0 4 8 12 16 20 24 28 32 36 40 448-Week 
Safety 
Follow -
upb16-
Week 
Safety 
Follow
-up/
Final 
visitb
Study Proceduresc
Infusion or injection -site reaction 
  evaluationj X X X X X X
Cutaneous Lupus Substudy Assessmentsk
Skin biopsywX X
Photograph lesion orarea of active diseasexX X X X X X
Efficacy Assessmentsl
SLEDAI -2K(S2K RI -50 -Baseline) X Xm
S2K RI -50(Follow -up) X X X X X X X X X X X X X
CLASInX X X X X X X X X X X X X X
BILAG X X X X X X X X X X X X X X X
Physician’s Global Assessment of Disease
  ActivityX X X X X X X X X X X X X X X
Patient’s Global Assessment s (Pain and 
  Disease Activity )X X X X X X X X X X X X X X
SF-[ADDRESS_327560] testp,qX X X X X X X X X X X X X X X
Coagulation Labs X X X X X X X X X X X X X X X
Chemistry X X X X X X X X X X X X X X X
Anti-dsDNA X X X X X X X X X X X X X X X
Other autoantibodiesrX X X X
Anti-phospholipid antibodiespX X X X
Ig isotype profile X X X
Urine Analyses (spot urine)
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
37
Approved, 18 January 2017Table 1: Time and Events Schedule for the Main Study Design (Screening through 8-Week/16 -Week Safety Follow -up)
Blinded Study Agent Administration PhaseCross -over Administration 
PhaseSafety Follow -up
Week Screen inga0 4 8 12 16 20 24 28 32 36 40 448-Week 
Safety 
Follow -
upb16-
Week 
Safety 
Follow
-up/
Final 
visitb
Study Proceduresc
Urinalysis (dipstick , all study subjects )qX X X X X X X X X X X X X X X
Urine sample for biomarkers (all subjects) X X X X X X X X X X
Protein/Creatinine ratiosX X X X X X X X X X X X X X X
Micr oscopy of urine sedimentqX X X X X X X X X X X X X X X
Pharm acokinetics/Immunogenicity
Serum ustekinumab concentrationss,t2XvX X X X X X X X X X
Antibodies to study agents,tX X X X X X X X
Pharm acogenomics (DNA)u
Whol e blood DNA X
Biomarkers
Serum sample X X X X X X X X X X X
Whole blood for RNA gene expression X X X X X X X X X
T cell and B cell repertoire X X X X
Epi[INVESTIGATOR_7009] X X X X
Flow  cytom etryvX X X X
a.Screening visit must be performed no more than 6 weeks prior to the randomization visit (Week 0). To be eligible for study participation, subjects must have SLEDAI 
score 4 (excluding laboratory results) forclinical features at W eek [ADDRESS_327561] received a pproval for study randomization following review and adjudication of 
screening lupus assessments by [CONTACT_1052]/or Sponsor -selected independent reviewer(s).
b.Subjects, who discontinue study agent administrations on or before the Week [ADDRESS_327562] study agent administration for 
safety follow -up visits. The 8 -week and/or 16 -week safety follow -up visits are not required for subjects who continue treatment in the study extension w ithin 8 (±2 
weeks) or 16 (±2 w eeks) weeks, respectively, of their Week 40 visit (refer to Table 2).
c.All assessments (except for injection -site evaluation) are to be completed prior to study agent administration, unless otherwise specified.
d.Intravenous administration of study agent at Week 0, all other doses w ill be SC.
e. Only required if QuantiFERON®-TBis not registered/approved locally or the tuberculin skin test (TST) is mandated by [CONTACT_72952].
f.If TB is suspected at any time during the study, a chest x -ray (local), and QuantiFERON®-TB Gold test should be performed. A TST is additionally required if the 
QuantiFERON®-TB Gol d test is not registered/approved locally or the TST is mandated by [CONTACT_72952].
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
38
Approved, 18 January 2017Table 1: Time and Events Schedule for the Main Study Design (Screening through 8-Week/16 -Week Safety Follow -up)
Blinded Study Agent Administration PhaseCross -over Administration 
PhaseSafety Follow -up
Week Screen inga0 4 8 12 16 20 24 28 32 36 40 448-Week 
Safety 
Follow -
upb16-
Week 
Safety 
Follow
-up/
Final 
visitb
Study Proceduresc
g.In addition to the screening evaluation, the pregnancy test may be repeated at any time at the discretion of investigator or subject.
h.May conduct urine pregnancy test more frequently (eg, monthly basis) if required by [CONTACT_427].
i.Posterior/anterior and lateral views must be taken within [ADDRESS_327563] administration of study agent for TB de tection.
j.Subjects should be monitored for the occurrence of infusion or injection -site reactions for 30 minutes after the infusion (IV administration) or injection.
k.Only for subjects who consented to participate in the cutaneous lupus substudy for biopsy and/or photograph collection.
l.All visit -specific patient reported outcome assessments should be conducted before any tests, procedures, or other consultations for that visit to preve nt influencing 
subjects’ perceptions.
m.Com plete SLEDAI -2K (Baseline) will be evaluated during screening and at Week 0, although at W eek 0 only the clinical (non -laboratory) features will be considered to 
confirm eligibility for study enrollment. The photographs and skin biopsies can target a different location of active disease , but the follow -up photographs or biopsies 
should re -evaluate the same area of active disease as originally assessed at week 0.
n.CLASI scoring will be obtained for all enrolled subjects w ith cutaneous lupus regardless of enrollment in the cutaneous lupus substudy.
o.Also perform B cell analyses at screening for sub jects previously exposed to B cell depleting therapi[INVESTIGATOR_014].
p.If abnormal test result is not obtained at screening or at Week 0, no additional follow -up testing is required. How ever, additional testing may be performed if needed.
q.These tests will be performed on -site or at local lab(s). 
r.Anti-dsDNA should be analyzed at every specified visit.  If the other autoantibody tests are negative at both the screening and We ek [ADDRESS_327564] be collected BEFORE the administration of the 
study agent.
t.At Week 0 visit, 2 separate samples for serum ustekinumab concentrations (indicated by “2X” in the Schedule above) will be collected (1 sample will be collected prior 
to IV infusion and the other collected 1 hour after the end of the infusion) for all subjects.
u.Only for subjects who consent to allow genomic analyses.
v.Flow  cytom etry samples will be analyzed from subjects at selected sites.
w.Biopsies are allow ed to occur 1 -2 days prior to randomization and at the Week 24 visit.
x.Photographs do not need to be taken at the same area of active disease as the biopsy; ho wever, follow -up photographs or biopsies should re -evaluate the same area of 
active disease as originally assessed at week 0.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
39
Approved, 18 January 2017Table 2: Time and Eve nts Schedule in the CNTO1275SLE2001 Study Extension (Week 48/56 through Extension Safety 
Follow -up)
Study Extension Extension Safety Follow -upa
WeekWk 
48Wk 
56Wk 
64Wk 
72Wk 
80 Wk 
88Wk 
96Wk 
104Extension 8 -
Week Safety 
Follow -upExtension 
16-Week
Safety 
Follow -
up/Final 
Visit
Study Proceduresb
Screening/Administrative
Informed consentcX X
Study Drug Administration
Study agent administration XcXcX X X X X X
Safety Assessments
Physical examination X X X X X X
TB evaluationdX X X X X X X X X X
Urine pregnancy testeX X X X X X X X X X
Vital signs X X X X X X X X X X
Concomitant therapy X X X X X X X X X X
Adverse Events X X X X X X X X X X
Injection -site reaction evaluationfX X X X X X X X
Efficacy Assessmentsg
S2K RI -50 X X X X X
CLASIhX X X X X
BILAG X X X X X
Physician’s Global Assessment of 
Disease
  ActivityX X X X X
Patient’s Global Assessments (Pain and 
  Disease Activity)X X X X X
SF-[ADDRESS_327565] testj,k (as needed) X X X X X
Coagulation Labs (as needed)i, jX X X X X
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
40
Approved, 18 January 2017Table 2: Time and Eve nts Schedule in the CNTO1275SLE2001 Study Extension (Week 48/56 through Extension Safety 
Follow -up)
Study Extension Extension Safety Follow -upa
WeekWk 
48Wk 
56Wk 
64Wk 
72Wk 
80 Wk 
88Wk 
96Wk 
104Extension 8 -
Week Safety 
Follow -upExtension 
16-Week
Safety 
Follow -
up/Final 
Visit
Study Proceduresb
ChemistrykX X X X X X X X X X
Anti-dsDNA X X X X X X X X X X
Other autoantibodieslX XlX
Anti-phospholipid antibodiesjX X X
Ig isotype profile X X
Urine Analyses (spot urine)i
Urinalysis (dipstick, all study subjects)i, 
m X X X X X X X X X X
Urine sample for biomarkers (all 
subjects) X X X X X
Protein/Creatinine ratioiX X X X X X X X X X
Microscopy of urine sedimentk,mX X X X X X X X X X
Pharm acokinetics/Immunogenicity
Serum ustekinumab concentrationsnX X X X X
Antibodies to study agentnX X X X X
Biomarkers
Serum sample X X X X X
Whole blood for RNA gene expression X X X X X
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
41
Approved, 18 January 2017Table 2: Time and Eve nts Schedule in the CNTO1275SLE2001 Study Extension (Week 48/56 through Extension Safety 
Follow -up)
Study Extension Extension Safety Follow -upa
WeekWk 
48Wk 
56Wk 
64Wk 
72Wk 
80 Wk 
88Wk 
96Wk 
104Extension 8 -
Week Safety 
Follow -upExtension 
16-Week
Safety 
Follow -
up/Final 
Visit
Study Proceduresb
a.Subjects, who complete all scheduled doses or discontinue study agent administration before the end of the study extension , must 
return at approximately [ADDRESS_327566] study agent administration for safety follow -up visits.
b.All assessments (except for injection -site evaluation) are to be completed prior to study agent administration.
c.Prior to dosing in the study extension , subjects must sign a revised ICF indicating agreement to participate in the extended study. 
d.TB evaluation includes an assessment of recent exposure or risk of TB including new or chronic cough, fever, night sweats, 
unintentional weight loss or recent co ntact with someone with active TB. If TB is suspected at any time during the study, a chest 
x-ray (local), and QuantiFERON®-TB Gold test should be performed. A TST is additionally required if the QuantiFERON®-TB 
Gold test is not registered/approved locally or the TST is mandated by [CONTACT_72952].
e.In addition to scheduled urine dipstick testing, a serum or urine pregnancy test may be conducted at any time at the discreti on of 
investigator or subject, or if required by [CONTACT_427].
f.Subjects s hould be monitored for the occurrence of injection -site reactions for 30 minutes after the injection.
g.All visit -specific patient reported outcome assessments should be conducted before any tests, procedures, or other consultations 
for that visit to prevent influencing subjects’ perceptions.
h.CLASI scoring will be obtained for all enrolled subjects who have cutaneous lupus.
i. If clinical concerns or abnormal results from prior visit observed in these assessments, then strong consideration should be given 
to mo re frequent testing (at least q4 w eek assessments) until normalized
j.If history of abnormal test result was observed in main study, then follow scheduled assessments. Additional testing may be 
performed if needed.
k.These tests will be performed on -site or at local lab(s).
l. If the “other autoantibody” tests were routinely negative prior to Week 48, then those autoantibody tests need only be analyz ed 
annually. However, if the other autoantibodies tests were positive at either screening or Week 0, then they shou ld be analyzed 
every [ADDRESS_327567] be collected 
BEFORE the administration of the study agent.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
42
Approved, 18 January 2017ABBREVIA TIONS
ACE angiotensin -converting enzyme
AE adverse event
ANA antinuclear antibodies
ANCOVA analysis of covariance 
anti-dsDNA anti-double stranded deoxyribonucleic acid
anti-HBc total HBV core antibody total
anti-HBs HBV surface antibody
ARB angiotensin II receptor blocker
AZA /6 MP azathioprine/6 -mercaptopurine
BAFF B cell activating factor, also known as B lymphocyte stimulator (BLyS)
BCG Bacille Calmette -Guérin
-hCG -human chorionic gonadotropin
BICLA BILAG- based Combined Lupus Assessment
BILAG British Isles Lupus Assessment Group 
BLyS B lymphocyte stimulator, also known as B cell activating factor (BAFF)
CLASI Cutaneous Lupus Erythematosus Disease A reaand Severity Index 
CLE cutaneous lupus erythematosus
CNS central nervous system
COX -2 cyclooxygenase -2
CRF case report form 
CD Crohn’s disease
CTCAE Common Terminology Criteria for Adverse Events 
CXCL10 C-X- C motif chem okine [ADDRESS_327568]
GCP Good Clinical Practice 
HBsAg HBV surface antigen
HBV hepatitis B virus 
HCV hepatitis C virus
HIV human immunodeficiency virus 
IA interim analyses
ICF informed consent form
ICH International Conference on Harmonisation 
IEC Independent Ethics Committee
Ig Immunoglobulin
IL Interleukin
IM Intramuscular
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327569] 
IV Intravenous
IWRS interactive web response system 
JAK janus kinase
mITT modified intent -to-treat
MMF mycophenolate mofetil 
MPA mycophenolic acid 
MTX Methotrexate
NAbs neutralizing antibodies 
NSAIDs nonsteroidal anti -inflammatory drugs 
PFS prefilled syringe 
PGA Physician’s Global Assessment of Disease Activity 
PK Pharm acokinetic
PQC product quality complaint 
PRO s patient reported outcomes
PsA psoriatic arthritis
PtGA Patient’s Global Assessment of Disease Activity 
q8w every 8 weeks
RA rheumatoid arthritis
RNA ribonucleic acid
RNP Ribonucleoprotein
S2K RI -50 SLEDAI -2K Responder Index
SAE serious AE
SAP statistical analysis plan
SC Subcutaneous
SF Short -form 
SLE Systemic Lupus Erythematosus
SLEDAI Systemic Lupus Erythematosus Disease Activity Index
SLEDAI -2K Systemic Lupus Erythematosus Disease Activity Index 2000 
SLICC Systemic Lupus International Collaborating Clinics
SRI-4 SLE Responder Index
SSA anti-Sjögren’s -syndrome- related antigen A
SSB anti-Sjögren’s -syndrome- related antigen B
TB Tuberculosis
Th T helper
TNF tumor necrosis factor alpha
ULN upper limit of normal
VAS visual analogue scale 
WBC white blood cells 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
44
Approved, 18 January [ZIP_CODE]. INTRODUCTION
STEL ARA®(ustekinumab) is a fully  human G1 kappa monoclonal antibody  that binds with high 
affinity  and specificit y to the shared p40 subunit of human interleukin (IL)-12 and IL-23 
cytokines. The binding of ustekinumab to the IL -12/23p40 subunit blocks the binding of IL -12 or 
IL-23 to the IL-12R1 receptor on the surface of natural killer and CD4+T cells, inhibiting 
IL-12-and IL-23-specific intracellular signaling and subsequent activation and cytokine 
production. Abnormal regulation of IL-12 and IL-23 has been associated with multiple 
immune -mediated diseases including systemic lupus erythematosus (SLE). Therefore, inhibition 
of IL -[ADDRESS_327570] any organ system, and which follows a relapsing and remitting disease 
course. Systemic lupus erythematosus occurs much more often in women than in men, up to 
9times more frequently in some studies, and often appears during the child- bearing years 
between 15 and 45. This disease is more prevalent in Afro- Caribbean, Asian, or Hispanic 
populations. In SLE, the immune system attacks the body 's cells and tissue, resulting in 
inflammation and tissue damage which can harm the heart, joints, skin, lungs, blood vessels, 
liver, kidney s and nervous system. About half of the subjects diagnosed with SLE present with 
organ -threatening disease, but it can take several years to diagnose subjects who do not present 
with organ involvement. Some of the primary  complaints of newly  diagnosed lupus patients are 
arthralgia (62%) andcutaneous symptoms (new photosensitivity ; 20%), followed by [CONTACT_269281] .39The estimated annual incidence of lupus varies from 1.[ADDRESS_327571] mostly  skin rashes and joint pain and require little medication; 
regimens include nonsteroidal anti-inflammatory  drugs (NSAID s), anti-malarials 
(eg,hydroxychloroquine, chloroquine, or quinacrine) and/or low dose corticosteroids. With more 
severe disease patients may experience a variety  of serious conditions depending on the organ 
systems involved, including lupus nephritis with potential renal failure, endocarditis or 
myocarditis, pneumonitis, pregnancy  problems, stroke, neurolog ical complications, vasculitis 
and cytopenias with associated risks of bleeding or infection. Common treatments for more 
severe disease include immunomodulatory agents, such as methotrexate (MTX) , azathioprine, 
cyclophosphamide, cy closporine, high dose cor ticosteroids, biologic B cellcytotoxic agents or B 
cellmodulators, and other immunomodulators . Patients with serious SLE have a shortening of 
life expectancy  by [ADDRESS_327572] of care therap y. Thus there is a large unmet need for 
new alternative treatments that can provide significant benefit in this disease without incurring a 
high safet y risk.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327573] organ involvement, the presence of certain laboratory measures (such as 
anti-phospholipid antibodies), race, gender, age of consent, access to health care, adherence to 
treatment, education and other comorbidities. Only about 5% of patients who are diagnosed with 
SLE will demonstrate a spontaneous remission without treatment.  A variety of new therapeutic 
agents are being evaluated for the treatment of subjects with refractory  lupus, however to date 
very few have demonstrated notable clinical efficacy  beyond those medications currentl y 
considered standard of care for patients with this disease.  
In this study , the target population is subjects with SLE according to Systemic Lupus 
International Collaborating Clinics (SLICC) criteria and Systemic Lupus Erythematosus Disease 
Activity  Index (SLEDAI )11score ≥6, despi[INVESTIGATOR_88913] (eg, immunomodulators, 
antimalarial drugs, corticosteroids, NSAIDs, anti-hypertensive drugs, and/or topi[INVESTIGATOR_146934]). In addition, subjects must have at least 1positive autoantibody  test (antinuclear 
antibodie s [ANA], anti-double stranded deox yribonucleic acid [anti-dsDNA ] antibodies, and/or 
anti-Smith antibodies) observed during screening, as well as a well-documented positive
autoantibody  testin medical history . Subjects must also demonstrate at least 1British Isles 
Lupus Assessment Group (BILAG )38A and/or [ADDRESS_327574] a SLEDAI  score ≥4 at Week 0 (prior to randomization) for clinical 
features (excluding laboratory  results). This level of disease activity is consistent with prior 
studies that have investigated an experimental therapy for s ystemic lupus.[ADDRESS_327575] version of the Investigator's Brochure and Addenda for u stekinumab.
The term "Sponsor" used throughout this document refers to the entities listed in the Contact 
[CONTACT_23774](s), which will be provided as a separate document.
1.1. Background
To date, ustekinumab has received marketing approval globally , includin g countries in North 
America, Europe, South America, and the Asia-Pacific region, for the treatment of adult patients 
including those with chronic moderate to severe plaque psoriasis and/or active psoriatic arthritis. 
Ustekinumab is also being evaluated in a Phase 3 studies for Crohn’s disease (CD) .
1.2. Overall Rationale for the Study
1.2.1. Scientific Rationale for Use of A nti-IL-12/23p40 Therapy  in Sy stemic 
Lupus Ery thematosus
Systemic lupus erythematosus is a complex ,immune -mediated inflammatory  disorder exhibitin g 
dysregulated B lymphocy tes that produce destructive autoantibodies. B celltargeted therapi[INVESTIGATOR_014] 
(eg, belimumab) for SLE, however, have shown only modest clinical results beyond a limited 
standard of care control,22suggesting that additional immune pathway s play an important role in 
SLE pathogenesis. Chronic immune activation in SLE leads to the increased production of 
inflammatory  cytokines that contribute actively to local inflammation and to processes that 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327576] also reported an elevation of IL-12, IL-6, and IL-23 in both serum and tissues of 
patients,4,20,24,26,30,44suggesting that the inflammatory  environment in SLE is prone to induce 
Thelper ( Th)[ADDRESS_327577] been established in SLE to the IL-12/IL -23/Th17 pathway ,18,28,[ADDRESS_327578] identi ﬁed STAT4, which mediates IL-12 
signaling, as a susceptibility  gene in both the Caucasian and Asian populations.12,16  In patients 
with active SLE, messenger RNA levels of p19, p40, and p35 were significantl y higher 
compared with those in the inactive SL E patients.14Targeting IL -12/23p40 with ustekinumab has 
been shown in [ADDRESS_327579] s in SLE pathogenesis, warranting further clinical 
investigation of ustekin umab as an interventional therapy  in this disease.
In addition, 2disease -related groups, the Alliance for Lupus Research and Lupus Research 
Institute, independently commissioned a scientific review of a large set of commerciall y 
available lupus drug candi dates, from which ustekinumab was recommended to be evaluated in 
SLE based on its molecular mechanism , which further supports the scientific rationale for a 
placebo- controlled clinical study  to evaluate the efficacy  and safet y of ustekinumab in subjects 
with active SL E.
[IP_ADDRESS]. Subgroup of Subjects with A ctive Cutaneous Manifestations of 
Systemic Lupus Ery thematosus
The above mentioned case reports of patients with refractory  cutaneous lupus responding to 
ustekinumab treatment prompts a nevaluation of the effects o f ustekinumab on cutaneous lesions. 
Given the relatively  common occurrence of cutaneous manifestations in SLE, the feasibility  of 
repeated punch biopsy  and/or photographs of an identified lesion or area of active disease , and 
the availability  of cutaneous lupus erythematosus (CLE)-specific disease assessment tools, this 
patient population may provide useful data regarding the effects of ustekinumab on SLE and the 
symptoms of cutaneous disease. All subjects with cutaneous disease will be evaluated using 
CLASI scoring. Additionally  subjects with cutaneous disease who consent to participate in the 
cutaneous lupus substudy  will be requested to provide potential collection of skin biopsies 
(optional conse nt) and/or photographs of an identified lesion or area of active disease (optional 
consent). There are no pre-specified numbers of subjects to be enrolled with cutaneous disease 
for either the main study  or the cutaneous lupus substudy .
1.3. Justification for D osing Regimen
The dosing regimen for this study  was selected based on experience with the use of ustekinumab 
in the treatment of subjects with moderatel y to severel y active CD (C0743T26, 
CNTO1275CRD3001 , and CNTO1275CRD3002 ).Both CD and SLE are immune -mediated 
inflammatory  disease s,which are commonly treate d with immunomodulators ,such as 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
47
Approved, 18 January 2017methotrexate (MTX), azathioprine and corticoste roids ,and thus this indication serve sas a useful 
model for risk assessment of ustekinumab in lupus .Although the dosing rationale has not 
changed, additional safety  and efficacy  information has become available from the ustekinumab 
Phase 3 CD (UNITI) studies which supports amending the protocol to further extend treatment 
with ustekinumab 90 mg SC q8w for an additional year. These results from the UNITI CD
studies are summarized later in this section.
Although the dosing rationale has not changed, some additional safet y and efficacy  information 
has become available from the ustekinumab Phase 3 CD (UNIT I) studies which supports the 
treatment extension planned for this study . These results from the UNITI CD studies are 
summarized later in this section (Section 1.3).
In the Phase 2 bdose ranging study  C0743T26, a single IV ustekinumab dose of 6 mg/kg was the 
highest loading dose tested in subjects with CD. In this study , the 6 mg/kg IV dose was shown to 
be effective in inducing clinical response through Week [ADDRESS_327580] that an IV loading dose may provide a rapid onset of clinical response 
following IL-12 and IL-23 inhibition. In the Phase 3 studiesCNTO1275CRD3001 and 
CNTO1275CRD3002 , body  weight -range dosing approach (ustekinumab 260mg [weight 
≤55 kg] ; ustekinumab 390 mg [weight >55 kg and ≤85kg]; ustekinumab 520mg [weight 
>85kg]) was used to approximate the IV loading dose of 6 mg/kg. The body  weight -range based 
dosing allows administration of complete vials to patients to simplify dose calculation and 
reduce the potential for errors in dosing. This weight range dosing is intended to achieve drug 
exposure similar to that observed with 6 mg/kg weight -adjusted dosing . Thus, in this study , a 
strategy  of IV loading dose based on body  weight range at Week 0 will be evaluated to assess the 
ability  of the drug to rapi[INVESTIGATOR_269244].
The ustekinumab maintenance dosing regimen of 90 mg SC every  8 weeks (q8w) was studied in 
subjects with CD (C0743T26). The results from C0743T26 study  suggest that ustekinumab 
[ADDRESS_327581] 
recentl y provided additional safety  and efficacy  data; UNITI-1, UNITI 2, and IM-UNIT I. 
UNITI -[ADDRESS_327582] but who had 
failed conventional immunomodulator or steroid therapi[INVESTIGATOR_014]. The IM-UNITI study  evaluated 
maintenance treatment for patients enrolled from both UNITI -1 and UNITI -2 studies. The UNITI 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
48
Approved, 18 January 2017studies randomized 1,367 subjects to either placebo, 130 mg IV or approximately  6 m g/kg IV. 
After Week [ADDRESS_327583] been published,7and the results 
supported the approval of ustekinumab in patients with active moderate to severe CD. The 
approved dose in induction is a single IV weight-based dose approximating 6mg/kg and the 
approved maintenance dose is 90 mg either every 8 or 12 weeks depending on the approval 
region. The results of these studies are particularly  relevant to the CNTO1275SL E2001 SLE 
study  in that a similar dose is being evaluated. In addition, similar to the SLE population, about 
1/3 of the CD patients enrolled into the UNITI studies were using concomitant 
immunomodulators (e.g MTX, AZA, 6-MP) and approximately  46% were on concomitant 
glucocorticoids. The results of these studies are reviewed in detail .in the primary  publication7
and the highl ights are presented below:
In the 2 UNIT I induction studies, the primary  endpoint and all major secondary endpoints 
were met for both doses studied including the 6 mg/kg dose.
In the IM-UNITI maintenance study , both the 90 mg every  8 or every  12 week regimens 
were superior to placebo in maintaining response or achieving remission compared to 
placebo at Week 44.
Importantly , the safet y profile sof both maintenance doses were comparable to placebo over 
44 weeks and no new safety  signals were identified .The safet y profile was similar to that 
seen in the psoriatic indications.
In summary , these CD studies support the dosing regimen planned for this proof -of concept SL E 
study  including body  weight -range based IV loading dose approximating 6 mg/kg followed by 
90mg SC q8w to ensure a high level of systemic exposure of ustekinumab to inhibit the actions 
of IL-12/23.
Open label 90 mg SC q8w ustekinumab dosing will be provided to subjects starting at Week 24 
though Week 40. Per the amended study  design, subjects who are able to continue q8w study  
treatment at approximately  8 weeks (±2 weeks ) after their Week 40 visit, or are able to resume 
study  treatment with no more than 16 weeks (±2 weeks) since their Week 40 visit will be eligible 
for continued 90 mg SC q8w ustekinumab treatment through Week 104, followed by [CONTACT_102160] 1 6-week safety  follow -up period.
2. OBJECTIVE SAND HYPOTHESIS
2.1. Objectives
Primary Objective
The primary  objective is to evaluate the efficacy  of ustekinumab as measured by a reduction in 
disease activity  for subjects with active SL E.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
49
Approved, 18 January 2017Secondary Objectives
The secondary  objectives are to evaluate:
The safet y and tolerability of ustekinumab in subjects with SLE.
The effect of ustekinumab administration onhealth -related qualit y of life in subjects with
SLE.
The effects of ustekinumab on cutaneous manifestations of SL E.
Pharmacokinetics and immunogenicit y of ustekinumab in subjects with SLE .
Exploratory Objectives
The exploratory  objectives are to evaluate:
Safety  and efficacy  during long -term administration of ustekinumab.
Reduction in corticosteroid dosing during long- term administration of ustekinumab.
Additional composite clinical endpoints or methods for calculation of response with 
potential for greate r sensitivity  to improvement and /orworsening of SLE.
Biomarkers related to lupus disease (genetic, s ystemic, and skin-related).
2.2. Hypothesis
The hypothesis is that ustekinumab is significantly  superior to placebo as measured by [CONTACT_269282] 2000 (SLEDAI -2K) Responder Index 
(SRI -4) composite measure at Week 24.
3. STUDY DESIGN A ND RA TIONA LE
A complete listdescribing all efficacy  evaluations and endpoints, and which evaluations are 
included in the composite endpoints is provided in Attachment 1.The main study  is defined from 
the original protocol as screening through the Main Study  8-week and 16-week safet y follow -up 
visits. Note that the Main Study  8-week and 16-week safet y follow -up visits were previously 
described in the origina l protocol as the Week 48 and Week 56 visits. However ,with this 
amendment, the Week 48 and Week 56 visits will only be used to describe treatment visits for 
those subjects who are participating in the study  extension. The study  extension (applicable to 
subjects meet ing the inclusion criteria) is defined as the Week [ADDRESS_327584] SLE according to SLICC criteria and SL EDAI -2K score ≥6, despi[INVESTIGATOR_88913] 
(eg,immunomodulators, antima larial drugs, corticosteroids, NSAIDs, anti-hypertensive drugs, 
and/or topi[INVESTIGATOR_5910]). In addition, subjects must have at least [ADDRESS_327585] 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
50
Approved, 18 January 2017(ANA, anti-dsDNA antibodies, and/or anti-Smith antibo dies) observed during screening, as well 
as a well-documented positive autoantibody  testin their medical history . Subjects must also 
demonstrate at least 1BILAG A and/or [ADDRESS_327586] a clinical SLEDAI -2K score ≥4 (excluding laboratory  results) at 
week 0, prior to randomization.
Subject randomization will be stratified according to consent for skin biopsy  collection (y /n), and 
other features (eg,presence of lupus nephritis [ y/n], baseline SLE medications and SLEDAI 
score), site/region, and race, or concomitant medications as described in Section 8. 
Approximately  100 subjects wi ll be randomly  assig ned by 3:2ratio to receive either ustekinumab 
or placebo through Week 24. Following randomization at Week 0, s ubjects will receive an initial 
body  weight -range based IV dose approximating 6 mg/kg of ustekinumab (ustekinumab 260 mg 
[weight ≥35 kg to ≤55 kg]; ustekinumab 390 mg [weight >55 kg and ≤85kg]; ustekinumab 
520mg [weight >85 kg]) followed by 90 mgSC administered q8w ( Section 6).At Week 24, 
subjects receiving placebo will cross -over and all subjects will receive ustekinumab 90 mg SC at 
Weeks 24, 32, and 40 followed by [CONTACT_211697] -up through Week 56 in a blinded fashion for 
16weeks (ie, approximately  5 half -lives) after last study  agent SC administration.
A placebo comparator (added to standard of care background therapy ) will be used through 
Week [ADDRESS_327587] other assessments including collection of skin biopsies (optional consent) and/or 
photographs of an identified cutaneous lesion or area of active disease (optional consent). There 
will not be any  restrictions on the number of subjects with cutaneous disease who can enroll into 
either the main stud y or the cutaneous lupus substudy .
Interim analy ses (IA) will be conducted when approximately  1/3 and 2/[ADDRESS_327588] across regions will be incorporated into the interim analyses. Database locks (DBLs) will 
occur at Weeks [ADDRESS_327589]’s Week [ADDRESS_327590] subjec t’s 
16-week safet y follow -up visit from the main study . In addition, an independent data monitoring 
committee (DMC) will review interim safet y data periodicall y including a formal review when 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
51
Approved, 18 January 2017approximately  1/3 and 2/3 of subjects reach Week 24 ,as well as at the Week 24 DBL .The DMC 
will make a recomme ndation to the Sponsor committee whether the study should be stopped for 
futility  or for safety  concerns or if data meet prespecified criteria demonstrating notable efficacy . 
The content of the summaries, the DMC role and responsibilities, and the general procedures 
(including communications) will be defined in the DMC charter .
The amended study  design will continue to provide open -label ustekinumab 90 mg q8w SC 
administration through Week 104(study  extension) . Subjects will be eligible to continue study 
treatment th rough Week 104 if they  meet the study  inclusion criteria (Section 4.1.3 ):
must not have permanently  discontinued study treatment on or before their Week 40 visit, 
and
are able to continue q8 week study  treatment at approximately  8 weeks (±2 weeks) after
their Week 40 visit
or
are able to resume study  treatment with no more than 16 weeks (±2 weeks) since their 
Week [ADDRESS_327591]’s Week 56 visit or the final 16-week 
safet y follow -up visit from the main study , there will be an additional DBL  following the 
Extension 16-Week Safety Follow -up period.
A diagram of the main study design is provided below in Figure 1, and a diagram of the extended 
study  is provided in Figure 2.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
52
Approved, 18 January 2017Figure 1: Schematic Overview of the Main Study (Screening through 16 -Week Safety Follow -Up)
Abbreviations: DBL=database lock; FU=follow -up; IV=intravenous; PE=prim ary endpoint; PL=placebo; 
q8w=every 8 weeks; SC=subcutaneous; SLE=systemic lupus erythematosus ; SRI=SLEDAI -2K Responder Index; 
Wks=weeks .
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
53
Approved, 18 January 2017Figure 2: Schematic Overview Including the Study Extension
3.2. Study Design Rationale
Blinding, Control, Study Phase/Periods, Treatment Groups
A placebo control will be used to establish the frequency  and magnitude of changes in clinical 
endpoints that may occur in the absence of active treatment . Randomization will be used to 
minimize bias in the assignment of subjects to treatment groups, to increase the likelihood that 
known and unknown subject attributes (eg,demographic and baseline characteristics) are evenl y 
balanced across treatment groups, and to enhance the validity  of statistical comparisons across 
treatment groups. Blinded treatment will be used to reduce potential bias during data collection 
and evaluation of clinical endpoints.
DNA and Biomarker Collection
It is recognized that genetic variation can be an important contributory  factor to interindividual 
differences in drug distribution and response and can also serve as a marker for disease 
susceptibility  and prognosis. Pharmacogenomic research may help to explain interindividual 
variability  in clinical outcomes and may help to identify  population subgroups that respond 
differentl y to a drug. The goal of the pharmacogenomic component is to collect deox yribonucleic 
acid (DNA )to allow the identification of genetic factors that may influence the 
pharmacokinetics, pharmacod ynamics, efficacy ,safet y, or tolerability  of ustekinumab and to 
identify  genetic factors associated with SLE.
Biomarker samples will be collected to evaluate the mechanism of action of ustekinumab or help 
to explain inter-individual variability  in clinical outcomes or may help to identify  population
subgroups that respond differentl y to a drug. The goal of the biomarker analyses is to evaluate 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327592] POPULA TION
The target study  population is subjects with SLE according to SLICC criteria and SLEDAI -2K
score ≥6, despi[INVESTIGATOR_88913] (eg, immunomodulators, antimalarial drugs, 
corticosteroids, NSAIDs, anti-hypertensive drugs, and/or topi[INVESTIGATOR_5910]). Subjects must 
have at least 1 BILAG A and/or [ADDRESS_327593] (ANA, anti-dsDNA antibodies, 
and/or anti-Smith antibodies) observed during screening, as well as a well- documented positive 
autoantibody  testin their medical history , and they must also have a clinical SLEDAI -2K score 
≥4 (excluding laboratory  results) prior to randomization at week [ADDRESS_327594] 
in the study .
Subjects with SLE enrolling into the main study  with active cutaneous lupus (including subjects 
with discoid lupus ery thematosus , subacute cutane ous lupus ery thematosus, or SL E malar rash or 
other SLE skin lesions characterized by [CONTACT_269283]/or scale) will be evaluated using CLASI 
scoring. In addition, subjects who provide consent will be enrolled in the cutaneous lupus 
substudy evaluating the histology  of cutaneous biopsies and/or skin photographs. Biops y samples 
(2 samples, 4 mm size) from consenting subjects will be collected prior to dosing at Week 0 and 
at Week 24 from a lesion demonstrating active cutaneous disease. Subjects participating in the 
cutaneous lupus substudy  are not required to undergo biopsies, and may allow only photographs 
to document changes in an identified cutaneous lesion or area of active disease. Subjects with 
cutaneous lupus deemed unsuitable for biopsy  (eg, malar rash or alopecia) can also be enrolled in 
the substudy , and may  be evaluated b y photo graphy .
If a subject has failed screening and investigator wishes to rescreen the subject, this should be 
discussed with the study  Sponsor and/or their designee. Onl y [ADDRESS_327595]
(also see Section9.1.2 ).
The study  extension population will be comprised of those subjects who have not permanentl y 
discontinued study  treatment before or at the Week [ADDRESS_327596] selection, refer to Section 11.2,
Sample Size Determination .
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327597] be between 18 (or older as per local requirements) and 75years of age, 
inclusive, and weigh at least [ADDRESS_327598] dose ( Table 3 ).
Subjects eligible for enrollment in this study  must qualify  as having SLE by [CONTACT_269284]25based upon 1 or both of the following :
Meeting [ADDRESS_327599] 1 immunologic 
criterion, or 
A diagnosis of lupus nephritis with presence of at least 1 of the immunological 
variables
Table 3: Clinical and Immunological Criteria Used in the SLICC Classification Criteria*25
Clinical Criteria Specific Criteria
1.Acute Cutaneous Lupus including 
lupus malar rash (do not count if malar 
discoid)Bullous lupus
Toxic epi[INVESTIGATOR_35819]
Maculopapular lupus rash
Photosensitive lupus rash (in absence of 
dermatomyositis )
Subacute cutaneous lupus (nonindurated psoriaform 
and/or annular polycyclic lesions that resolve 
without scarring, although occasionally with 
postinflammatory dyspi[INVESTIGATOR_269245])
2.Chronic cutaneous lupus including 
classical discoid rashLocalized (above the neck)
Generalized (above and below the neck)
Hypertroph ic (verrucous) lupus
Lupus panniculitis (profundus)
Mucosal lupus
Lupus erythematosus tumidus
Chilblains lupus
Discoid lupus / lichen planus overlap
3.Oral ulcers: palate Buccal
Tongue
Nasal
In the absence of other causes such as vasculitis, 
Behcets, infection (herpes), inflammatory bowel disease, 
reactive arthritis, and acidic foods
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
56
Approved, 18 January 2017Table 3: Clinical and Immunological Criteria Used in the SLICC Classification Criteria*25
4.Non-scarring alopecia (diffuse thinning 
or hair fragility with visible broken 
hairs)In the absence of other causes such as alopecia areata, 
drugs, iron deficiency and an drogenic alopecia
5.Synovitis involving two or more joints Characterized by [CONTACT_269285] 
2 or more joints and thirty minutes or more of morning 
stiffness
6.Serositis Typi[INVESTIGATOR_35821] 1 day
oOr pleural effusions
oOr pleural rub
Typi[INVESTIGATOR_35822] (pain with recum bency 
improved by [CONTACT_269286]) for more than 1 day
oOr pericardial effusion
oOr pericardial rub
oOr pericarditis by [CONTACT_269287], uremia 
and Dressler’s pericarditis
7.Renal Urine protein/creatinine (or 24 hour urine protein) 
representing 500 mg of protein/24 hour, or
Red blood cell casts
8.Neurologic Seizures
Psychosis
Mononeuritis multiplex (in the absence of other 
known causes such as primary vasculitis )
Myelitis
Peripheral or cranial neuropathy (in the absence of 
other known causes such as primary vasculitis, 
infection and diabetes mellitus )
Acute confusional state (in the absence of other 
causes including toxic- metabolic, uremia, drugs )
9.Hem olytic anemia Presence
10a. Leukopenia (<4000/mm3at least 
once), or
10b. Lymp hopenia (<1000/mm3 at least 
once)In the absence of other known causes such as Felty’s ,
drugs ,and portal hypertension
In the absence of other known causes such as 
corticosteroids, drugs ,and infection
11. Thrombocytopenia (<100,000/mm3at 
least once)In the absence of other known causes such as drugs, 
portal hypertension, and TTP
Immunological Criteria Specific Criteria 
1.ANA above laboratory reference range
2.Anti-dsDNA above laboratory reference range, except ELISA; twice 
above laboratory reference range
3.Anti-Smith Presence
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
57
Approved, 18 January 2017Table 3: Clinical and Immunological Criteria Used in the SLICC Classification Criteria*25
4.Anti-phospholipid antibody (any 
shown to right)Lupus anticoagulant
False -positive RPR
Medium or high titer anticardiolipin (IgA, IgG or 
IgM)
Anti-β2glycoprotein 1 (IgA, IgG or IgM)
5.Low Complement Low C3
Low C4
Low CH50
6.Direct Coombs test In the absence of hemolytic anemia
*Criteria are cumulative and do not need to be present concurrently
3. To be eligible for study enrollment, subjects must have:
At least 1well-documented (subject file, referring physician letter, or laboratory
result) unequivocally  positive ,documented t estfor autoantibodies in medical history
including either of the following: ANA, and/or anti-dsDNA antibodies, and/or 
anti-Smith antibodies (Section 9.1.2 ).
At least [ADDRESS_327600] including ANA and/or 
anti-dsDNA antibod iesand/or anti-Smit h antibodies (Section 9.1.2 ) detected during 
screening .
At least 1 BILAG A and/or [ADDRESS_327601] administration of study  agent .
4. Demonstrate active disease based on SLEDAI -2K score ≥[ADDRESS_327602] 
SLEDAI -2K ≥4 for clinical features (ie, SLEDAI excluding laboratory  results ) at Week 
[ADDRESS_327603] administration of study  agent.
5. Data from the SLICC, SLEDAI and BILAG evaluations will be reviewed and 
adjudicated by [CONTACT_1052]/or the Sponsor -selected independent reviewer(s). F or 
subject sto receive their first administration of study  agent, approval must be receive d 
by [CONTACT_1052]/or Sponsor -selected independent reviewers.  
6. If using oral corticosteroids, subjects must be receiving this medication for at least 
6weeks and on a stable dose equivalent to an average dose of ≤20 mg/day of 
prednisone for at least [ADDRESS_327604] administration of study  agent.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
58
Approved, 18 January [ZIP_CODE]. If using antimalarials (eg, chloroquine, hydroxychloroquine, or quinacrine), subjects 
must have used the medication for ≥[ADDRESS_327605] admi nistration of study agent.
8. If using immunomodulatory drugs (mycophenolate mofetil [MMF]/my cophenolic acid 
[MPA] ≤2g/day, azathioprine /6 mercaptopurine (AZA /6 MP) ≤2 mg/kg/day  and/or 
MTX ≤25 mg/wk with concomitant folic acid [recommend ≥5 mg/wk]), subjects must 
be receiving a stable dose for at least [ADDRESS_327606] be either:
Not of childbearing potential: premenarchal; postmenopausal (>[ADDRESS_327607] 12 months );permanently  sterilized (eg, tubal occlusion, 
hysterectomy, bilateral salpi[INVESTIGATOR_1656]); or otherwise be incapable of pregnancy.
Of childbearing potential and practicing a highly  effective method of birth control 
consistent with local regulations regarding the use of birth control methods for subjects 
participating in clinical studies : eg, established use of oral, injected or implanted 
hormonal methods of contraception associated with inhibition of ovulation; placement 
of an intrauterine device  or intrauterin e system; male partner sterilization (the 
vasectomized partner should be the sole partner for that subject); true abstinence (when 
this is in line with the preferred and usual lifest yle of the subject).  
Note: If the childbearing potential changes after start of the study  (eg, woman who is 
not heterosexually  active becomes active, premenarchal woman experiences menarche) 
a woman must begin a highly effective method of birth control, as described above.   
11. A wom an of childbearing potential must have a negative serum pregnancy test -human 
chorionic gonadotropin [-hCG]) at screening ,and a negative urine pregnancy  test at 
Week [ADDRESS_327608] agree to not donate eggs (ova, 
oocy tes) for the purposes of assisted reproduction during the study  and for [ADDRESS_327609] dose of study  agent. 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327610] agree to use a barrier method of birth control eg, either condom with 
spermicidal foam/gel/film/cream/suppository  or partner with occlusive cap (diaphragm 
or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository , and all men 
must also not donate sperm during the study  and for4 months after receiving the last 
dose of study  agent .
14. Are considered eligible according to the following tuberculosis (TB) screening criteria:
a.Have no history  of latent or active TB prior to screening . An exception is made 
for subjects who have a history  of latent TB and are currently  receiving 
treatment for latent TB, will initiate treatment for latent TB prior to first 
administration of study agent, or have documentation of having completed 
appropriate treatment for latent TB within 3years prior to the first 
administration of study  agent. It is the responsibility  of the investigator to verify  
the adequacy  of previous anti-tuberculous treatment and provide appropriate 
documentation.  
b.Have no signs or sy mptoms suggestive of active TB upon medical history and/or 
physical examination.
c.Have had no recent close contact [CONTACT_4490] a person with active TB or, if there has 
been such contact, will be referred to a physician specializing in TB to undergo 
additional evaluation and, if warranted, receive appropriate treatment for latent 
TB prior to the first administration of study  agent.
d.Within [ADDRESS_327611] a negative 
QuantiFERON®-TB Gold test result (Attachment 2), or have a newly  identified 
positive QuantiFERON®-TB Gold test result in which active TB has been ruled 
out and for which appropriate treatment for latent TB has been initiated prior to 
the first administration of study  agent.  Within 6weeks prior to the first 
administration of study  agent, a negative tuberculin skin test(Attachment 3), or 
a newly  identified positive tuberculin skin te st in which active TB has been ruled 
out and for which appropriate treatment for latent TB has been initiated prior to 
the first administration of study  agent, is additionally  required if the 
QuantiFERON®-TB Gold test is not approved/registered in that country or the 
tuberculin skin test is mandated b y local health authorities.
i. Subjects with persistently indeterminate QuantiFERON®-TB Gold test 
results may be enrolled without treatment for latent TB, if active TB is 
ruled out, their chest radiograph shows noabnormality  suggestive of TB 
(active or old, inactive TB), and the subject has no additional risk factors 
for TB as determined by [CONTACT_093]. This determination must be 
promptly  reported to the Sponsor’s medical monitor and recorded in the 
subject's source documents and initialed by  [CONTACT_093].
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
60
Approved, 18 January 2017ii. The QuantiFERON®-TB Gold test and the tuberculin skin test are not 
required at screening for subjects with a history  of latent TB and ongoing 
treatment for latent TB or documentation of having completed adequate 
treatment as described above; Subjects with documentation of having 
completed adequate treatment as described above are not required to 
initiate additional treatment for latent TB.  
e.Subjects who test positive for TB by a TB test other than Quant iFERON®-TB 
Gold and TB skin test and who have no evidence of TB on chest radiograph will 
in the context of this protocol be considered latent TB positive and be required 
to undergo evaluation by a TB specialist and receive treatment for TB to be 
eligible f or this study . 
f.Have a chest radiograph (both posterior -anterior and lateral views) taken within 
3months prior to the first administration of study agent and read by a qualified 
radiologist or pulmonologist , with no evidence of current, active TB or old, 
inactive TB.
15. Have laboratory  test results within the following parameters atscreening : 
Hemoglobin 8.5 g/dL  (SI:  85 g/L)
Lym phocy tes ≥0.5 x 103/L (SI:  ≥0.5 GI/L)
Neutrophils 1.0 x 103/L (SI:  1.0 GI/L)
Platelets 75x 103/L (SI:  75GI/L)
Serum creatinine 1.8 mg/dL  (SI:  159 mol/L)
White blood cells 2.0 x 103/L (SI:  2.0 GI/L)
The aspartate aminotransferase , alanine aminotransferase , and alkaline phosphatase 
levels must be within 2 x upper limit of normal (ULN )range for the laboratory  
conducting the test. For subjects within the range of 1.[ADDRESS_327612] be promptly  
reported to the Sponsor’s medical monitor and recorded in the subject's source 
documents and initialed by  [CONTACT_093].
Subjects with other marked diseas e-associated lab oratory abnormalities may  be included 
only if the investigator judges the abnormalities or deviations from normal to be not 
clinically  significant or to be appropriate and reasonable for the population under study . 
This determination must be promptly  reported to the Sponsor’s medical monitor and 
recorded in the subject’s source documents and initialed by  [CONTACT_093].
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327613] sign an informed consent form (ICF) indicating that he or she 
understands the purpose of and procedures required for the study  and are willing to 
participate in the stud y. 
18. Each subject must sign a separate informed consent form if he or she agrees to provide 
an optional DNA sample for research (where local regulations permit). Refusal to give 
consent for the optional DNA research sample does not exclude a subject from 
participation in the study .
4.1.2. Additional Inclusion Criteria for the Cutaneous Lupus Substudy
To be enrolled in the cutaneous lupus substudy , an SLE subject must satisfy  all previously  listed 
inclusion criteria (Section 4.1.1 ) in addition to the criteria listed below: 
1. Have diagnosis of active CLE at screening as well as documented cutaneous disease 
prior to study  enrollment, including subjects with discoid lupus ery thematosus, subacute 
cutaneous lupus erythematos us, or SLE malar rash or other SLE skin lesions including 
those characterized by [CONTACT_269283]/or scale.
2. Subjects taking systemic , topi[INVESTIGATOR_2855], or intra-lesional medications for CLE must be on a 
stable dose or treatment regimen for [ADDRESS_327614] swho consent to participate in the cutaneous lupus substudy  will be asked to 
provide biopsies of an active CLE target lesion prior to dosing at Weeks 0 and 24. An 
active CLE lesion is characterized by [CONTACT_269288]/or erythema, excluding previously  
scarred tissue. In addition, separate consent will be obtained to collect photographs of a 
cutaneous lesion or area of active disease according to the schedule defined in Table 1 .
4. Subjects with cutaneous lupus deemed unsuitable for biopsy  (eg, malar rash or alopecia) 
can also be enrolled in the substudy , and may  be evaluated b y photograph y.
4.1.3. Inclusion Criteria A pplicable to A ll Subjects Entering into the Study 
Extension (Week 48 or Week 56 visits)
Any subjects who do not meet the inclusion criteria for the study extension must follow the Time 
and Events schedule for the main study  design (Table 1), and have safet y follow -up visits 
conducted at 8 and 16 weeks following their Week 40 or final study  dose .
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327615] permanentl y discontinued study treatment on or before their 
Week 40 visit, and are able to either continue q8w SC dosing at approximately  8 weeks 
(±2 weeks) after their Week 40 visit, or are able to resume dosing at Week 56 with no 
more than 16 weeks (±2 weeks) since t heir Week [ADDRESS_327616] other inflammatory  diseases that might confound the evaluations of efficacy , 
including but not limited to rheumatoid arthritis (RA), psoriatic arthritis (PsA), 
RA/lupus overlap , psoriasis ,or active Lym e disease.
2. Are pregnant, nursing, or planning a pregnancy  or fathering a child while enrolled in the 
study  or within [ADDRESS_327617] received systemic or topi[INVESTIGATOR_68549]/ointment preparations ofcyclosporine A or 
other systemic immunomodulatory agents other than those described in inclusion 
criteria within the past 3months prior to first administration of study  agent 
(Section 4.1). Corticosteroi ds are not included in this criterion; see Sections 4.3and 8.[ADDRESS_327618] study  agent 
administration; or received more than [ADDRESS_327619] administration of the study 
agent ;or received B celldepleting therap y (eg, rituximab) within [ADDRESS_327620] ever received ustekinumab.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327621] received prior immunomodulatory  biologic therap y for lupus not described in 
Exclusion Criterion #[ADDRESS_327622] a known hy persensitivity  to human immunoglobulin (Ig) proteins (eg, intravenous 
Ig).
8. Have used oral cyclophosphamide within [ADDRESS_327623] had a Bacille Calmette -Guérin (BCG) vaccination within [ADDRESS_327624] had a nontuberculous mycobacterial infection or opportuni stic infection 
(eg,cytomegalovirus, pneumocy stosis, aspergillosis) within [ADDRESS_327625] administration of study  agent. For BCG vaccin ation criterion , see 
Exclusion Criterion 10 and Prohibition/Restriction Criterion 8.
14. Have had a serious infection (including but not limited to, hepatitis, pneumonia, sepsis, 
or pyelonephritis), or have been hospi[INVESTIGATOR_269246], or have been treated with 
intravenous antibiotics for an infection within 2months prior to first administration of 
study  agent. Less serious infections (eg, acute upper respi[INVESTIGATOR_2826], simple 
urinary  tract infection) need not be considered exclusionary  at the discretion of the 
investigator.
15. Have a history  of, or ongoing, chronic or recurrent infectious disease, including but not 
limited to, chron ic renal infection, chronic chest infection (eg,bronchiectasis), sinusitis, 
recurrent urinary  tract infection (eg, recurrent pyelonephritis), an open, draining, or 
infected skin wound, or an ulcer.
16. Subject has a history  of human immunodeficiency  virus (HIV) antibody positive, or 
tests positive for HIV at screening.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327626] undergo screening for hepatitis B virus 
(HBV) (Attachment 4). At a minimum, this includes testing for HBsAg (HBV surface 
antigen), anti-HBs (HBV surface antibody ), and anti-HBc total (HBV core antibody  
total).
18. Subjects who are seropositive for antibodies to hepatitis C virus (HCV), unless they 
have [ADDRESS_327627] 4 months are excluded. Those with multi- dermatomal herpes zoster or central 
nervous s ystem ( CNS )zoster within the past [ADDRESS_327628] urinary  protein >4 g /day or protein/crea tinine ratio >4.
22. Have inherited complement deficiency  or combined variable immunodeficiency .
23. Have end-stage renal disease, or severe or rapi[INVESTIGATOR_269247], 
including severe, active lupus nephritis reported in recent biops y and/or other 
assessments such as active urinary  sediment, rapi[INVESTIGATOR_269248], or other 
factors that suggest severe or rapi[INVESTIGATOR_269249] (see also limits on serum 
creatinine in Inclusion Criterion # 15).
24. Have severe CNS lupus including but not limited to seizures, psychosis, transverse 
myelitis, CNS vasculitis and optic neuritis.
25. Have severe, progressive, or uncontrolled hepatic, hematological, gastrointestinal, 
endocrine, pulmonary , cardiac, neurologic/ cerebral, or psychiatric disease, or current 
signs and s ymptoms thereof.
26. Have a known history  of ly mphoproliferative disease, including ly mphoma, or signs and 
symptoms suggestive of possible ly mphoproliferative disease, such as ly mphadenopathy 
of unusual size or l ocation, clinically  significant splenomegal y, or history of monoclonal 
gammopath y of undetermined significance.
27. Subject has a history  of malignancy  within 5 years before screening (exceptions are 
squamous and basal cell carcinomas of the skin that has been treated with no evidence 
of recurrence for at least [ADDRESS_327629] study  agent administration and 
carcinoma in situ of the cervix that has been surgically  cured).
28. Has known allergies, hypersensitivity , or intolerance to ustekinumab, i ts excipi[INVESTIGATOR_269250] (contained in the syringe needle cover, see Section 14.1)(refer to the ustekinumab 
Investigator’s Brochure) .
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
65
Approved, 18 January 201729. Are curre ntly receiving venom immunotherap y (honey bee, wasp, yellow jacket, hornet, 
or fire ant).
30. Has received an investigational drug that is not previously  defined in other exclusion 
criteria (including investigational vaccines orother medications specified in section 4.3, 
Prohibition/R estric tion No.3) within 5half-lives or [ADDRESS_327630] 
dose of study  drug, or is currentl y enrolled in an interventional study .
31. Has any condition for which, in the opi[INVESTIGATOR_11922]/or Sponsor, 
participation would not be in the best interest of the subject (eg, compromise the 
well-being) or that could prevent, limit, or confound the protocol -specified assessments 
including a previous pattern of non-compliance with medical follow -up or being 
deemed unlikel y to be compliant with a study visit schedule.
32. Has had major surgery, (eg, requiring general anesthesia) within [ADDRESS_327631] fully recovered from surgery , or has major surgery 
(eg,requiring general anesthesia) planned during the time the subject is expected to 
participate in the study  or within [ADDRESS_327632] dose of study  drug 
administration.
Note: Subjects with planned minor surgical procedures to be conducted under local 
anesthesia may  participate .
33. Have a transplanted organ (with the exception of a corneal transplant performed 
>3months prior to first administration of study  agent).
34. Have or have had a substance abuse (drug or alcohol) problem within the previous 
3years.
35. Are unwilling or unable to undergo multiple venipuncture s because of poor tolerability  
or lack of eas y venous access.
36. Subject is an employ ee of the investigator or study  site(i.e. personnel to whom the 
investigator has delegated a role or responsibility  for conducting the study) , with direct 
involvement in the proposed study  or other studies under the direction of that 
investigator or study  site, as well as family members of the employ ees or the 
investigator.
37. Lives in an institution on court or authorit y order , unless permitted by  [CONTACT_427].
NOTE: Investigators should ensure that all study enrollment criteria have been met at screening. 
If a subject's status changes (including laboratory  results or receipt of additional medical records) 
after screening but before the first dose of study  drug is given such that he or she no longer meets 
all eligibility  criteria, then the subject should be excluded from participation in the study . 
Section 17.4, Source Documentation, describes the required documentation to support meeting 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327633] be willing and able to adhere to the following prohibitions and 
restrictions during the course of the study  (including the study  extension) to be eligible for 
continued dosing in the study :
1. If a woman is capable of pregnancy , she must remain on a highly effective method of 
birth control during the study  and for [ADDRESS_327634] or her male partner is sterilized; this situation 
does not require birth control. A woman must not donate eggs (ova, oocy tes) for the 
purposes of assisted reproduction during the study  and for [ADDRESS_327635] or his female partner is sterilized; this situation does not require birth 
control.
3. Use of additional immunosuppressants or immunomodulators, other than those explicitly  
allowed in the inclusion/exclusion criteria ,are prohibited including but not limited to the 
following:
Biologic agents targeted at reducing TNF (including but not limited to infliximab, 
golimumab, certolizumab pegol, etanercept, yisaipu, CT-P13 [Remsima®] and 
adalimumab)
B cell depleting agents (anti-CD20 [eg, rituximab], anti-B cell activating factor 
[BAFF], also known as B lymphocy testimulator [BLy S], [eg,belimumab], or
anti-CD22 [eg, epratuzumab])
Interleukin -1 inhibitors (eg, canakinumab)
Interferon inhibitors 
IL-1ra (eg, anakinra)
Tocilizumab or any  other biologic targeting IL -6 or IL -6 receptor
Tofacitinib or an y other janus kinase ( JAK)inhibitor
Abatacept
Anti- IL-17 agents (eg, brodalumab, secukinumab, and ixekizumab) 
Leflunomide
Cyclosporine A (oral or topi[INVESTIGATOR_125053]/cream preparations)
Tacrolimus orpi[INVESTIGATOR_180781] , oral or topi[INVESTIGATOR_12469]
Toll-like receptor inhibitors
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
67
Approved, 18 January 2017Thalidomide or lenalidomide
Dapsone
Adrenocorticotropic hormone (ACTH )by [CONTACT_17838]
4. Use of cytotoxic drugs isprohibited including ,but not limited to,cyclophosphamide, 
chlorambucil, nitrogen mustard, or other alky lating agents.
5. Multiple administ rations of high doses of corticosteroids ,andinitiation of medium or 
high potency  topi[INVESTIGATOR_11930], are prohibited during the study  as defined in Section 
8.3.
6. The initiation of a new permitted immunomodulatory agent (MTX, azathioprine, 6-
mercaptopurine, mycophenolate mofetil/my cophenolic acid) in addition to an ongoing 
immunomodulatory  therapy is prohibited.
7. Initiation of new angiotensin II receptor blocker (ARB )or angiotensin -converting 
enzy me (ACE )inhibitor therap y after first dose of study  agent is not permitted for the 
treatment of lupus -related disease through W eek 28.
8. Must agree not to receive a live virus or live bacterial vaccination during the study . 
Subjects must also agree not to receive BCG vaccination for [ADDRESS_327636] agree not to receive an investigational medical device or an investigational drug 
other than study  agent for the duration of this study .
10. The use of complementary  therapi[INVESTIGATOR_269251], including but not limited to, traditional medicine 
(eg,herbal/alternative preparations [eg, Echinacea], Chinese, acupuncture, ayurvedic) is 
prohibited through W eek 40 .  
11. Study  subjects should avoid excessive sun exposure and may not participate in 
commercial ultraviolet tanning or ultraviolet phototherapy during the study .
12. Skin concealers or topi[INVESTIGATOR_269252] .
13. Sulfa -based antibiotics, where reasonable, should generall y be avoided.
5. TREA TMENT ALLOCA TION AND BLINDING
5.1. Procedures for Randomization
Dynamic central randomization will be implemented in conducting this study . Subjects will be 
assigned to 1 of 2 treatment groups based on a minimization randomization algorithm 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
68
Approved, 18 January 2017implemented in the interactive web response system (IWRS) before the study . Dynamic central 
randomization targets to balance the distribution of subjects to achieve the randomization ratio 
(3:2) at the study  level and within the levels of each individual stratification factor: skin biopsy  
(y/n, when n<16 for y), presence of lupus nephritis (y/n), baseline SLE medications and 
SLEDAI -2K score (combined factor) *, site, region (approximately  4 categories), and race 
(3categories). Based on the algorithm, each subje ct will be assigned to the treatment group 
which will produce minimum total imbalance score with a high probability , where the total 
imbalance score is a weighted average of the imbalance scores for each stratification factor and 
for the whole study . The IWRS will the assign a unique treatment code, which will dictate the 
treatment assignment for the subject.
* The baseline SLE medications and SLEDAI -2Kscore will be calculated as a combined factor, 
including:
SLEDAI -2K score (<10 or ≥10) combined with
Baseline m edications:
High medications defined as ≥15 mg/wk MTX, or ≥1.5 mg/kg/day  AZA/6- MP, or 
≥1.5 g/day  MMF/MPA, and/or ≥15 mg/day  prednisone.
Low medications defined as˂15mg/wk MTX, or ˂1.5 mg/kg/day  AZA/6 -MP, or 
˂1.5 g/day  MMF/MPA, and/or ˂15 mg/day prednisone .
5.2. Blinding
The investigator will not be provided with randomization codes. The codes will be maintained 
within theIWRS, which has the functionality  to allow the investigator to break the blind for an 
individual subject.
Under normal circumstanc es, the blind should not be broken until all subjects have completed 
the study  at Week 56 or terminated study  participation, and the database is finalized. Otherwise, 
the blind should be broken only if specific emergency  treatment/course of action would be
dictated by [CONTACT_169762]. In such cases, the investigator may in an 
emergency  determine the identity  of the treatment by [CONTACT_269289] . It is recommended that 
the investigator contact [CONTACT_269290] e to discuss the particular situation, 
before breaking the blind. Telephone contact [CONTACT_269291] 
24hours per day, 7days per week. In the event the blind is broken, the Sponsor must be 
informed as soon as possible. Th e date and reason for the unblinding must be documented by [CONTACT_129212], in the appropriate section of the case report form (CRF), andin the source document. The 
docum entation received from the IWRSindicating the code break must be retained with the 
subject' s source documents in a secure manner .
Subjects who have had their treatment assignment unblinded may be discontinued from further 
administration of study  agent and should return for safet y follow -up.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327637] (IP) Manual.
6.1. IV administration
For IV administration, the study  agent will be administered to each subject over a period of not 
less tha n 1 hour. 
Ustekinumab 5mg/mL  Final Vialed Product (FVP) (IV) is supplied as a single -use, sterile 
solution in 30 mL vials with 1 dose strength (ie, 130 mg in 26 mL nominal volume). In addition 
to ustekinumab, the solution contains 10 mM L-histidine, 8.5% (w/v) sucrose, 0.04% (w/v) 
polysorbate 80, 0.4 mg/mL L-methionine, and 20 µg/mL  ethylenediaminetetraacetic acid 
(EDTA ) disodium salt dihydrate at pH 6.0. No preservatives are present.
Placebo for FVP (IV) is supplied as single -use, sterile solution in 30 mL vials with a 26 mL 
nominal volume. The composition of the placebo is 10 mM L-histidine, 8.5% (w/v) sucrose, 
0.04% (w/v) polysorbate 80, 0.4 mg/mL  L-methionine, and 20 µg/mL EDTA disodium salt 
dihydrate at pH 6.0. No preservatives are present. 
Body weight -range based dosing will allow administration of complete vials to patients to 
simplify  dose calculation and reduce the potential for errors in dosing. This body  weight -range 
based IV dosing is intended to achieve drug exposure similar to that observed with weight 
adjusted 6 mg/kg dosing. Comparable numbers of vials will be administered to subjects receiving 
placebo based on their body  weight -range. The body  weight -range doses are based on the 
following:
Body weight ≥35 kg and ≤55 kg: 260 mg uste kinumab (2 vials)
Body weight ˃55 kg and ≤85 kg: 390 mg ustekinumab (3 vials)
Body weight ˃85 kg: 520 mg ustekinumab (4 vials)
6.2. SC administration
Ustekinumab will also be supplied as a single -use latex -free prefilled syringe (PFS) in a strength 
of 90mg in 1mL nominal volume for SC administration. Each 1 mL of ustekinumab solution in 
the PFS contains 90 mg ustekinumab with nominal excipi[INVESTIGATOR_269253] 6.7 mM 
L-histidine , 7.6% (w/v) sucrose, 0.004% (w/v) polysorbate 80, at pH 6.0. No preservatives are
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
70
Approved, 18 January 2017present. The needle cover on the PFS contains dry natural rubber (a derivative of latex), which 
may cause allergic reactions in individuals sensitive to latex.
Placebo administrations will have the same appearance as the respective ustekinumab 
administrat ions. Liquid placebo will also be supplied in a [ADDRESS_327638] a composition 
10mM L-histidine , 8.5% (w/v) sucrose, 0.004% (w/v) polysorbate 80, at pH 6.0. No 
preservatives are present.  The needle cover on the PFS contains dry natural rubber (a deriva tive 
of latex), which may  cause allergic reactions in individuals sensitive to latex.  
Week 0 up to Week 24 (Blinded Study Agent Administration Phase)
Group 1:Subjects will receive weight -range based IV dosing of approximately  6  m g/kg of 
ustekinumab at W eek 0 followed by  [CONTACT_269276] 90 mg SC administrations at Weeks 8 and 16.
Group 2:Subjects will receive weight -range based IV dosing of placebo at Week 0 followed by 
[CONTACT_269292] 8 and 16.
Week 24 to Week 40 (Cross -over Administration Phase)
Group 1:Subjects will receive an ustekinumab 90 mg SC administration at Week 24 followed 
by q8w administrations through Week 40 .
Group 2:Subjects will cross -over to ustekinumab 90 mg SC administrations at Week 24 
followed b y q8w administrations through Week 40.
After Week 40 to 16-Week safety Follow- up(Safety Follow -up Phase)
Groups 1 and 2:Subjects who do not participate in the study  extension are expected to return 
for safety  follow -up visits at Weeks 44 and for 8 -and 16- weeks safety  follow -up.
Study Extension (Week 48 /Week 56 through Week 120)
Subjects who meet the study  extension inclusion criteria will receive open -label ustekinumab 
administration for the purpose of expanding the safet y experience and maintenance of efficacy  in 
lupus patients continuously  exposed to ustekinumab [ADDRESS_327639] be recorded.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327640] make every  effort to come for scheduled assessments. Through the Week 32
visit, the visit and study  agent administration should occur within ± 7 daysof thescheduled visit
day (relative to Week 0). Following the Week 32visit, the study  agent administrations are 
allowed to occur within ±2 weeks of the scheduled visit day (relative to Week 0). The study 
agent administrations are sche duled to occur approximately  8 weeks apart, and cannot occur ˂[ADDRESS_327641] should resume the normal study  schedule 
relative t o the baseline visit (Week 0).
All subject’s electronic case report forms ( eCRFs )will be monitored by  a site monitor designated 
by [CONTACT_1034]. During these monitoring visits, all procedures will be evaluated for compliance 
with the protocol. Subject charts will be reviewed and compared with the data entries on the 
eCRFs to ensure accuracy . The Sponsor must be contact[CONTACT_269293].
8. CONCOMITA NT THERA PY
All pre study therapi[INVESTIGATOR_43710] [ADDRESS_327642] through 
Week 28, and if possible also through the main study  8-week safet y follow -up or through the 
study  extension (if applicable) .With the exception of corticosteroids (see S ection 8.3regarding 
corticosteroid tapering ), all other concomitant medications should be maintained at stable doses 
through outthe study . A concomitant medication may be reduced or medication temporarily 
discontinued because of abnormal laboratory  values, side effects, concurrent illness, or the 
performance of a surgical procedure, but the change and reason for the medication change should 
be clearl y docu mented in the subject’s medical record. If concomitant medications have been 
adjusted after randomization as allowed per protocol, every  effort should be made to return 
subject back to the baseline (Week 0) dose level by [CONTACT_269294] 12 visit; or increased medication 
use (relative to baseline) may render a subject to be considered a treatment failure. Corticosteroid 
adjustments for cause are permitted as defined in Section 8.3.
The Sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapi[INVESTIGATOR_23730].
All pharmacologic therapi[INVESTIGATOR_014] (prescription or over-the-counter medications, including vaccines, 
vitamins, herbal supplements) different from the study  agent must be recorded in the 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327643] also be recorded in the concomitant therap y section of the 
eCRF .
8.1. Immunomodulators  
If receiving immunomodulators, subjects should be receiving stable dosing from screening 
through Week 28. Subjects can be receiving MMF/MPA (≤2 g/day ), 
azathioprine/6- mercaptopurine ( ≤2mg/kg/day ) and/or MTX ( ≤25 mg/wk) with concomitant folic 
acid (recommend ≥5 mg/wk), during screening and through Week 28. A reduction in 
immu nomodulators from Week [ADDRESS_327644] interpretation of the subjects’ 
clinical data. A higher dose of an immunomodulator (relative to the basel ine dose) or the 
addition of a new immunomodulator to the existing treatment regimen between the Week [ADDRESS_327645] be considered for 
subjects receiving an increase (relative to baseline) in their immunomodulator dose. Beyond
Week 28, i mmunomodulators should remain as stable as possible through the 8-week safety 
follow -upor through the study  extension (if applicable); however, dose adjustment is allowed for 
unacceptable side effects.
8.2. Antimalarial Medications
Stable treatment with hydrox ychloroquine ,chloroquine , or quinacrine is permitted through the 
8-week safet y follow -up. Beyond Week 28, itis permitted to introduce or adjust dosing of 
antimalarials. Antimalarials produced by a licensed compounding pharmacy  (eg, quinacrine) in 
the country  of administration and using pharmacaceutical grade components are allowed.
8.3. Corticosteroid Therapy
Unnece ssary  dose changes are discouraged, and any dose adjustments should be made in 
increments. Changes in corticosteroids through the 8-week safet y follow -upor through the study  
extension (if applicable) are allowed for medical necessity , but the degree and timing of the 
adjustment should be carefull y considered as this may have an impact on the study  results,
especiall y during the period between 12 and 2 8 weeks.
Oral Corticosteroids *
If using oral corticosteroids, must be receiving this medication for at least 6 weeks and on a
stable dose equivalent to an average dose of ≤20 mg of prednisone/day  for at least [ADDRESS_327646] administration of study  agent. Corticosteroid dose adjustment (increase or decrease) 
of no more than 5 mg prednisone (equivalent/day )to a maximum dose of 25 mg/day  is permitted 
through Week 6. From Week 6through Week 12, nocorticosteroid dose increases are permitted, 
and within this window only a gradual decrease of up to5.0mg prednisone (equivalent/day )
adjustment toward s the baseline dose areallowed up to the Week 12 visit. No further 
adjustments in doses of corticosteroid for the treatment of SLE disease are permitted between 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327647] on the study . Dose increases of oral 
corticosteroids of 40mg/day  or more should be discussed with the medica l monitor and may 
result in discontinuation of study  agent administration.
Subjects may receive short courses (2 weeks or less) of oral corticosteroids for reasons such as 
prophy lactic therapy  before surgery  (stress -dose corticosteroids) or therap y for limited 
infections, exacerbation of asthma, or chronic obstructive pulmonary  disease.
Subjects likely  to require multiple courses of steroids for reasons other than SLE should be 
excluded from study  participation .
Gradual tapering of oral corticosteroid dosing in the study  extension (recommended reductions 
of no more than 10 to 20% of the original dose per week) is encouraged starting after the 
Week [ADDRESS_327648] possible 
maintenance dose of corticosteroids is recommended, including complete weaning off of 
corticosteroids if possible. It is recommended that subjects should be educated and monitored by 
[CONTACT_269295]  (eg, Addisonian symptoms) during periods of 
steroid tapering, as appropriate.
If subjects experience a worsening in their disease activity  while tapering corticosteroids, further 
dose decreases may be suspended, and/or their oral corticosteroid dose may be temporarily 
increased if deemed necessary  by [CONTACT_093]. For subjects whose corticosteroid taper is 
interrupted, investigators are encouraged to resume tapering within [ADDRESS_327649] to be considered a treatment or steroid 
tapering failure. Sustained oral corticosteroid doses of 40 mg/day  or higher may result in 
discontinuation of study  agent.
*Rectal administration of corticosteroids , if necessary ,should be short -term and using topi[INVESTIGATOR_85127].
Epi[INVESTIGATOR_13873], Intravenous, Intramuscular, Intra -articular, and Intra- lesional Corticosteroids
Epi[INVESTIGATOR_13873], IV, IM, IA, or intra-lesional administration of corticosteroids is strongl y discouraged 
within [ADDRESS_327650] administration 
of study  agent and throughout the study . Short -term (≤2 weeks) epi[INVESTIGATOR_13873], IV, IM, IA, or intra-
lesional corticosteroid use for the treatment of indications other than SLE should be limited to 
situations where, in the opi[INVESTIGATOR_021], there are no adequate alternatives. If 
clinically  necessary , a total of 1 or 2 IA injections may be permitted up to the Week 16dosing, 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
74
Approved, 18 January 2017however this would render those joints unevaluable for subsequent assessments. For conditions 
other than SLE, corticosteroid therap y should be limited to situations in which, in the opi[INVESTIGATOR_79465], there are no adequate alternatives. Intravenous corticosteroids of >625 mg 
prednisone equivalent/day  for 2 or more days total in the 24-week period will be evaluated for 
treatment failure as per the statistical anal ysis plan ( SAP).
Inhalation Corticosteroids
Cortico steroids administered by [CONTACT_269296] E may  be given as needed.
Corticos teroid Use in Cutaneous Lupus Sub study
For subjects in the cutaneous lupus substudy , the initiation of, or an increase from baseline in,
the use of potent topi[INVESTIGATOR_11930], or intra-lesional corticosteroid injections, is not allowed
and should be avoided through the 8-week safet y follow -up or in the study  extension .
8.4. Nonsteroidal A nti-inflammatory  Drugs
Subjects treated with NSAIDs, including aspi[INVESTIGATOR_269254] -2 
(COX -2)inhibitors, and other analgesics should receive the usual marketed doses approved in 
the country  in which the study  is being conducted. Prescriptions of NSAIDs and other regularl y 
administered analgesics should not be adjusted for at least 2weeks prior to the first 
administration of the study  drug and through Week 28,and may be changed only if the subject 
develops unacceptable side effects. After Week [ADDRESS_327651] dose of study 
agent is not permitted for the treatment of lupus -related disease through Week 28. Subjects 
should not initiate any  new ARB or ACE inhibitor therapy  between randomization and Week 28.
New or adjusted ARB or ACE inhibitor therapy  is allowed bey ond Week 28.
8.6. Topi[INVESTIGATOR_269255]; however, topi[INVESTIGATOR_269232] a prohibited 
medication. Topi[INVESTIGATOR_269233] A are prohibited through Week 28;
however ophthalmic use is permitted. Low potency  topi[INVESTIGATOR_269256] d except on day of 
study  visit. Medium to high potency  topi[INVESTIGATOR_269257] 8-week safety  follow -up, and high potency  topi[INVESTIGATOR_269258] . For subjects in the cutaneous lupus substudy , topi[INVESTIGATOR_269259]. For 72 hours 
prior to study  visit, topi[INVESTIGATOR_269260] .
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327652]'s participation in the study .
The total blood volume to be collected from each subject over the course of the main portion of 
the study  will be approximately [ADDRESS_327653] consented to participate in the cutaneous lupus substudy  will be requested to 
allow collection of skin biopsy  samples at Week 0 and at Week 24. In addition, p hotographs will 
be taken of a target cutaneous lesion or area of active disease as noted in the Time and Event s
Schedule (Table 1). For additional detail regarding the cutaneous lupus substudy , refer to 
Section 9.7.
9.1.2. Screening Phase
[IP_ADDRESS]. Screening Procedures
Written informed consent must be obtained and reviewed by [CONTACT_269297].
Screening procedures will be performed as indicated in the Time and Events Schedule ( Table 1).
The screening visit must be performed no more than 6 weeks prior to the randomization visit 
(Week 0). In addition, to be eligible for study  participation, subjects must have SLEDAI score 
[ADDRESS_327654] received approval for study  randomization following 
review and adjudication of screening lupus assessments by [CONTACT_1052]/or Sponsor -selected 
independent reviewer(s).
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327655] consent to use highly  effective methods of contraception (see inclusion 
criteria , Section 4.1) and continue to use contraception for the duration of the study  and for 
4months after the last study  agent administration. The method(s) of contraception used by [CONTACT_118082].
All screening evaluations establishing subject eligibility  will be performed and reviewed by 
[CONTACT_269298]. Although the SLICC criteria may not have been 
formally  assessed, to be eligible for enrollment subjects must have demonstrated symptoms 
(documented in subject file) of SLE sufficient to meet SLICC criteria for a minimum of 
3months prior to first dose of study agent. Subjects eligible for enrollment in this study  must 
qualify  as having SLE by [CONTACT_269299] 1 or both 
of the following (as described in I nclusion Criterion #2):
Meeting [ADDRESS_327656] 1 immunologic criterion, or 
A diagnosis of lupus nephritis with presence of at least [ADDRESS_327657] 1well-documented (subject file, referring physician letter, or laboratory
result) medical historical value for unequivocall y positive ANA, anti-dsDNA antibodies, and/or 
anti-Smith antibodies. Medical historical documentation of a positive test of ANA (eg, ANA by 
[CONTACT_178121]-2 titer, ANA by[CONTACT_269300]-linked immunosorbent assay ) or anti-dsDNA (eg, anti-dsDNA by 
[CONTACT_269301]) must include the date and type of the test, the testing laboratory  name, 
numerical reference range, and a key that explains that the values provided are positive versus 
negative/ equivocal or borderline. Only  unequivocally positive values as defined in the 
laboratory ’s reference range are acceptable; borderline values will not be accepted .
In addition, in order to assess the stability  of SLE disease activity , subjects must demonstrate 
SLEDAI -2K score ≥6, despi[INVESTIGATOR_269261] l treatment (eg, immunomodulators, antimalarial 
drugs, corticosteroids, NSAIDs, anti-hypertensive drugs, and/or topi[INVESTIGATOR_5910]). In 
addition, subjects must have at least 1positive autoantibody  test (ANA, anti-dsDNA antibodies, 
and/or anti-Smith antibodies ) observed during screening. Subjects must also demonstrate at 
least 1BILAG A and/or [ADDRESS_327658] administration of 
study  agent.
[IP_ADDRESS]. Retesting
If a subject has signed the ICF and failed to meet at least [ADDRESS_327659](s) will be allowed in the event of suspected error in sample 
collection or analysis performance, or a study  entry procedure may be repeated once during the 
screening period if needed. A request to use a local test to replace the central lab test should be 
discussed with the medical monitor prior to retesting. This is inclusive of only  1 additional blood 
draw to be completed for retesting, regardless of whether an additional laboratory value is found 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327660] or do not meet disease 
activity  criteria following the repeat procedure are to be deemed a screen failure. Exceptions to 
this are positive QuantiFERON® -TB Gold, hepatitis C or B, or HIVtests; unless there is a 
suspected error in sample collection or analysis performance, these tests may not be repeated to 
meet eligibility  criteria.
[IP_ADDRESS]. Rescreening
If a subject has failed screening and investigator wishes to rescreen the subject, this should be 
discussed with the study  Sponsor and/or their designee. Only [ADDRESS_327661] number, undergo the 
informed consent process, and then restart a new screening phase.
9.1.3. Double -Blind Treatment Phase
[IP_ADDRESS]. Week 0/Day  of Randomization
At Week 0, eligible subjects will be randomly  assigned by [CONTACT_53806] a 3:2 ratio to receive 
either ustekinumab or placebo in a blinded manner .  Assessments will be performed as indicated 
in the Time and Events Schedule (Table 1). Subjects participating in the cutaneous lupus 
substudy  will have baseline, pre-treatment photographs and/or skin biopsies collected. Subject’s 
diary  card which was distributed during screening will be reviewed at Week 0, and a new card 
will be provided at each study  visit to record medication changes during the subsequent 4 weeks
through the main portion of the study .
[IP_ADDRESS]. Placebo -controlled Treatment Period (Through Week 24)
After randomization and the first administration of study  agent by  [CONTACT_16228], subjects will have 
blinded study  agent administrations SC q8w through the Week 24 visit. Assessments will be 
performed as indicat ed in the Time and Events Schedule ( Table 1). 
9.1.4. Cross -over Treatment (Through Week 40)
At Week 24, subjects in the placebo group will cross -over to receive ustekinumab dosing, and all 
subjects will continue to receive SC administrations q8w through Week 40.All subjects will 
continue to remain blinded to study  treatment received during the placebo -controlled treatment 
period as described in Section [IP_ADDRESS] .
9.1.5. Study Extension (Week 48 /Week 56 through Week 1 04)
Subjects who qualify  for participation in the study  extension through Week 104 will continue 
ustekinumab 90 mg q8w SC dosing at approximately  8 weeks (±2 weeks) after their Week 40 
visit, or resume ustekinumab dosing at Week 56 with no more than 16 weeks (±2 weeks) since 
their Week 40 visit.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327662] -treatment Safety Follow -up
Subjects who permanently  discontinue study  agent at or before Week 40, or permanently 
discontinue at or before Week 104 if they are participating in the study  extension, but do not 
withdraw from study  participation, should be followed for approximately  16 weeks (5 half-lives) 
after the last study  agent administr ation according to the visit schedule and assessments indicated 
in the appropriate Time and Events Schedule s (Table 1and Table 2). Follow -up visits should 
occur approximately  [ADDRESS_327663] has died, the date and cause of death will be colle cted and docu mented 
on the CRF.
9.2. Efficacy
All efficacy evaluations should be consistently  performed by [CONTACT_269302]-investigator to achieve comparable measures over time. Independent adjudication by 
[CONTACT_63098] -designated independent reviewer(s) will be performed for key lupus 
assessments (eg, SLEDAI, BILAG, and CLASI) .These data will be reviewed at every  visit that 
these data are collected and may  require reconciliation of inconsistencies across assessments.
9.2.1. Evaluations
A complete list describin g all efficacy  evaluations and endpoints, and which evaluations are 
included in the composite endpoints is provided in Attachment 1.
[IP_ADDRESS]. SLEDA I-2Kand S2K RI -50
The SLE disease activity  index 2000 (SLEDAI -2K / S2K RI-50 [ Baseline ]) is an established, 
validated SLE activity  index .It is based on the presence of 24features in 9 organ systems and 
measures disease activity in SL E patients in the previo us 30 days. It is weighted according to the 
featur e. At screening (Attachment 5), features are scored by [CONTACT_269270] 30 day s wit h more severe features having higher scores, and then simply  added to 
determine the total SLEDAI -2K score, which ranges from 0 to 105.33At baseline (Attachment 
6), the features assessed in the SLEDAI -2K areused for comparison to the S2K RI-50 index 
described below.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
79
Approved, 18 January 2017The SLEDAI -2K has been adapted and developed into the SLEDAI -2K Responder Index (S2K 
RI-50 [ Follow -up],Attachment 7)35, ameasure that can document partial improvement in the 
24disease features between SLEDAI -2K assessments.34A threshold of 50% improvement was 
judged to reflect clinically  significant improvement and is scored as half the weight for the 
feature. “When a descriptor is recorded as present at the init ial visit, 1 of 3 situations can follow: 
(1) the descriptor achieves complete remission at follow -up, in which case the score would be 
“0”; (2) the descriptor does not achieve a minimum of 50% improvement at follow -up, in which 
case the score would be identical to its corresponding SLEDAI -2K value; or (3) the descriptor 
improves by ≥50% (according to the S2K RI-50 definition) but has not achieved complete 
remission, in which case the score is evaluated as one-half the score that would be assigned for 
SLEDAI -2K.”32The S2K RI-50 score is the sum of the 24 scored items, which ranges from 0 to 
105.
[IP_ADDRESS]. BILA G
The BILAG13,17index scores subjects based on the need for alterations or intensification of 
therap y (Attachment 8). The assessing physician will evaluate 97items divided into the 
following 9 organ/sy stems domains.
Constitutional
Mucocutan eous
Neurops ychiatric
Musculoskeletal
Cardiorespi[INVESTIGATOR_696]
Gastrointestinal
Ophthalmic
Renal
Hematological
The assessing physician ought to consider each item as to its presence in the past 4 weeks, and 
answer 0=not present, 1=improving, 2=same, 3=worse, or 4=new as compared with a specified 
reference visit. Each organ/sy stem domain is classified as BILAG A, B, C, D, or E based upon 
organ/sy stem specific items and c riteria specific to the domain.
[IP_ADDRESS]. CLASI
Cutaneous lupus erythematosus disease activity  will be measured by [CONTACT_225363]. The CLASI is 
an instrument the assessing physician will use to assess the disease activity  and damage caused 
to the skin for CLE patients with or without systemic involvement . The CLASI consists of 
2scores; the first summarizes the activity  of the disease while the second is a measure of the 
damage done by [CONTACT_90050] (Attachment 9). Activity  is scored on the basis of erythema, 
scale/h yperkeratosis, mucous membrane involvement, acute hair loss and non-scarring alopecia. 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
80
Approved, 18 January 2017Damage is scored in terms of dyspi[INVESTIGATOR_231727], including scarring alopecia. The 
scores are calculated by [CONTACT_269303].1Higher activity 
and damage scores indicate worse disease activity.
[IP_ADDRESS]. Physician Global A ssessment of Disease A ctivity
The physician must complete the Physician Global Assessment of Disease Activity8independent 
of subjects’ assessment (Attachment 10). The assessments will be recorded on a visual analogue 
scale (VAS; 0 to 10 cm). The scale for the assessment ranges f rom “no Lupus activity ”(0) to 
‘extremely  active Lupus ”(10).
The physician assessor should preferabl y be the same person at every  study visit for a given 
subject.
[IP_ADDRESS]. Patient Global A ssessment s
The subject must complete the Patient Global Assessment of Disease Activity  and Patient’s 
Assessment of Pain independent of the Physician’s Global A ssessment of Disease Activity .
[IP_ADDRESS].1. Patient Global A ssessment of Disease A ctivity
The Global Assessment of Disea se Activit y will be recorded on a visual analogue scale (VAS; 0 
to 10 cm). The scale for the assessment ranges from “very well”(0) to “very poor” (10) (see 
Attachment 11).
[IP_ADDRESS].2. Patient Assessment of Pain
The Patient’s Assessment of Pain is used to assess the patient reported pain intensit y. The 
patient's will be asked to assess their average pain during the past week on a visual analogue 
scale (VAS; 0 to 10 cm ). The anchor s of the instrument include 0 to represent ‘no pain’ and 10 to 
repre sent ‘the worst possible pain.’
[IP_ADDRESS]. Short -Form -36 
The RAND short -form (SF)-36 questionnaire is a self-administered multi-domain scale with 
36items. Eight health domains cover a range of functioning ( Attachment 12):
Limitations in phy sical function
Limitations in usual role activities
Bodily  pain
General mental health (psychological distress and well -being)
Vitality  (energy  and fatigue)
Limitations in social functioning due to ph ysical or mental health problems
Limitations in usual role activities due to personal or emotional problems
General health perception
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327664] languages; the instrument has undergone 
extensive linguistic and cultural validation. Version [ADDRESS_327665] validation was established through comparison to several 
other generic he alth survey s.
[IP_ADDRESS]. Fatigue Severity  Scale
The Fatigue Severity  Scale (FSS) is a 9-item questionnaire designed to assess the severit y of 
fatigue and its impact on daily  living using 7 response options (1=Completely  Disagr ee, 
7=Completely  Agree) during a recall p eriod of the past week (Attachment 13). It can be 
completed within [ADDRESS_327666] describing all efficacy  evaluations and endpoints, and which evaluations are 
included in the composite endpoints is provided in Attachment 1.
[IP_ADDRESS]. SRI-[ADDRESS_327667] a 4 point reduction in SLEDAI 2K score (Section [IP_ADDRESS] ), 
no worsening (˂10 mm increase) from baseline in the Phy sician’s Global Assessment of Disease 
Activity  score (PGA) (Section [IP_ADDRESS] ), and no new BILAG Domain A and no more than 1 new 
BILAG Domain B scores (Section [IP_ADDRESS] ).9SRI-5 and SRI-6 are similarl y defined with response 
requiring a ≥5 point reduction or ≥6 point reduction in SL EDAI 2K, respectively .SRI-5 and SRI -
6 are similarly  defined with response requiring a ≥5 point reduction or ≥6 point reduction in 
SLEDAI -2K, respectively .
[IP_ADDRESS]. BILAG-based Combined Lupus A ssessment 
The BILAG -based Combined Lupus Assessment (BICLA) requires patients to meet response 
criteria across 3 assessment tools: (1) the BILA G-2004 index (2) the SLEDAI index and (3) a 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
82
Approved, 18 January 2017PGA. Patients are identified as responder s or non-responders based upon the following 
requirements:39
Requirements for BICLA Response
BILAG BILAG improvement classified as:
All BILAG A scores at baseline improved to either BILAG B,C or D
All BILAG B scores at baseline improved to either BIL AG C or D
No worsening in disease activity defined as no new BILAG A scores 
and ≤1 new BILAG B score
SLEDAI -2K No worsening of total SLEDAI -2K from baseline (change ≤0)
PGA No significant deterioration (<10 mm increase) in 100 mm visual analogue 
PGA
Treatment Failure No treatment failure (see SAP for definition of treatment failure)
[IP_ADDRESS]. Flares
[IP_ADDRESS]. S2K RI -[ADDRESS_327668] 6 points from baseline in the SL EDAI -2K 
score.
[IP_ADDRESS]. No Worsening in P GA
No worsening in P GAis defined as less than a 10 mm increase on 1 00 mm VAS . 
9.2.3. Endpoints
Primary Endpoint
The primary  endpoint of this study is the proportion of subjects with a composite SRI -4 response 
at Week 24.
Major Secondary Endpoints
The major secondary  endpoints are listed in order of importance as specified below:
1.The change from baseline in SL EDAI -2K at Week 24.
2.The change from baseline in PGA at Week 24.
3.The proportion of subjects with BI CLA response at Week 24.
Other Endpoints
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
83
Approved, 18 January 2017 
 
 
SLE Disease activity:
6.The proportion of subjects with responses in SRI-4, S RI-5, SRI-6, S2K RI-50 response and 
BICLA over time.
7.   
 
9.The absolute change from baseline in SL EDAI -2K, S2K RI -50, PGA over time.
10.The percent change in serological activity  (eg, ANA, anti-dsDNA, other autoantibodies, C3, 
C4) or SL EDAI feature measurements over time.
11.
 
 
 
 
Medications:
16.The proportion of subjects with meaningful changes in selected SLE medications from 
Week 12 through Main Study  8-week Safet y Follow -up Visit /Week 48 .
17.Change in corticosteroid dose from Week 48 through Week 104 for subjects who participate 
in the study  extension .
Development and analyses of the new endpoint(s) will be included ina separated technical 
report.
9.3. Pharmacokinetics and Immunogenicity
Serum samples will be used to evaluate the pharmacokinetics (PK)of ustekinumab, as well as 
the immunogenicity  of ustekinumab (antibodies to ustekinumab). Serum collected for PK and 
immunogenicit y analy ses may additionall y be used to evaluate safet y or efficacy  aspects that 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327669] confidentiality  will be maintained.
9.3.1. Serum Collection and Handling
Venous blood samples will be collected at the time points shown in the Time and Events 
Schedule for the determination of serum ustekinumab concentration s and antibodies to 
ustekinumab. Serum samples will also be collected at the final visit from subjects who terminate 
study  participation early. At visits where PK and immunogenicit y will be evaluated, 1 blood 
draw of sufficient volume can be used. Each sample will be split into 3 aliquots (1 aliquot for 
serum ustekinumab concentration, 1 aliquot for antibodies to ustekinumab, and 1 aliquot as a 
back -up). Samples must be collected before study drug administration at visits when study  drug 
administration is scheduled. The exact dates and times of blood sample collection must be 
recorded in the laboratory  requisition form.
Additional information about the collection, handling, and shipment of biological samples can be 
found in the Laboratory Manual.
9.3.2. Analytical Procedures
Serum samples will be analyzed to determine ustekinumab concentrations using a validated, 
specific, and sensitive immunoassay  method by [CONTACT_2728]’s bioanal ytical facility  or under the 
supervision of the Sponsor. The Sponsor, or its designee, under conditions in which the subjects’ 
identity  remains blinded, will assay  these samples.
9.3.3. Immunogenicity  Assessments
Antibodies to ustekinumab will be detected using a validated immunoassay  method in serum 
samples collected from all subjects. Serum samples that test positive for antibodies to 
ustekinumab will be further characterized to determine if antibodies to ustekinumab could 
neutralize the biological effects of ustekinumab in vitro (ie, neutralizing antibodies [NAbs] to 
ustekinumab). All samples wi ll be tested b y the Sponsor or S ponsor's designee.
9.4. Biomarkers
The collection, preparation, storage and shipment of skin biopsies, blood, serum and urine are 
detailed in the Time and Events schedule ( Table 1) and the Laboratory  Manual. Biomarkers may  
include, but are not limited to, inflammatory markers, RNA, cell surface markers, 
auto-antibodies, T cell and B cell repertoire, target specific markers, and other categories of 
biomarkers potentiall y involved in the development and the progression of lupus.
Serum Analyses
Serum will be analy zed for levels of specific proteins  
 
 
.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327670] 
relevance in SLE.
Skin Biopsy Analyses
Skin biopsies will be utilized for cellular, molecular, and gene expression analy ses.
Whole Blood Gene Expression Analyses
Whole blood will be collected from all subjects for RNA, fl ow cy tometry (samples from selected 
sites will be analy zed at central laboratory or other analytical laboratory), T cell and B cell
repertoire (nucleic acid analy ses [RNA and DNA] for specific T and B cellreceptors only) and 
epi[INVESTIGATOR_269262] (eg, DNA methy lation).
9.5. Pharmacogenomic Evaluations
The DNA samples will be used for research related to this study  (CNTO1275 SLE2001). Specific 
genomic testing will be undertaken forconsenting subjects (subjects participating in this portion 
of the study  must sign a separate ICF). The procedure will involve taking a blood sample that 
may be analyzed for specific target genes that may play a role in lupus. Any genomic 
assessments will be performed in strict adherence to current subject confidentiality  standards for 
genetic testing. Refusal to participate in genomics testing will not result in ineligibility  for 
participation in the rest of the clinical stud y.
9.6. Serologic Markers
Sample for autoantibodies (including ANA, anti-dsDNA , anti-Smith), complement C3, C4, and 
other analytes will be collected as described in the Table of Events (Table 1)and Section 9.8
Safety  Evaluations ( Clinical Laboratory  Tests ).
9.7. Cutaneous Lupus Substudy
Subjects with cutaneous disease will be evaluated using CLASI scoring. Additionally , subjects 
with cutaneous disease who conse nt to participate in the cutaneous lupus substudy  will have 
additional assessments including collection of skin biopsies (optional consent) prior to study  
agent administration at Week 0 and at Week 24 and/or photographs of a cutaneous lesion or an 
area of active disease (optional consent) to be performed as shown in the Table of Events (Table 
1). There will not be any restrictions on the number of subjects with cutaneous disease who can 
enroll into either the main study  or the cutaneous lupus substudy .
Subjects who consent to the optional biopsy  collection will have 2 skin biopsies (4 mm) excised 
from an active target lesion at Week 0, followed by 2 additional biopsies of the same lesion 
(regardless of cutaneous disease activity ) at Week 24 (Cutaneous Lupus Substudy  Manual) . Skin 
biopsies will be utilized for cellular, molecular, and gene expression anal yses.
Independent of cutaneous biopsy  collection, subjects who participate in the cutaneous lupus 
substudy  will be requested to provide consent for photographs to be collected from an identified 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
86
Approved, 18 January 2017cutaneous lesion or an area of active disease . Consenting subjects with cutaneous lupus 
unsuitable for biopsy  (eg, malar rash or alopecia) may be evaluated by [CONTACT_269304] y. The 
photographs are for exploratory  purposes only. The photographs will be used to assist in a 
qualitative evaluation of clinical response . The photographs and skin biopsies can target a 
different area of active disease, but the follow -up photographs or biopsies should re-evaluate the 
same area of active disease as originally  assessed at week 0.Confidentiality  of the subjects 
involved in this study  will be maintained; specifically  photographs of subjec ts in this study  will 
not be published or otherwise made public without blocking adequate portions of the subject’s 
face or bod y so that the individual cannot be id entified.
9.8. Safety  Evaluations
Safety  assessments include vital signs, general physical exam inations and skin evaluations
(assessed during S2K RI-50 and CLASI evaluations) , adverse events, concomitant medication 
review, pregnancy  testing (refer to Section 12.3.3 ), administration reactions, chemistry  and 
hematology  laboratory  tests, and antibodies to ustekinumab. Chest x-ray and TB, HIV, hepatitis 
B, and hepatitis C testing will be required at time of screening (Table 1). Refer to Section 4.1for 
tuberculosis screening criteria. Subjec t diary  cards will be used to capture medication changes 
that occur in between study  visits through the main portion of the study .
Any clinicall y significant abnormalities persisting at the end of the study  will be followed by  [CONTACT_269305] a clinica lly stable endpoint is reached.
The study  will include the following evaluations of safet y and tolerability  according to the time 
points provided in Table 1 and Table 2 for the extended study .
Adverse Events
Adverse events (AE) will be reported by [CONTACT_423] (or, when appropriate, by a caregiver) for 
the duration of the stud y,and will be followed b y the in vestigator.
Infections
Subjects will be provided an alert card of signs and symptoms for infections, and will be 
instructed to contact [CONTACT_269306]. At 
each site visit, i nvestigators or other site personnel are required to evaluate subjects for any  signs 
or symptoms of infection, and ask about symptoms of infection or other AEs that may have 
occurred in between site visits .
Study  agent should not be administered to a subject with a clinicall y important, active infection. 
Treatment with study  agent should be withheld until serious and/or severe infections are 
completely  resolved. If a subject develops a serious or severe infection, including but not limited 
to sepsis or pneumonia, discontinuation of study  treatment must be considered. Treatment must 
be permanentl y discontinued for subjects who develop an opportunistic infection. For active 
varicella -zoster infection or a significant exposure to varicella zoster infection in a subject 
without history  of chickenpox, the subject should be evaluated for symptoms of infection and if 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327671] has received appropriate treatment and/or recove red or no symptoms of infection, 
may continue study  administration after discussion with the study  Sponsor.
Clinical Laboratory Tests 
Blood samples for serum chemistry  and hematology  will be collected according to the Time and 
Events Schedule (Table 1and Table 2for the extended study ). The investigator must review the 
laboratory  report immediately  upon availability , document this review, and record any clinically 
relevant changes occurring during the study  in the AE section of the eCRF. Coomb’ s direct test, 
urine dipstick, urine sediment microscop yandurine pregnancy  test will be performed by [CONTACT_269307] . With the approval of the study  Sponsor , the use of local laboratories 
may also be allowed in cases where initiation of treatment or safet y follow -up is time -critical and 
the central laboratory  results are not expected to be available before the need to provide study  
agent treatment or if actions need to be taken for safet y reasons.
A one-time retest of screening laboratory  test(s)analyzed by [CONTACT_269308].
Hematology  Panel
-hemoglobin
-hematocrit
-white blood cell (WBC) count with differential (basophils, eosinophils, lymphocy tes, 
monocy tes, neutrophils)
-platelet count
-CD 19 -cell anal yses during screening only if needed for subjects previously  
exposed to cell depleting therapi[INVESTIGATOR_014] (Section 4.1.3 )
-Coomb’s direct test (local lab oratorie s, if available )
Serology  Laboratory
-Ig isoty pe profile (Ig G, IgM, IgAlevels)
-C3 and C4 Complement
-ANA
-anti-dsDNA 
-anti-phospholipid antibodies including lupus anticoagulant, anti -cardiolipin ,and 
anti-β2-glycoprotein -I antibodies
-other autoantibod iesincluding anti-Smith , anti-Sjögren’s -syndrome -related antigen 
A (SSA [anti-Ro], and B ( SSB [ anti-La]), anti -ribonucleoprotein (anti -RNP )
Coagulation Labs
-Prothrombin Time 
-Partial Thromboplastin Time 
-International Normalized Ratio 
Serum Chemistry  Panel
-sodium -alkaline phosphatase
-potassium -calcium
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
88
Approved, 18 January 2017-chloride -phosphorous
-bicarbonate -albumin
-blood urea nitrogen -total protein
-creatinine -creatinine kinase
-glucose -aspartate aminotransferase 
-aldolase (if creatine kinase is elevated at 
screening then aldolase test at Week 0 and 
follow -up as needed)-alanine aminotransferase 
-total bilirubin, and if total bilirubin is 
abnormally  elev ated, then direct bilirubin, 
and indirect bilirubin
Urine Anal yses – Fresh spot urine
Urinaly sis using urine dipstick. Urine sample will be further analyzed at 
Central laboratory .
Urinary  protein/creatinine ratio9will be analyzed at the central laboratory
using an aliquot of spot urine collected from subjects .
Urine Sediment Microscopy (Local Laboratory Assessment using spot urine 
samples)
-Red blood cells
-WBC, with note if urinary  tract infection is present/absent
-epi[INVESTIGATOR_1663]
-crystals
-Red blood cells , WBC, or heme -granular casts
-bacteria
Serum and urine pregnancy  testing for women of childbearing potential only
Viral serology  (HIV antibody , HBsAg, anti-HBs, anti-HBc total, and hepatitis C virus 
antibody )
Vital Signs
Weight and temperature will be assessed. Blood pressure and heart rate measurements will be 
assessed.
Physical Examination
A full body  physical examination will be performed pre-treatment and during the study  as shown 
in Table [ADDRESS_327672] be recorded on the laboratory  requisition 
form.
Refer to the Time and Event s Schedule (Table 1and Table 2for the extended study ) for the 
timing and frequency  of all sample collec tions.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327673] COMPLETION/W ITHDRA WAL
10.1. Completion
A subject who does not enter into the study  extension will be considered to have completed the 
main study  if he or she has completed assessment sthrough 16-week safet y follow -up of the main 
study . A subject who has enrolled into the study  extension will be considered to have completed 
themain portion of thisstudy  if he or she has completed assessments through the 8-weeksafet y 
follow -up visit of themain study. Subjects who prematurel y discontinue study  treatment for any 
reason before the Week 8 or Week 16 safety  follow -up visits (from the main study ),will not be 
considered to have completed the main portion of the study .A subject who has enrolled into the 
study  extension will be considered to have completed the study  extension if he or she has 
completed assessments through Week 120.
10.2. Discontinuation o f Study Treatment
If a subject's study  treatment must be discontinued before or at Week 40 (for subjects who do not 
participate in the study  extension) or before Week 104 (for subjects who do participate in the 
study  extension) , this will not result in automatic withdrawal of the subject from the study and 
follow -up assessments should be obtained approximately  [ADDRESS_327674]'s study  treatment must bepermanently discontinued if any  of the following occur:
1.An AE temporally  associated with study  agent infusion or injection, resulting in 
bronchospasm with wheezing and/or dyspnea requiring ventilatory  support, or symptomatic 
hypotension with a greater than [ADDRESS_327675] study  agent injection.
4. The initiation of prohibited medications or treatments (as per Section 4.3).
5.Malignancy , with the exception of no more than 2 localized basal cell skin cancers that are 
treated with no evidence of recurrence or residual disease.
6.An opportunistic infection.
7.The investigator or S ponsor’s medical monitor deems it is in th e subject’s best interest.
8.The subject is deemed ineligible according to the following TB criteria:
A diagnosis of active TB is made.
A subject has symptoms suggestive ofactive TB based on follow -up assessment 
questions and/or physical examination, or has had recent close contact [CONTACT_4490] a person 
with active TB, and cannot or will not continue to undergo additional evaluation.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
90
Approved, 18 January 2017A subject undergoing continued screening has a chest radiograph with evidence of 
current active TB and/or a positive QuantiFERON®-TB Gold test and/or a positive 
tuberculin skin test result in countries in which the QuantiFERON®-TB Gold is not 
approved/registered result and/or an indeterminate QuantiFERO N®-TB Gold test result 
on repeat testing, unless active TB can be ruled out and appropriate treatment for latent 
TB can be initiated either prior to or simultaneously  with the next administration of 
study  agent and continued to completion.
A subject receiv ing treatment for latent TB discontinues this treatment prematurely  or is 
noncompliant with the therap y.
9.Significant worsening of SLE disease activity  from baseline or having high disease activit y 
for 2 or more consecutive visits starting at Week 16 bas ed on overall clinical assessments; or 
if a subject requires the addition of a new immunomodulator to the existing treatment 
regimen after Week 16.
In addition, permanent discontinuation of study  agent treatment must be considered for subjects
who:
Receiv e an increase (relative to baseline) in their immunomodulator dose .
Develop any of the following adverse events that are reported as serious or severe: study 
agent infusion reaction, injection -site reaction, or infection.
10.3. Withdrawal from the Study
A subject will be withdrawn from the stud y for any of the following reasons:
Lost to follow -up
Withdrawal of consent
Death
If a subject is lost to follow -up, every reasonable effort must be made by  [CONTACT_43757]/withdrawal. The measures 
taken to follow -up must be documented.
When a subject withdraws before completing the study , the reason for withdrawal is to be 
documented in the CRF and in the source document. Study  drug assigned to the withdrawn 
subject may not be assigned to another subject. Subjects who withdraw from this study  will not 
be replaced.
A subject who withdraws from the study  will have the following options regarding the optional
research sample s:
The collected sampl eswill be retained and used in accordance with the subject's original 
informed consent for optional research samples .
The subject may withdraw consent for optional research samples, in which case the sample s
will be destroy ed and no further testing will take place. To initiate the sample destruction 
process, the investigator must notify  the Sponsor study  site contact (or appropriate designee) 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327676] may withdraw consent for use of sample sfor research (refer toSection 16.2.5 , 
Long -Term Retention of Samples for Additional Future Research). In such a case, samples will 
be destro yed after they are no longer needed for the clinical study . Details of the sample 
retention for research are presented in the main ICF and in the separate ICF for optional research 
samples.
11. STATISTICA L METHODS
Statistical analy sis will be done by [CONTACT_23815]. A general 
description of the statistical methods to be used to anal yze the efficacy  and safet y data is outlined 
below. Specific details will be provided in the Statistical Analy sis Plan.
11.1. Subject Information
For all subjects who receive at least [ADDRESS_327677] 1dose of study  agent, and will be 
analyzed according to the actual study  agent received.
11.2. Sample Size Determination
The sample size calculation is based upon the primary  endpoint, proportion of SRI-4responders 
at Week 24.Approximately  60subjects treated with ustekinumab and approximately  40 subjects 
with placebo is projected to give approximately  80% power to detect a significant difference in 
response rate compared with placebo (assume 35% and 60% response rates in placebo and 
ustekinumab respectively, which translates to 25% absolute increase over placebo or an odds 
ratio of 2.79) with an alpha level of 0.1.The assumption of a 35% responder rate for placebo is 
based upon a previous study  in which a similar SLE population was treated.36Recent studies 
have shown very high placebo rates in certain regions, thus the power for the study  could be 
reduced.[ADDRESS_327678] a significant treatment difference at α=0.1 (2-sided) is calculated under
various assumptions (see Table 4 ).
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
92
Approved, 18 January 2017Table 4: Power to D etect a Significant Treatm ent Difference in the P roportion of Subjects with SRI -4 
Response at Week 24
Proportion of Placebo 
Group w ith Response (%)Absolute Increase in 
Response (%)Proportion of Ustekinumab 
Group w ith Response (%)Odds Ratio Power
20 20 40 2.67 70%
25 45 3.27 85%
30 50 4.00 94%
25 20 45 2.45 67%
25 50 3.00 82%
30 55 3.67 92%
30 20 50 2.33 64%
25 55 2.85 80%
30 60 3.50 91%
35 20 55 2.27 62%
25 60 2.79 79%
30 65 3.45 91%
40 20 60 2.25 62%
25 65 2.79 79%
30 70 3.50 91%
*Note:  SRI-4 response is defined as a ≥ 4 point reduction in SLEDAI -2K score, no new domain scores in either BILAG A or 
BILAG B  and no worsening (˂10 mm increase) from baseline in the PGA .10
11.3. Efficacy  Analyses 
All efficacy  analyses will be performed on the modified intent -to-treat (mITT) analysis set. The 
mITT analysis set will include all subjects who are randomized and received at least 1 dose of 
study  agent. The efficacy anal yses will be calculated according to their assigned treatment group.
11.3.1. Primary  Endpoint Analysis
The primary  endpoint of this study is the proportion of subjects with a composite measure of 
SLE disease activity  (SRI -4 response) at Week 24 (Section [IP_ADDRESS] ). The primary  analysis will be 
based upon the primary  endpoint and will be conducted on the mITT population, which includes 
all randomized subjects who receive at least 1dose of study agent, have at least [ADDRESS_327679] not achieved the primary  endpoint, SRI-4 response at Week 24 (full details 
will be provided in the SAP):
Between the Week 12 visit and the Week 24 visit, either the dose of an immunomodulator is 
higher than at baseline, or a new immunomodulator has been added to the existing treatment 
regimen.
The addition of a new immunomodulator to the existing treatment regimen before Week [ADDRESS_327680] still was receiving that immunomodulator after Week 12.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
93
Approved, 18 January 2017Initiate treatment with disallowed dose or disallowed use of oral, IV or IM or other type of 
corticosteroid administration for SLE, or increase the dose of oral corticosteroids for SLE 
above baseline between the Week 12 and 24 visits.
Subjects who were not receiving ARB or ACE inhibitor therapy  who then initiated a new 
ARB or ACE inhibitor therap y between Week 12 and Week 24. Subjects who substitute an 
ARB or ACE inhibitor for a comparable medication would not be considered treatment 
failures.
Discontinue study  agent due to lack of efficacy for an AE of worsening of SLE prior to 
Week 24.
For subjects who use systemic corticosteroids for another indication, the efficacy  measurement 
will be carried forward from the last observation prior to the initiation of the treatment, for the 
period of [ADDRESS_327681]’s 
calculated value will be as measured.
Other situations may confound the primary  endpoint, such as a subject initiating NSAID safter 
Week 16, or using epi[INVESTIGATOR_13873], IV, IM, IA, or intra-lesional, inhal ed corticosteroids, and topi[INVESTIGATOR_73264]. Data handling rules will be specified in the Statistical Analy sis Plan.
Logistic regression, adjusting for baseline stratifications and baseline SLEDAI, will be used to 
analyze the primary  endpoint. The baseline SLEDAI value is defined as the closest non-missing 
measurement taken prior to the Week 0 infusion. If significant non-normality  is observed, 
appropriate nonparametric tests will be used to evaluate the differences between treatments.
The study  will be considered positive if the primary  analysis achieves statistical significance at a 
significance level of 0.1 (2-sided) and ustekinumab shows a positive treatment effect relative to 
placebo treatment .
In addition to the primary analysis, sensitivity  analyses will be performed to explore the effects 
with different data handling rules. If it is deemed necessary , the primary  endpoint will be 
analyzed on the per protocol population. Details of the inclusion/exclusion rules for per protocol 
population will be provided in the SAP.
Subgroup analysis based on region will be performed . This is due to potential regional 
differences in evaluating efficacy , and high placebo response rates in certain regions. Subgroup 
analysis of the primary  endpoint by [CONTACT_269309]. 
Details will be outlined in the SAP.
11.3.2. Major Secondary  Analyses
The change from baseline in SL EDAI -2K at Week 24.
The change from baseline in P GAat Week 24. 
The proportion of subjects with BI CLA response at Week 24.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
94
Approved, 18 January 2017Continuous responses will be analy zed using an analy sis of covariance model with treatment 
group as a fixed factor and baseline stratifications (eg, regions) as a covariate. Nonparametric 
methods will be adopted when the normalit y assumption is violated . 
11.3.3. Other Planned Efficacy  Analyses
For the other efficacy  endpoints listed in Section 9.2.3 , the following statistical methods will be 
applied:
Binary  data will be analy zed using the same statistical method as in the primary  efficacy 
analysis. Continuous responses will be analyzed using an analysis of covariance model with 
treatment group as a fixed factor and baseline stratifications (eg, regions) as a covariate. 
Nonparametric methods will be adopted when the normality  assumption is violated. Log-rank 
tests will be used to compare endpoints def ined by  [CONTACT_269310].
11.3.4. Efficacy  Analyses in the Study  Extension
Long -term evaluations of efficacy  including SRI-4, SLEDAI -2K, PGA, reduction in 
corticosteroid dosing, and evaluations of flare over time will also be performed for those subjects 
who participate in the study  extension .
11.4. Interim A nalyses
Interim analy ses (I A) will be conducted when approximately  1/3 and 2/[ADDRESS_327682] appropriate samples for detection of 
antibodies to ustekinumab (ie, subjects with at least [ADDRESS_327683] dose of 
ustekinumab).
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327684] samples evaluable for NAbs.
11.7. Biomarker Analyses
The following results from treated and untreated SLE s ubjects will be summarized:
The concentration of individual serum and urine markers.
Results from selected biomarkers in skin biopsy  tissue by [CONTACT_16638]-sequencing and 
immunohistochemistry .
Results from whole blood gene expression profiling, flow cytometry , T cell and B cell
repertoire, and epi[INVESTIGATOR_7009].
Additional exploratory  analy ses may  be performed following evaluation of the data.
The samples collected from other ongoing clinical studies may  also be included in the biomarker 
data anal yses. Results of biomarke r anal yses may be presented in a separate report.
11.8. Pharmacogenetics Analyses
The DNA research may  consist of the analy sis of 1 or more candidate genes or of the analy sis of 
genetic markers throughout the genome (as appropriate) in relation to this study .
Results of genomic analy ses will be presented in a separate report once the overall number of 
samples including those collected from other sources is appropriate.
11.9. Pharmacokinetic and Pharmacody namic Analy sis
If data permit, the relationships between serum ustekinumab concentration and efficacy  or 
pharmacod ynamic measures may  be anal yzed graphically .
11.10. Safety  Analyses
Safety  analyses will be based on the population of subjects who received at least 1 dose of either 
study  agent; subjects will be summarized by  [CONTACT_269311].
Adverse Events
The verbatim terms used in the CRF by [CONTACT_43760]. All reported AEs with onset during the treatment 
phase (ie, treatmen t-emergent AEs, and AEs that have worsened since baseline) wil l be included 
in the analy sis. For each AE, the percentage of subjects who experience at least 1 occurrence of 
the given event will be summarized by [CONTACT_1570]. Routine safety  evaluations w ill be 
performed. Adverse events, serious AEs (SAEs), reasonably  related AEs, and AEs by [CONTACT_11370] y 
will be summarized by  [CONTACT_1570].
The incidence and ty pes of infections, infusion reaction, and inject site reactions will be anal yzed 
for this study . Aninfusion reaction is defined as an AE that occurs during or within 1 hour 
following the infusion of study agent, with the exception of laboratory  abnormalities.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
96
Approved, 18 January 2017Special attention will be given to those subjects who died, or who discontinued treatment due to 
an adverse event, or who experienced a severe or a serious adverse event(eg, summaries, listings, 
and narrative preparation may  be provided, as appropriate).
Clinical Laboratory Tests
Laboratory  data will be summarized by [CONTACT_269312]. Reference ranges and 
Common Terminology  Criteria for Adverse Events (CTCAE) will be used in the summary  of 
laboratory  data. Descriptive statistics will be calculated for each laboratory  analyte at baseline 
and at each scheduled time point. Changes from basel ine results will be presented in pre-versus 
post-treatment cross- tabulations (with classes for below, within, and above normal ranges based 
on laboratory  reference ranges). The baseline is defined as the last measurement prior to the first 
dose of the randomized treatment. The number and percentage of subjects by [CONTACT_269313]. The laboratory  
parameters and change from baseline in selected laboratory  parameters (hematology  and 
chemistry ), and the number of subjects with abnormal laboratory  parameters (hematology  and 
chemistry ) based onCTCAE toxicity  grading will be summarized treatment group. Listings of 
SAEs will also be provided. All safet y analyses will be based on the population of subjects who 
received at least 1 dose of either study  agent; subjects will be summarized by [CONTACT_269314] y received.
Urine protein and creatinine measurements will be used to calculate the urine protein to 
creatinine ratio. Descriptive statistics will be calculated for these ratios at baseline and at each 
scheduled time point.
Vital Signs
Vital sign measures at each scheduled time point and their changes from baseline will be 
summarized using descriptive statistics. The baseline is define d as the last measurement prior to 
the first do se of the randomized treatment.
11.11. Data Monitoring Committee
An independent DMC will be established to monitor data on an ongoing basis to ensure the 
continuing safet y of the subjects enrolled in this study  and to conduct interim efficacy  analysis. 
The committee will meet at least twice to review interim data, including when 1/3 and 2/[ADDRESS_327685] 1 statistician. The DMC 
responsibilit ies, authorities, and procedures will be documented in its charter.
The DMC will no longer be active after the assessment of the primary  endpoint in this study .
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327686] Operating Procedures in 
conformity  with regulatory  requirements worldwide to ensure appropriate reporting of safet y 
information; all clinical studies conducted by [CONTACT_269315].
12.1. Definitions
12.1.1. Adverse Event Definitions and Classifications
Adverse Event
An adverse event is any untoward medical occurrence in a clinical study  subject administered a 
medicinal (investigational or non-investigational) product. An adverse event does not necessaril y 
have a causal relationship with the treatment. An adverse event can therefore be any  unfavorable 
and unintended sign (including an abnormal finding), sy mptom, or disease temporally  associated 
with the use of a medicinal (investig ational or non-investigational) product, whether or not 
related to that medicinal (investigational or non-investigational) product. (Definition per 
International Conference on Harmonis ation [I CH])
This includes any occurrence that is new in onset or aggrav ated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
Note: The Sponsor collects adverse events starting with the signing of the ICF (refer to 
Section 12.3.[ADDRESS_327687] adverse event recording).
Serious Adverse Event
A serious adverse event based on ICH and EU Guidelines on Pharmacovigilance for Medicinal 
Products for Human Use is any  untoward medical occurrence that at an y dose:
Results in death
Is life -threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that 
hypothetically  might hav e caused death if it were more severe.)
Requires inpatient hospi[INVESTIGATOR_1081]
Results in persistent or significant disability /incapacity
Is a congenital anomal y/birth defect
Is a suspected transmission of an y infectious agent via a medicinal product
Is Medicall y Important*
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
98
Approved, 18 January 2017*Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
also appropriate in other situations, such as important medical events that may not be 
immediat ely life threatening or result in death or hospi[INVESTIGATOR_43714] 1 of the other outcomes listed in the definition above. 
These should usually  be considered serious.
If a serious and unexpected adverse event occurs for which there is evidence suggesting a causal 
relationship between the study  drug and the event (eg, death from anaph ylaxis), the event must 
be reported as a serious and unexpe cted suspected adverse reaction.
Unlisted (Unexpected) A dverse Event/Reference Safety Information
An adverse event is considered unlisted if the nature or severity  is not consistent with the 
applicable product reference safety  information. For ustekinumab, the expectedness of an 
adverse event will be determined by w hether or not it is listed in the Investigator's Brochure. For 
ustekinumab with a marketing authorization, the expectedness of an adverse event will be 
determined b y whether or not it is listed in the Investigator’s Brochure.
Adverse Event Associated With the Use of the Drug
An adverse event is considered associated with the use of the drug if the attribution is possible, 
probable, or very  likel yby [CONTACT_269316].
12.1.2. Attribution Definitions
Not Related
An adverse event that is not related to the use of the drug.
Doubtful
An adverse event for which an alternative explanation is more likely, eg,concomitant drug(s), 
concomitant disease(s), or the relationship in time suggests that a causal relationship is unlikely .
Possible
An adverse event that might be due to the use of the drug. An alternative explanation, 
eg,concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; therefore, the causal relationship cannot be excluded.
Probable
An adverse event that might bedue to the use of the drug. The relationship in time is suggestive 
(eg,confirmed by [CONTACT_23827]). An alternative explanation is less likely, eg,concomitant 
drug(s), concomitant disease(s).
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
99
Approved, 18 January 2017Very Likely
An adverse event that is listed as a possible advers e reaction and cannot be reasonabl y explained 
by [CONTACT_4867], eg,concomitant drug(s), concomitant disease(s). The relationship 
in time is very  suggestive (eg, it is confirmed b y dechallenge and rechallenge).
12.1.3. Severity Criteria
An assessment of severity  grade will be made using the following general categorical 
descriptors:
Mild : Awareness of symptoms that are easily tolerated, causing minimal discomfort and not 
interfering with every day activities.
Moderate : Sufficient discomfort is present t o cause interference with normal activity .
Severe : Extreme distress, causing significant impairment of functioning or incapacitation. 
Prevents normal every day activities.
The investigator should use clinical judgment in assessing the severit y of events notdirectly  
experienced b y the subject (eg, laboratory  abnormalities).
12.2. Special Reporting Situations
Safety  events of interest on a Sponsor study  drugthat may require expedited reporting and/or 
safet y evaluation include, but are not limited to:
Overdose of a Sponsor study  drug
Suspected abuse/misuse of a Sponsor study  drug
Inadvertent or accidental exposure to a Sponsor study  drug
Medication error involving a Sponsor product (with or without subject/patient exposure to 
the Sponsor study  drug , eg, name [CONTACT_2976])
Adverse events of special interest: anynewl y identified malignancy , opportunistic infection 
(ie,infection by [CONTACT_269317]), or case of active TBoccurring after the first 
administration of study  agent in subjects participating in this clinical trial must be reported 
by [CONTACT_269318]. Investigators are also advised that active TB is 
considered a reportable disease in most countries. These events are to be considered serious 
only if they  meet the definition of an SAE.
Special reporting situations should be recorded in the CRF. Any special reporting situation that 
meets the criteria of a serious adverse event should be recorded on the serious adverse event page 
of the CRF.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327688]'s last 
study -related procedure (which may include contact [CONTACT_20687] -up of safety ). Serious adverse 
events, including those spontaneously  reported to the investigator within 16weeks after the last 
dose of study  drug, must be reported using the Serious Adverse Event Form. The Sponsor will 
evaluate an y safet y information that is spontaneously  reported b y an investigator bey ond the time 
frame specified in the protocol.
All events that meet the definition of a serious adverse event will be reported as serious adverse 
events, regardless of whether they  are protocol -specific assessments.
All adverse events, regardless of seriousness, severity , or presumed relationship to study  drug, 
must be recorded using medical terminology  in the source document and theCRF. Whenever 
possible, diagnoses should be given when signs and symptoms are due to a common etiology 
(eg,cough, runny nose, sneezing, sore throat, and head congestion should be reported as "upper 
respi[INVESTIGATOR_23739]"). Investigators must record in the CRF their opi[INVESTIGATOR_23740] . All measures required for adverse event 
management must be recorded in the source document and reported according to Sponsor
instructions.
The Sponsor assumes responsibi lity for appropriate reporting of adverse events to the regulatory 
authorities. The Sponsor will also report to the investigator (and the head of the investigational 
institute where required) all serious adverse events that are unlisted (unexpected) and associated 
with the use of the study  drug. The investigator (or Sponsor where required) must report these 
events to the appropriate Independent Ethics Committee/I nstitutional Review Board (IEC/IRB) 
that approved the protocol unless otherwise required and doc umented by  [CONTACT_6179]/I RB. 
The subject must be provided with a "wallet (study )card" and instructed to carry this card with 
them for the duration of the study  indicating the following:
Study number
Statement, in the local language(s), that the subject is pa rticipating in a clinical study
Investigator's name [INVESTIGATOR_1238] 24-hour contact [CONTACT_23828]
Local Sponsor 's name [INVESTIGATOR_1238] 24-hour contact [CONTACT_23828] (for medical staff only )
Site number
Subject number
Any other information that is required to do an emergency breaking of the blind
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327689] be completed and signed by a physician from the study  site, 
and transmitted to the Sponsor within 24 hours. The initial and follow -up reports of a serious 
adverse event should be made b y facsimile (fax) .
All serious adverse events that have not resolved by [CONTACT_2054] , or that have not 
resolved upon discontinuation of the subject's participation in the study , must be followed until 
any of the fo llowing occurs:
The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the study  drug or to factors unrelated to 
study  conduct
It becomes unlikely  thatany additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow -up after demonstration 
of due diligence with follow- up ef forts)
Suspected transmission of an infectious agent by a medicinal product will be reported as a 
serious adverse event. Any event requiring hospi[INVESTIGATOR_059] (or prolongation of hospi[INVESTIGATOR_059]) 
that occurs during the course of a subject's participation in a study  must be reported as a serious 
adverse event , except hospi[INVESTIGATOR_23741]:
Hospi[INVESTIGATOR_23742] (eg, social reasons 
such as pending placement in long -term care facility )
Surgery  or procedure planned before entry  into the study  (must be documen ted in the CRF ). 
The cause of death of a subject in a study  within 16weeks of the last dose of study  drug , whether 
or not the event is expected or associated with the study  drug, is considered a serious adverse 
event.
12.3.3. Pregnancy
All initial reports of pregnancy must be reported to the Sponsor by [CONTACT_1758] -site personnel
within [ADDRESS_327690]. Abnormal 
pregnancy  outcomes (eg, spontaneous abortion, stillbirth, and congenital anomal y) are 
considered serious adverse events and must be reported using the Serious Adverse Event Form. 
Any subject who becomes pregnant during the study  must discontinue further study  treatment , 
and followed for [ADDRESS_327691] stud y dose.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327692] of the study  drug on sperm is unknown, pregnancies in partners of male subjects 
included in the study  will be reported by [CONTACT_1758] -site personnel within 24 hours of their 
knowledge of the event using the appropriate pregnancy  notification form.   
Follow -up information regarding the outcome of the pregnancy  and any  postnatal sequelae in the 
infant will be required .
12.4. Contact[CONTACT_23830] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_23831] y issues or questions regarding the study  are listed on the Contact [CONTACT_23832](s), which will be provided as a separate document.
13. PRODUCT QUA LITY COMPLA INT HA NDLIN G
A product qualit y complaint (PQC) is defined as any suspi[INVESTIGATOR_1884] a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity , quality , 
durability , or reliabilit y of a product, in cluding its labeling or package integrity . A PQC may  have 
an impact on the safet y and ef ficacy  of the product. T imely , accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protection of subjects, investigators, 
and the Sponsor , and are mandated by [CONTACT_23824]. The Sponsor has 
established procedures in conformity  with regulatory  requirements worldwide to ensure 
appropriate reporting of PQC information; all studies conducted by [CONTACT_41034].
13.1. Procedures
All initial PQCs must be reported to the Sponsor by [CONTACT_1758] -site personnel within [ADDRESS_327693] report the 
PQC to the Sponsor according to the serious adverse event reporting timelines (refer to 
Section 12.3.2 , Serious Adverse Events). A sample of the suspected product should be 
maintained for further investigation if requested by [CONTACT_1034] .
13.2. Contact[CONTACT_23834] (and corresp onding telephone numbers) of the individuals who should be contact[CONTACT_41035](s), which will be 
provided as a separate document.
14. STUDY DRUG INFORMA TION
14.1. Physical Description of Study Drug
14.1.1. IVadministration
Ustekinumab 5mg/mL FVP (IV) is supplied as a single -use, sterile solution in 30 mL vials with 
1dose strength (ie,130 mg in 26 mL nominal volume). In addition to ustekinumab, the solution 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
103
Approved, 18 January 2017contains 10 mM L-histidine , 8.5% (w/v) sucrose, 0.04% (w/v) polysorbate 80, 0.4 mg/mL 
L-methionine, and 20 µg/mL  EDTA disodium salt, dihydrate at pH 6.0. No preservatives are 
present.
Placebo for FVP (IV) is supplied as single -use, sterile solution in 30 mL vials with a 26 mL 
nominal volume. The composition of the placebo is 10 mM L-histidine, 8.5% (w/v) sucrose, 
0.04% (w/v) polysorbate 80, 0.4 mg/mL L-methionine, and 20 µg/mL EDTA disodium salt, 
dihydrate at pH 6.0. No preservatives are present.
14.1.2. SC administration
Ustekinumab will also be supplied as a single -use latex -free PFS in a strength of 90 mg in 1 mL 
nominal volume for SC administration. Each 1 mL of ustekinumab solution in the PFS contains 
90mg ustekinumab with nominal excipi[INVESTIGATOR_269253] 6.7 mM L-histidine, 7.6% (w/v) 
sucrose, 0.004% (w/v) polysorbate 80, at pH 6.0. No preservatives are present. The needle cover 
on the PFS contains dry natural rubber (a derivative of latex), which may cause allergic reactions 
in individuals sensitive to latex.
Placebo administrations will have the same appearance as the respective ustekinumab 
administrations. Liquid placebo will also be supplied in a [ADDRESS_327694] a composition 
10 m M L-histidine, 8.5% (w/v) sucrose, 0.004% (w/v) polysorbate 80, at pH 6.0. No 
preservatives are present. The needle cover on the PFS contains dry natural rubber (a derivative 
of latex), which may  cause allergic reactions in individuals sensitive to latex. 
14.2. Packaging
The investigational supplies will be uniquel y packaged to assure that they are appropriatel y 
managed throughout the supply  chain process.
14.3. Labeling
Study  drug labels will contain information to meet the applicable regulatory requirements. 
14.4. Prepa ration, Handling, and Storage
All study  agent must be stored at controlled temperatures ranging from 36°F to 46°F (2°C to 
8°C), not frozen, and protected from light. Vigorous shaking of the product should be avoided. 
Prior to administration, the product should be inspected visually  for particulate matter and 
discoloration. If discoloration (other than a slight y ellow color), visible opaque particles, or other 
foreign particles are observed in the solution, the product should not be used.
Study  agent in glass vials of PFS will be ready to use. The infusions will be prepared according 
to the subject’s treatment assignment and weight (for weight -range based infusions ). The 
pharmacist (or designated personnel) will prepare the required volume of study  agent to be 
infused using the appropriate number of vials.
Aseptic procedures must be used during the preparation and administration of the study  material. 
Exposure to direct sunlight should be avoided during preparation and administration.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327695] be 
documented on the drug accountability  form. All study  drug will be stored and disposed of 
according to the Sponsor's instructions. Study -site personnel must not combine contents of the 
study  drug containe rs.
Study  drug must be handled in strict accordance with the protocol and the container label, and 
must be stored at the study  site in a limited -access area or in a locked cabinet under appropriate 
environmental conditions. Unused study  drug, and study  drug returned by [CONTACT_423], must be 
available for verification by [CONTACT_1034]'s study  site monitor during on-site monitoring visits. 
The return to the Sponsor of unused study  drug, or used returned study  drug for destruction, will 
be documented on the drug return form. When the study  site is an authorized destruction unit and 
study  drug supplies are destroy ed on -site, this must also be documented on the drug return form.
Potentially  hazardous materials such as used infusion bags, needles, sy ringes and vials should be 
disposed of immediately  in a safe manner and therefore will not be retained for drug 
accountability  purposes. 
Study  drug should be dispensed under the supervision of the investigator or a qualified member 
of the study -site personnel, or by a hospi[INVESTIGATOR_307]/clinic pharmacist. Study  drug will be supplied only 
to subjects participating in the study . Returned study  drug must not be dispensed again, even to 
the same subject. Study  drug may not be relabeled or reassigned for use by [CONTACT_23837]. The 
invest igator agrees neither to dispense the study  drug from, nor store it at, any site other than the 
study sites agreed upon with the S ponsor.
15. STUDY -SPECIFIC MATERIA LS
The investigator will be provided with the following supplies:
Investigator Brochure 
Package Insert for Ustekinumab
Study  site investigational product procedures manual
Central Laboratory  manual
Cutaneous lupus s ubstudy  manual
Investigational Product manual
PRO questionnaires and efficacy  worksheets
IWRS manual 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
105
Approved, 18 January 2017Sample I CF
Subject diar y card
16. ETHICA L ASPECTS
16.1. Study -Specific Design Considerations
Potential subjects will be fully informed of the risks and requirements of the study  and, during 
the study , subjects will be given any new information that may affect their decision to continue 
participa tion. They  will be told that their consent to participate in the study is voluntary  and may 
be withdrawn at any time with no reason given and without penalt y or loss of benefits to which 
they would otherwise be entitled. Only subjects who are fully  able tounderstand the risks, 
benefits, and potential adverse events of the study, and provide their consent voluntarily  will be 
enrolled.
The total blood volume to be collected will be approximately  [ADDRESS_327696] over the course 
of the study , which is appro ximately  1.5 times the amount of a ty pi[INVESTIGATOR_269263].
16.2. Regulatory  Ethics Compliance
16.2.1. Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good C linical Practice (GCP), and applicable regulatory  and 
country -specific requirements.
Good Clinical Practice is an international ethical and scientific qualit y standard for designing, 
conducting, recording, and reporting studies that involve the participati on of human subjects. 
Compliance with this standard provides public assurance that the rights, safety , and well being of 
study  subjects are protected, consistent with the principles that originated in the Declaration of 
Helsinki, and that the study  data ar e credible.
16.2.2. Independent Ethics Committee or Institutional Review  Board
Before the start of the study , the investigator (or Sponsor where required) will provide the 
IEC/IRB with current and complete copi[INVESTIGATOR_23747] (as required by [CONTACT_13125]):
Final protocol and, if applicable, amendments
Sponsor -approved ICF (and any  other written materials to be provided to the subjects)
Investigator's Brochure (or equivalent information) and amendments/addenda
Sponsor -approved subject recruiting m aterials
Subject diary  card
Information on compensation for study -related injuries or payment to subjects for 
participation in the study , if applicable
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
106
Approved, 18 January 2017Investigator's curriculum vitae or equivalent information (unless not required, as 
documented b y the IEC /IRB)
Information regarding funding, name [CONTACT_17008] S ponsor, institutional affiliations, other potential 
conflicts of interest, and incentives for subjects
Any other documents that the I EC/IRB requests to fulfill its obligation
This study  will be undertaken only after the IEC/I RB has given full approval of the final 
protocol, amendments (if any, excluding the ones that are purely  administrative, with no 
consequences for subjects, data or study  conduct), the ICF, applicable recruiting materials, and 
subject compensation programs, and the Sponsor has received a copy of this approval. This 
approval letter must be dated and must clearly  identify  the IEC/I RB and the documents being 
approved.
Approval for the collection of optional pharmacogenetics samples and / or cutaneous skin 
biopsies for research and for the corresponding ICF must be obtained from the IEC/IRB. 
Approval for the protocol can be obtained independent of this optional research component.
During the study the investigator (or S ponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:
Protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct)
Revision(s) to ICF and any  other written materials to be provided to subjects
If applicable, new or revised subject recrui ting materials approved b y the S ponsor
Revisions to compensation for study -related injuries or payment to subjects for participation 
in the study , ifapplicable
New edition(s) of the Investigator's Brochure and amendments/addenda
Summaries of the status of the study  at intervals stipulated in guidelines of the IEC/IRB (at 
least annuall y)
Reports of adverse events that are serious, unlisted/unexpected, and associated with the 
study  drug
New information that may adversel y affect the safet y of the subjects or the conduct of the 
study
Deviations from or changes to the protocol to eliminate immediate hazards to the subjects
Report of deaths of subjects under the investigator's care
Notification if a new investigator is responsible for the study  at the site
Development Safet y Update Report and Line Listings, where applicable
Any other requirements of the IEC/I RB
For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct), the amendment and applicable ICF 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327697] be submitted promptly  to the IEC/I RB for review and approval before 
implementation of the change(s). 
At least once ayear, the IEC/IRB will be asked to review and reapprove this study . The 
reapproval should be documented in writing (excluding the ones that are purel y 
administrative, with no consequences for subjects, data, or stud y conduct).
At the end of the study , the investigator (or S ponsor where required) will notify  the IEC/I RB 
about the study  completion.
16.2.3. Informed Consent
Each subject must give written consent according to local requirements after the nature of the 
study  has been fully  explained. The ICF(s) must be signed before performance of any 
study -related activity . The ICF(s) that is/are used must be approved by [CONTACT_265241]/I RB and be in a language that the subject can read and understand. The 
informed consent should be in accor dance with principles that originated in the Declaration of 
Helsinki, current ICH and GCP guidelines, applicable regulatory  requirements, and Sponsor 
policy .
Before enrollment in the study , the investigator or an authorized member of the study -site 
personn el must explain to potential subjects the aims, methods, reasonably anticipated benefits, 
and potential hazards of the study , and any discomfort participation in the study  may entail. 
Subjects will be informed that their participation is voluntary  and that they  may withdraw 
consent to participate at any time. They  will be informed that choosing not to participate will not 
affect the care the subject will receive for thetreatment of his or her disease. Subjects will be 
told that alternative treatments are available if they refuse to take part and that such refusal will 
not prejudice future treatment. Finally , they will be told that the investigator will maintain a 
subject identification register for the purposes of long-term follow -up if needed and that their 
records may be accessed by [CONTACT_269319] S ponsor personnel without 
violating the confidentiality  of the subject, to the extent permitted by [CONTACT_6983](s) or 
regulations. By [CONTACT_269320] s, and agrees to allow his or 
her study  physician to recontact [CONTACT_269321] y evaluations, if needed , and subsequent disease -related treatments, or to obtain information 
about his or her survival stat us.
The subject will be given sufficient time to read the ICF and the opportunity  to ask questions. 
After this explanation and before entry  into the study , consent should be appropriatel y recorded 
by [CONTACT_19720]'s personally  dated signature. After having obtained the consent, a copy 
of the I CF must be given to the subject.
Subjects will be asked for consent to provide optional samples for research where local 
regulations permit. After informed consent for the study  is appropriatel y obtained, the subject 
will be asked to sign and personally date a separate ICF indicating agreement to participate in the 
optional research component. Refusal to participate in the optional research will not result in 
ineligibility  for the stud y. A cop y of this signed ICF will be given to the subject.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327698] includes explicit consent for the processing of 
personal data and for the investigator/institution to allow direct access to his or her original 
medical records (source data/documents) for study -related monitoring, audit, IEC/IRB review , 
and regulatory  inspection. This consent also addresses the transfer of the data to other entities 
and to other countries.
The subject has the right to request through the investigator access to his or her personal data and 
the right to request rectificat ion of any data that are not correct or complete. Reasonable steps 
will be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study , and the applicable laws and regulations.
Exploratory  DNA, pharm acod ynamic, biomarker, PKand immunogenicity research is not 
conducted under standards appropriate for the return of data to subjects. In addition, the Sponsor 
cannot make decisions as to the significance of any findings resulting from exploratory  research . 
Therefore, exploratory  research data will not be returned to subjects or investigators, unless 
required by [CONTACT_67827]. Privacy  and confidentiality  of data generated in the future 
on stored samples will be protected b y the same standards applicable to all other clinical data.
16.2.5. Long -Term Retention of Samples for A dditional Future Research
Samples collected for PK, immunogenicit y and biomarker analysesin this study  may be stored 
for up to 15 years (or according to local regulations) for additional research. Samples will only 
be used to understand ustekinumab, to understand lupus, to understand differential drug 
responders, and to develop tests/assay s related to ustekinumab and lupus . The research may 
begin at an y time during the study  or the post -study  storage period. 
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be 
stored for research (refer to Section 10.3, Withdrawal From the Study  [Withdrawal From the Use 
of Samples in Future Research ]).
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327699] not be implemented without prior IEC/I RB 
approval, or when the relevant competent authority  has raised any grounds for non-acceptance, 
except when necessary to eliminate immediate hazards to the subjects, in which case the 
amendment must be promptly  submitted to the IEC/I RB and relevant competent authority . 
Docume ntation of amendment approval by  [CONTACT_23846]/IRB must be provided to the 
Sponsor. When the change(s) involves only logistic or administrative aspects of the study , the 
IRB (and IEC where required) onl y needs to be notified.
During the course o f the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendanc e will contact [CONTACT_269322] (see Contact [CONTACT_23774](s) provided separatel y). Except in emergency 
situations, this contact [CONTACT_41042]. In 
all cases, contact [CONTACT_41043]. The data recorded inthe CRF and source documents 
will reflect any departure from the protocol, and the source documents will describe this 
departure and the circumstances requiring it.
17.2. Regulatory  Documentation
17.2.1. Regulatory  Approval/Notification
This protocol and any amendment( s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulatory 
requirements are met.
17.2.2. Required Prestudy  Documentation
The following docum ents must be provided to the Sponsor before shipment of study  drug to the
study  site:
Protocol and amendment(s), if an y, signed and dated by [CONTACT_458]
[INVESTIGATOR_269264]0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
110
Approved, 18 January 2017A copy of the dated and signed (or sealed, where appropriate per local regulations), written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approval must clearly  identify  the specific 
protocol by [CONTACT_23850] (or sealed, where appropriate per local 
regulati ons) b y the chairman or authorized designee.
Name [CONTACT_23875]/IRB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a  letter of explanation, or equivalent, 
from the IEC/I RB, a general statement may be substituted for this list. I f an investigator or a 
member of the study -site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the 
vote/opi[INVESTIGATOR_23748].
Regulatory  authority  approval or notification, if applicable
Signed and dated statement of investigator (eg,Form Food and Drug Administration 1572), 
if applicab le
Documentation of investigator qualifications (eg, curriculum vitae)
Completed investigator financial disclosure form from the principal investigator, where 
required
Signed and dated clinical trial agreement, which includes the financial agreement
Any other documentation required b y local regulations
The following doc uments must be provided to the S ponsor before enrollment of the first subject:
Completed investigator financial disclosure forms from all subinvestigators
Documentation of subinvestigator qualifications (eg, curriculum vitae)
Name [CONTACT_23876] , and a dated copy  of 
current laboratory  normal ranges for these tests, if applicable
Local laboratory  documentation demonstrating competence and test reliability 
(eg,accreditation/license), if applicable
17.3. Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study . This document will be reviewed by [CONTACT_23852] -site contact [CONTACT_23853].
The subject identification and enrollment log will be treated as confidential and will be filed by 
[CONTACT_23854]. To ensure subject confidentialit y, no copy  will be made. All 
reports and communications relating to the study  will identify  subjects by [CONTACT_66887]. In cases where the subject is not randomized into the study , the date seen and 
date of birth will be use d.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment [ADDRESS_327700] be available for the following to confirm data 
collected in the CRF: subject identification, eligibility , and study  identification; study  discussion 
and date of signed informed consent; dates of visits; results of safety  and efficacy  parameters as 
required by [CONTACT_760]; record of all adverse events and follow -up of adverse events; 
concomitant medication; drug receipt/dispensing/return records; study drug administration 
information; and date of study  completion and reason for early discontinuation of study  drug or 
withdrawal from the stud y, if applicable. 
In addition, the author of an entry  in the source documents should be identifiable.
At a minimum, the type and level of detail of source data available for a subject should be 
consistent with that commonly  recorded at the study  site as abasis for standard medical care. 
Specific details required as source data for the study  will be reviewed with the investigator 
before the study  and will be described in the monitoring guidelines (or other equivalent 
document).
The following data will be recorded directl y into the CRF and will be considered source data: 
Race
History  of smoking 
Blood pressure , temperature, and pulse/heart rate 
Height and weight
The minimum source documentation requirements for Section 4.1, Inclusion Criteria and 
Section 4.1.3 , Exclusion Criteria that specify  a need for documented medical history  are as 
follows:
Referral letter from treating ph ysician or
Complete history  of medical notes at the site
Discharge summ aries
Inclusion and exclusion criteria not requiring documented medical history must be verified at a 
minimum by [CONTACT_41047] (eg, physical examination, 
laboratory  assessment) and documented in the source document s.
17.5. Case Report Form Completion
Case report forms are provided for each subject in [electronic format]. 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
112
Approved, 18 January 2017Electronic Data Capture (eDC) will be used for this study . The study  data will be transcribed by 
[CONTACT_3449] -site personnel from the source documents onto an electronic CRF (eCRF) , and transmi tted 
in a secure manner to the Sponsor within the timeframe agreed upon between the Sponsor and 
the study  site. The electronic file will be considered to be the eCRF.
Worksheets may be used for the capture of some data to facilitate completion of the eCRF. Any 
such worksheets will become part of the subject's source documentation. All data relating to the 
study  must be recorded in eCRFs prepared by [CONTACT_1034]. Data must be entered into eCRFs in 
English. Study  site personnel must complete the eCRF as soon as possible after a subject visit, 
and the forms should be available for review at the next scheduled monitoring visit.
All subjective measurements (eg, pain scale information or other questionnaires) will be 
completed by [CONTACT_23856]. The investigator must verify  that all data entries in the eCRFs are accurate and correct.
All eCRF entries, correction s, and alterations must be made by [CONTACT_97528] -site personnel. If necessary , queries will be generated in the eDC tool. The 
investigator or stud y-site personnel must adjust the eCRF (if applicable) and complete the query . 
Ifcorrections to the eCRF are needed after the initial entry  into the eCRF, this can be done in 
3different way s:
Study  site personnel can make corrections in the eDC tool at their own initiative or as a 
response to an auto query (generated b y the eDC tool) .
Study  site manager can generate a query  for resolution by  [CONTACT_1758] -site personnel.
Clinical data manager can generate a query  for resolution by  [CONTACT_1758] -site personnel.
17.6. Data Quality  Assurance/Quality  Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
study -site personnel before the study , periodic monitoring visits by [CONTACT_1034], and direct 
transmi ssion of clinical laboratory  data from a central laboratory  into the Sponsor's data base. 
Written instructions will be provided for collection, handling, storage, and shipment of samples. 
Guidelines for CRF completion will be provided and reviewed with study-site personnel before 
the start of the study . The Sponsor will review CRFs for accuracy  and completeness during 
on-site monitoring visits and after transmission to the Sponsor; any discrepancies will be 
resolved with the investigator or designee, as appropriate. After upload of the data into the study  
database they  will be verified for accuracy  and consistency  with the data sources. 
17.7. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all CRFs 
and all source documents that support the data collected from each subject, as well as all study  
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
113
Approved, 18 January 2017Clinical Trial, and all study  documents as specified by [CONTACT_23859](s). 
The investigator/institution will take measures to prevent accidental or premature destruction of 
these documents.
Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applica tions in an ICH region or until at least 2years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents will be 
retained for a longer period if required by [CONTACT_23859] s or by [CONTACT_269323]. It is the responsibility  of the Sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdra ws from the 
responsibility  of keepi[INVESTIGATOR_13274], custody  must be transferred to a person who will 
accept the responsibility . The S ponsor must be notified in writing of the name [CONTACT_23877]. Under no circumstance shall the inves tigator relocate or dispose of any study  
documents before having obta ined written approval from the S ponsor.
17.8. Monitoring
The Sponsor will use a combination of monitoring techniques (central, remote and/or on-site 
monitoring) to monitor this study .
The Spons or will perform on-site monitoring visits as frequently  as necessary . The monitor will 
record dates of the visits in a study  site visit log that will be kept at the study  site. The first 
post-initiation visit will be made as soon as possible after enrollme nt has begun. At these visits, 
the monitor will compare the data entered into the CRFs with the hospi[INVESTIGATOR_40961] 
(source documents). The nature and location of all source documents will be identified to ensure 
that all sources of original data required to complete the CRF are known to the Sponsor and 
study -site personnel and are accessible for verification by [CONTACT_23861] -site contact. If 
electronic records are maintained at the study  site, the method of verification must be discussed 
with th e study -site personnel. 
Direct access to source documentation (medical records) must be allowed for the purpose of 
verify ing that the data recorded in the CRF are consistent with the original source data. Findings 
from this review of CRFs and source docum ents will be discussed with the study -site personnel. 
The Sponsor expects that, during monitoring visits, the relevant study -site personnel will be 
available, the source documentation will be accessible, and a suitable environment will be 
provided for revi ew of study -related documents. The monitor will meet with the investigator on a 
regular basis during the study  to provide feedback on the study  conduct.
In addition to on-site monitoring visits, remote contacts can occur. It is expected that during 
these r emote contacts, study -site personnel will be available to provide an update on the progress 
of the study  at the site. It is important that the study  data be recorded promptly  in order to 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
114
Approved, 18 January 2017facilitate continuous remote monitoring of data, as well as to conduc t interim assessments of 
study  futility  and/or notable efficacy .
Central monitoring will take place for data the identified by [CONTACT_269324]. 
17.9. Study Completion/Termination
17.9.1. Study Completion
The study  is considered completed with the last visit for the last subject participating in the 
study . The final data from the study  site will be sent to the Sponsor (or designee) after 
completion of the final subject visit at that study  site, in the time frame specified in the Clinical 
Trial Agr eement.
17.9.2. Study Termination
The Sponsor reserves the right to close the study site or terminate the study  at any time for any 
reason at the sole discretion of the Sponsor. Study sites will be closed upon study  completion. A 
study  site is considered closed when all required documents and study  supplies have been 
collected and a study -site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance o f the intended termination.
Reasons for the early closure of a study  site by [CONTACT_23863]:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/I RB or
local health authorities, the S ponsor's procedures, or GCP guidelines
Inadequate recruitment of subjects by  [CONTACT_093]
Discontinuation of further study  drug development
17.10. On-Site A udits
Representatives of the Sponsor's clinical quality  assurance depa rtment may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
with regulatory  guidelines and company  policy . These audits will require access to all study 
records, including source docume nts, for inspection and comparison with the CRFs. Subject 
privacy  must, however, be respected. The investigator and study -site personnel are responsible 
for being present and available for consultation during routinely  scheduled study -siteaudit visits 
conducted b y the S ponsor or its designees. 
Similar auditing procedures may also be conducted by [CONTACT_23865], either as 
part of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission. The investigator should immediately  notify  the Sponsor if he or she has 
been contact[INVESTIGATOR_530] b y a regulatory agency  concerning an upcoming inspection.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
115
Approved, 18 January 201717.11. Use of Information and Publication
All information, including but not limited to information regarding ustekinum abor the Sponsor's 
operations (eg,patent application, formulas, manufacturing processes, basic scientific data, prior 
clinical data, formulatio n information) supplied by [CONTACT_269325], and any data, includ ing pharmacogenomic or exploratory  biomarker 
research data, generated as a result of this study , are considered confidential and remain the sole 
propert y of the Sponsor. The investigator agrees to maintain this information in confidence and 
use this information only to accomplish this study, and will not use it for other purposes without 
the S ponsor's prior written consent.
The investigator understands that the information developed inthe study will be used by [CONTACT_269326], and thus may be 
disclosed as required to other clinical investigators or regulatory  agencies. To permit the 
information derived from the clinical studies to be used, the investigat or is obligated to provide 
the S ponsor with all data obtained in the study .
The results of the study  will be reported in a Clinical Study  Report generated by [CONTACT_941] S ponsor and 
will contain CRF data from all study sites that participated in the study , and direct transmission 
of clinical laboratory  data from a central laboratory  into the Sponsor's database. Recruitment 
performance or specific expertise related to the nature and the key assessment parameters of the 
study  will be used to determine a coordinating investigator. Results of pharmacogenomic or
exploratory  biomarker analy ses performed after the Clinical Study  Report has been issued will 
be reported in a separate report and will not require a revision of theClinical Study  Report. 
Study  subject identifiers will not be used in publication of results. Any work created in 
connection with performance of the study  and contained in the data that can benefit from 
copy right protection (except any publication by [CONTACT_40999] ) shall be 
the propert y of the S ponsor as author and owner of copy right in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, the Sponsor shall have the right to publish such primary  (multicenter) data 
and information without approval from the investigator. The investigator has the right to publish 
study  site-specific data after the primary  data are published. If an investigator wishes to publish 
informati on from the study , a copy of the manu script must be provided to the sponsor for review 
at least 60days before submission for publication or presentation. Expedited reviews will be 
arranged for abstracts, poster presentations, or other materials. If requested by [CONTACT_67845], the investigator will withhold such publication for up to an additional 60days to allow 
for filing of a patent application. In the event that issues arise regarding scientific integrity or 
regulatory  compliance, the Sponsor will review these issues with the investigator. The Sponsor 
will not mandate modifications to scientific content and does not have the right to suppress 
information. For multicenter study  designs and substudy  approaches, secondary  results generall y 
should not be published before the primary  endpoints of a study  have been published. Similarly , 
investigators will recognize the integrity  of a multicenter study  by [CONTACT_269327], within 12 months of the availability  of the final data (tab les, 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
116
Approved, 18 January 2017listings, graphs), or the Sponsor confirms there will be no multicenter study  publication. 
Authorship of publications resultin g from this study  will be based on the guidelines on 
authorship, such as those described in the Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals, which state that the named authors must have made a significant 
contribution to the desig n of the study  or analy sis and interpretation of the data, provided critical 
review of the paper, and given final approval of the final version.
Registration of Clinical Studies and Disclosure of Results
The Sponsor will register and/or disclose the existe nce of and the results of clinical studies as 
required b y law.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
117
Approved, 18 January 2017REFERENCES
1. Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity 
Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005;125(5):889 -894.
2. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus 
blood. J Exp Med. 2003;197:711 –723.
3. Chen XQ, Yu YC, Deng HH, et al. Plasma IL -17A is increased in new -onset SLE p atients and associated with 
disease activity. J Clin Immunol. 2010;30:221 –225.
4. Crispín JC, Oukka M, Bayliss G, et al. Expanded double negative T cells in patients with systemic lupus 
erythematosus produce IL -17 and infiltrate the kidneys. J Immunol. 2008;1 81:8761 –8766.
5. Dahl C, Johansen C, Kragballe K, Olesen AB. Ustekinumab in the treatment of refractory chronic cutaneous 
lupus erythematosus: a case report. Acta Derm Venereol. 2013;93:368 –369. 
6. De Souza A, Ali -Shaw T, Strober BE, Franks Jr AG. Successful treatment of subacute lupus erythematosus 
with ustekinumab. Arch Dermatol. 2011;147: 896 –898.
7. Feagan, BG, Sandborn WJ, Gasink C, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's 
Disease. N Engl J Med. 2016;375(20):1946 -1960.
8. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of 
improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727 -735.
9. Fine DM, Ziegenbein M, Petri M, et al. A prospective study of protein excretion using short -interval timed 
urine collections in patients with lupus nephritis. Kidney Int. 2009;76(12):1284 -1288.
10. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence -based sy stemic lupus erythematosus responder index.  
Arthritis & Rheumatism. 2009;61(9):1143 -1151.
11. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 
2002;29(2):288 -291.
12. Han JW, Zheng HF, Cui Y, et al. Genome -wide association study in a Chinese Han population identi ﬁes nine 
new susceptibility loci fo r systemic lupus erythematosus. Nat Genet .2009;41:1234e7.
13. Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical 
disease activity in systemic lupus erythematosus. Quart J Medicine. 1993;86:447 -458.  
14. Huang X, Hua J, Shen N, Chen S. Dysregulated expression of interleukin -23 and interleukin -12 subunits in 
systemic lupus erythematosus patients. Mod Rheumatol. 2007;17(3):220 -223.
15. Illei, G., Wang, L., Greth, W., & Khamashta, M. (2015). The effect of geography on the efficacy of 
sifalimumab, an anti -interferon alpha monoclonal antibody, in moderate to severe systemic lupus 
erythematosus. Gaithersburg: MedImmune . Clin Exp R heumatol. 2015; 33( [ADDRESS_327701].90 ):abstr P5.10 (11th 
International Congress on Systemic Lupus Erythematosus, 2 -6 September 2015, Vienna, Austria ). 
16. International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN), Harley J, Alarcón -
Riquelme M, et al. Genome -wide association scan in w omen w ith systemic lupus erythematosus identifies 
susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet. 2008;40(2):204 -210.
17. Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated 
version of the Bri tish Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus 
erythematosus. Rheumatology. 2005;44:902 -906.
18. Kim  HS, Kim I, Kim JO, Bae JS, Shin HD, Bae SC, No association between interleukin 23 receptor gene 
polymorphisms and systemic lupus erythematosus. Rheumatol Int. 2009;30: 33 –38.
19. Krupp LB, LaRocca NG, Muir -Nash J, Steinberg AD. The fatigue severity scale: application to patients with 
multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10);1121 -1123.
20. Linker -Israeli M, Deans RJ, Wallace DJ, et al. Elevated levels of endogenous IL -6 in systemic lupus 
erythematosus. A putative role in pathogenesis. J Immunol. 1991;147:117 –123.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
118
Approved, 18 January 201721. McHorney CA, Wa re JE Jr, L u JF, Sherbourne CD. The MOS 36 -item Short -Form  Healt h Survey (SF -36): III. 
Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care.
1994;32(1):40 -66.
22. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active 
systemic lupu s erythematosus: a randomised, placebo -controlled, phase 3 trial. Lancet. 2011; 377:721 –731.
23. Niew old TB, Hua J, Lehman TJA, Harley JB, Crow  MK. High serum IFN -α activity is a heritable risk factor 
for systemic lupus erythematosus. Genes Immuno. 2007, 8(6):492- 502.
24. Oh SH, Roh HJ, Kw on JE, et al. Expression of interleukin -17 is correlated w ith interferon -α expression in 
cutaneous lesions of lupus erythematosus. Clin Exp Dermatol. 2011;36:512 –520.
25. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International 
Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 
2012;64(8):2677 -2686. 
26. Qiu F, Song L, Yang N, Li X. Glucocorticoid downregulates expression of IL -12 family cytokines in s ystemic 
lupus erythematosus patients. Lupus. 2013;22(10):1011 -1016.
27. Samsa G, Edelman D, Rothman ML, et al. Determining clinically important differences in health status 
measures: a general approach with illustration to the Health Utilities Index Mark II. P harmacoeconomics. 
1999;15(2):141 -155.  
28. Sánchez E, Rueda B, Callejas JL, et al. Analysis of interleukin -23 receptor (IL23R) gene polymorphisms in 
systemic lupus erythematosus. Tissue Antigens. 2007;70:233 –237.
29. Sestak AL, Fürnrohr BG, Harley JB, Merrill JT, Namjou B. The genetics of systemic lupus erythematosus and 
implications for targeted therapy. Ann Rheum Dis. 2011;70(S1): i37 –i43.
30. Shah K, Lee WW, Lee SH, et al. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. 
Arthritis Res The r. 2010;12:R53.
31. Tanasescu CE, Balanescu P, Balanescu R, et al. IL -17 in cutaneous lupus erythematosus. Eur J Intern Med. 
2010;21:202 –207.
32. Touma Z, Gladman DD, Ibanez D, Urowitz MB. Development and initial validation of the systemic lupus 
erythematosus dise ase activity index 2000 responder index 50. J Rheumatol. 2011; 38:2; 
doi:10.3899/jrheum.100724.
33. Touma Z, Gladman DD, Urowitz MB. SLEDAI -2K for a 30 day window . Lupus. 2010a;19(1):[ADDRESS_327702] PO2.D.6.
35. Touma Z; Urowitz M, Gladman D. SLEDAI -2K Responder Index -50 (SRI -50).  Lup us.  The 9th International 
Congress on SLE June [ADDRESS_327703] PO2.D.7.
36. Van Vollenhoven RF, Petri MA, Cervera R. et al. Belimumab in the treatment of systemic lupus 
erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71(8):1343 -1349. 
37. Vincent FB, Northcott M, Hoi A, et al. Clinical associations of serum interleukin -17 in systemic lupus 
erythematosus. Arthritis Res Ther. 2013;15: R97.
38. Wallace DJ, Strand D, Furie V, et al. Evaluation of Treatment Success in Systemic Lupus Erythematosus 
Clinical Trials: Development of the British Isles Lupus Assessment Group -based Composite Lupus 
Assessment Endpoint. Arthritis Rheum. 2011;63 (S10):S885.
39. Wallace DJ. Lupus: The essential clinician’s guide. New  York, NY: Oxford University Press, Inc; 2008.
40. Ware JE. SF -36 Health Survey Update. Spi[INVESTIGATOR_050]. 2000;25(24):3130 -3139.
41. Ware JE, Kosinski M, Keller SK. SF -36 Phy sical and Mental Health Summary Scales: A User’s Manual. 
[LOCATION_011] MA. The Health Institute, 1994.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
119
Approved, 18 January 201742. Ware JE Jr, Sher bourne CD. The MOS 36 item short -form health survey (SF 36), I: conceptual framework and 
item selection. Med Care. 1992;30(6):473 -483.
43. Winchester D, Duffin KC, Hansen C. Response to ustekinumab in a patient with both severe psoriasis and 
hypertrophic cutan eous lupus. Lupus. 2012; 21:1007 –1010.
44. Wong CK, Lit LCW, Tam LS, et al.  Hyperproduction of IL -23 and IL -17 in patients with systemic lupus 
erythematosus: implications for Th17 -mediated inflammation in auto -immunity. Clin Immunol. 2008;127: 
385–393.
45. Yang X, Wang H, Zhao X, et al. Th22, but not Th17 might be a good index to predict the tissue involvement of 
systemic lupus erythematosus. J Clin Immunol. 2013; 33:767 –774.
46. Zhao XF, Pan HF, Yuan H, et al. Increased serum interleukin 17 in patients with systemic lupus 
erythematosus. Mol Biol Rep. 2010;37:81 –85.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
120
Approved, 18 January 2017ATTACHMENT 1: EFFICA CY EV ALUATIONS A ND ENDPOINTS
Efficacy Evaluations Description Composed of Other 
Assessments
BILAG British Isles Lupus Assessment 
GroupMeasure of alterations to therapy consisting of 9 7questions in 9 organ 
systems, each put into 1of 5 categories (A,B,C,D,E) depending on 
presence of items.  Higher scores indicat emore disease involvement.
BICLA BILAG- based Combined Lupus 
AssessmentCom posite requiring subjects to meet response criteria across the 
BILAG, PGA and SLEDAI -2K index.BILAG
PGA
SLEDAI -2K
CLASI Cutaneous Lupus Erythematosus 
Disease A reaand Severity IndexAssesses the disease activity and damage caused to the skin for CLE 
patients.  Scored [ADDRESS_327704].  Scored 9 -63.
Pain VAS Patients Numeric Rating Scale of 
PainMeasures the patient’s assessment of pain on a visual analogue scale 
(VAS; 0 to 10 cm). The anchors of the instrument include 0 to represent 
‘no pain’ and 10 to represent ‘the worst pain.’
PGA Physician’s Gl obal Assessment of 
Disease ActivityMeasures the PGA on a VAS scale. Each scored from 0 -10 with higher 
scores indicating worse activity.
PtGA Patient’s Gl obal Assessment of 
Disease ActivityMeasures the PtGA on a VAS scale. Each scored from 0 -10 with higher 
scores indicating worse activity.
SF-36 RAND Short -Form -36 Health 
SurveyMeasures 36 items w ithin 8 health domains.  Scored 0 -100 for each 
health concept with higher scores indicating an improved health state .  
In addition, health concepts can be combined into either a physical or 
mental component, also scored 0 -100.
SLEDAI -2K
(Baseline)Systemic Lupus Erythematosus 
Disease Activity Index 2000Measures 24 features in 9 organ domains over the previous 30 days.  
Scored 0 -105 w ith higher scores indicating more disease activity.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
121
Approved, 18 January 2017S2K RI -50
(Follow-up)SLEDAI -2K Responder Index 50 Measures clinically important 50% reduction in SLEDAI -2K score . SLEDAI -2K
SRI-[ADDRESS_327705] a 4 point reduction in SLEDAI 
2K, no w orsening ( ˂10 mm increase) from baseline in PGA and no new 
BILAG Domain A and no more than 1 new BILAG Domain B scores 
(see Section [IP_ADDRESS].).SLEDAI -2K
PGA
BILAG
SRI-[ADDRESS_327706] a 
5point or 6 point reduction in SLEDAI -2K respectively .SLEDAI -2K
PGA
BILAG
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
122
Approved, 18 January 2017ATTACHMENT 2:  QUA NTIFERON-TB GOLD TESTING
The QuantiFERON-TB Gold test is one of the interferon -(IFN-) based blood assays for TB screening 
(Cellestis, 2009). It utilizes the recently identified M. tuberculosis -specific antigens ESAT -[ADDRESS_327707] format, as well as TB7.7 (p4) in the In-Tube format, to detect in vitro cell-mediated 
immune responses in infected individuals. The QuantiFERON-TB Gold assay measures the amount of 
IFN-produced by [CONTACT_269328] M. tuberculosis -specific 
antigens. In M.tuberculosis -infected persons, sensitized Tlymphocytes will secrete IFN-in response to 
stimulation with the M. tuberculosis -specific antigens and, thus, the QuantiFERON-TB Gold te st should 
be positive. Because the antigens used in the test are specific to M.tuberculosis and not found in BCG, 
the test is not confounded by [CONTACT_14400], unlike the tuberculin skin test. However, there is some 
cross -reactivity with the 3Mycobacter ium species, M. kansasii , M. marinum , and M. szulgai . Thus, a 
positive test could be the result of infection with one of these 3 species of Mycobacterium, in the absence 
of M. tuberculosis infection.
In a study of the QuantiFERON-TB Gold test (standard format) in subjects with active TB, sensitivity 
has been shown to be approximately 89% (Mori et al, 2004). Specificity of the test in healthy 
BCG -vaccinated individuals has been demonstrated to be more than 98%. In contrast, the sensitivity and 
specificity of the tuberculin skin test was noted to be only about 66% and 35% in a study of Japanese 
patients with active TB and healthy BCG -vaccinated young adults, respectively. However, sensitivity and 
specificity of the tuberculin skin test depend on the populatio n being studied, and the tuberculin skin test 
performs best in healthy young adults who have not been BCG -vaccinated.
Data from a limited number of published studies examining the performance of the QuantiFERON-TB 
Gold assay in immunosuppressed population s suggest that the sensitivity of the QuantiFERON-TB Gold 
test is better than the tuberculin skin test even in immunosuppressed patients (Ferrara et al, 2005; Kobashi 
et al, 2007; Matulis et al, 2008). The ability of IFN--based tests to detect latent infection has been more 
difficult to study due to the lack of a gold standard diagnostic test; however, several TB outbreak studies 
have demonstrated that the tests correlated better than the tuberculin skin test with the degree of exposure 
that contacts had to the index TB case (Brock et al, 2004; Ewer et al, 2003). In addition, TB contact 
[CONTACT_41057] a positive QuantiFERON-TB Gold test result and were 
not treated for latent TB infection were much more likely to develop active TB during longitudinal 
follow -up than those who had a positive tuberculin skin test and a negative QuantiFERON-TB Gold test 
result (Higuchi et al, 2007; Diel et al, 2008).
Although the performance of the new IFN--based blood tests for active or latent M. tuberculosis
infection have not been well validated in the immunosuppressed population, experts believe these new 
tests will be at least as, if not more, sensitive, and definitely more specific, than the tuberculin skin test 
(Barnes, 2004; personal communication, April, [ADDRESS_327708]).
Performing the QuantiFERON-TB Gold In Tube Test
The QuantiFERON-TB Gold test In-Tube format will be provided for this study.  The In-Tube format 
contains 1 additional M. tuberculosis -specific antigen, TB7.7 (p4), which is thought to increase the 
specificity of the test. 
To perform the test using the In -Tube format, blood is drawn through standard venipuncture into supplied 
tubes that already contain the M. tuberculosis -specific antigens.  Approximately [ADDRESS_327709], each requiring 1 mL of blood.  One tube contains the M. tuberculosis -specific antigens, while 
the remaining tubes contain positive and negative control reagents.  Thorough mixing of the blood with 
the antigens is necessary pr ior to incubation.  The blood is then incubated for 16 to 24 hours at 37°C, after 
which tubes are centrifuged for approximately 15 minutes at 2000 to 3000g.  Following centrifugation, 
plasma is harvested from each tube, frozen, and shipped on dry ice to the central laboratory.  The central 
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
123
Approved, 18 January 2017laboratory will perform an ELISA to quantify the amount of IFN-present in the plasma using 
spectrophotometry and computer software analysis.
The central laboratory will analyze and report results for each subject, and sites will be informed of the 
results.  Subjects who have an indeterminate result should have the test repeated.
Adherence to Local Guidelines
Local country guidelines for immunocompromised patients should be consulted for acceptable anti-
tuberculous treatment regimens for latent TB.  If no local country guidelines for immunocompromised 
patients exist, US guidelines must be followed.
In countries in which the QuantiFERON-TB Gold test is not considered approved/registered, a 
tuberculin skin test is additionally required.
References
Barnes PF.  Diagnosing latent tuberculosis infection:  Turning glitter to gold [editorial].  Amer J Respir Crit Care 
Med. 2004;170:[ADDRESS_327710] in 
tuberculosis contacts.  Am J Respir Crit Care Med. 2004;170:65 -69.
Cellestis.  QuantiFERON -TB Gold clinicians guide and QuantiFERON -TB Gold In-Tube Method package insert.  
Downloaded from www.cellestis.com, February 2009.
Diel R, Lodden kemper R, Meywald -Walter K, Niemann S, Nienhaus A.  Predictive value of a whole blood IFN-
assay for the development of active tuberculosis disease after recent infection with mycobacterium tuberculosis.  
Am J Respir Crit Care Med. 2008;177:[ADDRESS_327711] for diagnosis of 
Mycobacterium tuberculosis infection in a school tuberculosis outbreak.  Lancet. 2003;361:1168 -73.
Ferrara G, Losi M, Meacci M, et al.  Routine hospi[INVESTIGATOR_40964] a new commercial whole blood interferon -assay for 
the diagnosis of tuberculosis infection.  Am J Respir Crit Care Med. 2005; 172:631 -635.
Higuchi K, Nobuyuki H, Mori T, Sekiya Y.  Use of QuantiFERON -TB Gold to investigate tuberculosis contac ts in a 
high school.  Respi[INVESTIGATOR_16921].  2007;12:[ADDRESS_327712] for immunocompromised 
patients.  Eur Respir J. 2007; 30:945 -950.
Matulis G, Jüni P, Villiger PM, Gadola SD.  Detection of latent tuberculosis in immunosuppressed patients with 
autoimmune diseases: performance of a  M ycobacterium tuberculosis antigen -specific interferon assay.  Ann 
Rheum Dis. 2008;67:84 -90
Mori T, Sakatani M, Yamagishi F, et al.  Specific detection of tubercu losis infection:  An interferon --based assay 
using new antigens.  Am J Respir Crit Care Med. 2004;170:59 -64.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
124
Approved, 18 January 2017ATTACHMENT 3:  TUBERCULIN SKIN T ESTING
Administering the Mantoux Tuberculin Skin Test
The Mantoux tuberculin skin test (CDC, 2000) is the standard method of identifying persons infected 
with Mycobacterium tuberculosis.  Multiple puncture tests (Tine and Heaf) should not be used to 
determine whether a person is infected because the amount of tuberculin injected intradermally cannot be 
precisely controlled.  Tuberculin skin testing is both safe and reliable throughout the course of pregnancy.  
The Mantoux tuberculin test is performed by [CONTACT_269329] 0.[ADDRESS_327713] the same 
strength as either 5 tuberculin units (TU) of standard purified protein derivative ([COMPANY_003]) S or 2 TU of [COMPANY_003] 
RT 23, Statens Seruminstitut, as recommended by [CONTACT_38375].  [COMPANY_003] strengths of 
1TU or 250 TU are not acceptable (Menzies, 2000). Using a disposable tuberculin syringe with the 
needle bevel facing upward, the injection should be made just beneath the surface of the skin. This shoul d 
produce a discrete, pale elevation of the skin (a wheal) 6 mm to 10 mm in diameter. To prevent 
needle -stick injuries, needles should not be recapped, purposely bent or broken, removed from disposable 
syringes, or otherwise manipulated by [CONTACT_35681].  After they are used, disposable needles and syringes should 
be placed in puncture -resistant containers for disposal. Institutional guidelines regarding universal 
precautions for infection control (eg, the use of gloves) should be followed.  A trained health care wo rker, 
preferably the investigator, should read the reaction to the Mantoux test [ADDRESS_327714], tuberculin testing should be 
repeated. The area of induration (palpable raised hardened area) around the site of injection is the reaction 
to tuberculin. For standardization, the diameter of the induration should be measured transversely 
(perpendicular) to the long axis of the forearm.  Erythema (redness) should not be measured. All reactions 
should be recorded in millimeters, even those classified as negative.
Interpreting the Tuberculin Skin Test Results
In the US and many other countries, the most conservative definition of positivity for the tuberculin skin 
test is reserved for immunocompromised patients, and this definition is to be applied in this study to 
maximize the likelihood of detecting latent TB, even though the subjects may not be 
immunocompromised at baseline.
In the US and Canada, an induration of [ADDRESS_327715] be followed.
References
Centers for Disease Control and Prevention.  Core curriculum on tuberculosis:  What the clinician should know 
(Fourth Edition).  Atlanta, GA:  Department of Health and Human Services; Centers for Disease Control and 
Prevention; National Center for HIV, STD, and TB Prevention; Division of Tuberculosis Elimination; 2000:25 -86.
Menzies RI.  Tuberculin skin testing.  In:  Reichman LB, Hershfield ES (eds). Tuberculosis, a comprehensive 
international approach.  2nd ed.  N ew Y ork, NY:  M arcel Dekker, Inc; 2000:279 -322.
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
125
Approved, 18 January 2017ATTACHMENT 4:  HBV SCREENING A NDMONITORING
Subjects must undergo screening for hepatitis B virus (HBV). At a minimum, this includes 
testing for HBsAg (HBV surface antigen), anti-HBs (HBV surface antibody ), and anti-HBc total 
(HBV core antibod y total): 
1)Subjects who test negative for all HBV screenin g tests (ie, HBsAg -, anti -HBc-, and 
anti-HBs-) are eligible for this study .
2)Subjects who test negative for surface antigen (HBsAg -) and test positive for core 
antibody  (anti -HBc+) andsurface antibod y (anti -HBs+) are eligible for this study .
3)Subjects who test positive only for surface antibody (anti-HBs+) are eligible for 
this study .
4)Subjects who test positive for surface antigen (HBsAg+) are NOT eligible for this 
study , regardless of the results of other hepatitis B tests.
5)Subjects who test positive only for core antibody (anti-HBc+) must undergo 
further testing for the presence of hepatitis B virus deox yribonucleic acid (HBV 
DNA test). If the HBV DNA test is positive , the subject is NOT eligible for this 
study . If the HBV DNA test is negative , the subject is eligible for this study . In the 
event the HBV DNA test cannot be performed, the subject is NOT eligible for this 
study . 
For subjects who are not eligible for this study due to HBV test results , consultation with a 
physician with experti se in the treatment of hepatitis B virus infection is recommended.  
Eligibility based on hepatitis B virus test results
Hepatitis B test result
ActionHepatitis B 
surface antigen
(HBsAg)Hepatitis B 
surface antibody
(anti -HBs)Hepatitis B core 
antibody
(anti -HBc total)
Include— — —
— + —
— + +
Exclude + —or+ —or+
Require testing for 
presence HBV DNA*— — +
* If HBV DNA is detectable, exclude from the clinical study . If HBV DNA testing 
cannot be performed, or there is evidence of chronic liver disease, exclude from the 
clinical study .  
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
126
Approved, 18 January 2017ATTACHMENT 5: SLEDA I-2K/S2K RI -50 AT SCREENING VISIT
            
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
127
Approved, 18 January 2017     
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
128
Approved, 18 January 2017        
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
129
Approved, 18 January 2017ATTACHMENT 6: SLEDA I-2K / S2K RI -50 (BA SELINE)
       
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
130
Approved, 18 January 2017   
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
131
Approved, 18 January 2017
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
132
Approved, 18 January 2017
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
133
Approved, 18 January 2017ATTACHMENT 7: S2K RI -50 (FOLLOW -UP)
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
134
Approved, 18 January 2017
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
135
Approved, 18 January 2017
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
136
Approved, 18 January 2017
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
137
Approved, 18 January 2017ATTACHMENT 8: BILA G 2004
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
138
Approved, 18 January 2017ATTACHMENT 9: CLA SI
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
139
Approved, 18 January 2017ATTACHMENT 10: PHYSICI AN GLOB AL ASSESSMENT OF DISEA SEACTIVITY
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
140
Approved, 18 January 2017ATTACHMENT 11: PA TIENTS GLOBA L ASSESSMENTS OF DISEA SEAND P AIN 
ACTIVITY
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
141
Approved, 18 January 2017ATTACHMENT 12: SF -36
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
142
Approved, 18 January 2017
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
143
Approved, 18 January 2017
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
144
Approved, 18 January 2017
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
145
Approved, 18 January 2017
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
146
Approved, 18 January 2017
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
147
Approved, 18 January 2017ATTACHMENT 13: FA TIGUE SEVERITY S CALE
NCT0239061
Stelara®(ustekinumab)
Clinical Protocol CNTO1275SLE2001 Amendment 3
148
Approved, 18 January 2017INVESTIGA TOR AGREEME NT
NCT0239061